# Appendix H: deleted text from NICE clinical guideline 35 (CG35)

### 1.1 Retained recommendations summary table

The only recommendations from NICE clinical guideline 35 (CG35) which have not been directly updated by an evidence review are being retained and are listed in the table below.

<table>
<thead>
<tr>
<th>Rec. no.</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1.1</td>
<td>Communication with people with Parkinson’s disease should aim towards empowering them to participate in judgements and choices about their own care.</td>
</tr>
<tr>
<td>1.1.2</td>
<td>In discussions, aim to achieve a balance between providing honest, realistic information about the condition and promoting a feeling of optimism.</td>
</tr>
</tbody>
</table>
| 1.1.3    | Because people with Parkinson’s disease may develop impaired cognitive ability, communication problems and/or depression, provide them with:  
  • both oral and written communication throughout the course of the disease, which should be individually tailored and reinforced as necessary  
  • consistent communication from the professionals involved |
| 1.1.4    | Give family members and carers (as appropriate) information about the condition, their entitlement to a Carer’s Assessment and the support services available |
| 1.1.5    | People with Parkinson’s disease should have a comprehensive care plan agreed between the person, their family members and carers (as appropriate), and specialist and secondary healthcare providers |
| 1.1.6    | Offer people an accessible point of contact with specialist services. This could be provided by a Parkinson’s disease nurse specialist |
| 1.1.7    | Advise people with Parkinson’s disease who drive that they should inform the Driver and Vehicle Licensing Agency (DVLA) and their car insurer of their condition when Parkinson’s disease is diagnosed |
| 1.2.1    | Suspect Parkinson’s disease in people presenting with tremor, stiffness, slowness, balance problems and/or gait disorders |
| 1.2.2    | If Parkinson’s disease is suspected, refer people quickly and untreated to a specialist with expertise in the differential diagnosis of this condition. (The 2006 GDG considered that people with suspected mild Parkinson’s disease should be seen within 6 weeks, but new referrals in later disease with more complex problems require an appointment within 2 weeks.) |
| 1.2.3    | Diagnose Parkinson’s disease clinically, based on the UK Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria |
| 1.2.4    | Encourage healthcare professionals to discuss with people the |
| 1.2.5 | Revise the diagnosis of Parkinson's disease regularly, and reconsider if atypical clinical features develop. (The 2006 GDG considered that people diagnosed with Parkinson's disease should be seen at regular intervals of 6–12 months to review their diagnosis.) |
| 1.2.3 | Consider 123I-FP-CIT SPECT for people with tremor if essential tremor cannot be clinically differentiated from parkinsonism. [2006 amended 2017] |
| 1.2.7 | 123I-FP-CIT SPECT should be available to specialists with expertise in its use and interpretation. |
| 1.2.8 | Do not use PET in the differential diagnosis of parkinsonian syndromes, except in the context of clinical trials. [2006 amended 2017] |
| 1.2.9 | Do not use structural MRI in the differential diagnosis of Parkinson's disease. [2006 amended 2017] |
| 1.2.10 | Structural MRI may be considered for the differential diagnosis of parkinsonian syndromes |
| 1.2.11 | Do not use magnetic resonance volumetry in the differential diagnosis of parkinsonian syndromes, except in the context of clinical trials. [2006 amended 2017] |
| 1.2.12 | Do not use magnetic resonance spectroscopy in the differential diagnosis of parkinsonian syndromes. [2006 amended 2017] |
| 1.2.13 | Do not use acute levodopa and apomorphine challenge tests in the differential diagnosis of parkinsonian syndromes. [2006 amended 2017] |
| 1.2.14 | Do not use objective smell testing in the differential diagnosis of parkinsonian syndromes, except in the context of clinical trials. [2006 amended 2017] |
| 1.5.3 | Advise people with Parkinson’s disease who have somnolence and/or sudden onset of sleep not to drive and to consider any occupation hazards. Adjust their medication to reduce its occurrence |
| 1.5.4 | Take care to identify and manage restless leg syndrome (RLS) and rapid eye movement (REM) sleep behaviour disorder in people with Parkinson’s disease and sleep disturbance |
| 1.7.12 | Do not use vitamin E as a neuroprotective therapy for people with Parkinson's disease |
| 1.7.13 | Do not use co-enzyme Q10 as a neuroprotective therapy for people with Parkinson's disease, except in the context of clinical trials |
| 1.7.14 | Do not use dopamine agonists as neuroprotective therapies for people with Parkinson's disease except in the context of clinical trials |
| 1.7.15 | Do not use monoamine oxidase B inhibitors as neuroprotective therapies for people with Parkinson's disease, except in the context of clinical trials |
The National Collaborating Centre for Chronic Conditions

Funded to produce guidelines for the NHS by NICE

PARKINSON’S DISEASE

National clinical guideline for diagnosis and management in primary and secondary care
Acknowledgements

The National Collaborating Centre for Chronic Conditions would like to thank Rob Grant, Susan Varney, Ian Lockhart, Lina Bakhshi, Alison Richards, Jane Ingham, Ester Klaeijzen, Nick Latimer and Bernard Higgins for their work and advice on this project.

The Royal College of Physicians

The Royal College of Physicians plays a leading role in the delivery of high quality patient care by setting standards of medical practice and promoting clinical excellence. We provide physicians in the United Kingdom and overseas with education, training and support throughout their careers. As an independent body representing over 20,000 Fellows and Members worldwide, we advise and work with government, the public, patients and other professions to improve health and healthcare.

The National Collaborating Centre for Chronic Conditions

The National Collaborating Centre for Chronic Conditions (NCC-CC) is a collaborative, multi-professional centre undertaking commissions to develop clinical guidelines for the NHS in England and Wales. The NCC-CC was established in 2001. It is an independent body, housed within the Clinical Standards Department at the Royal College of Physicians of London. The NCC-CC is funded by the National Institute for Health and Clinical Excellence (NICE) to undertake commissions for national clinical guidelines on an annual rolling programme.

Citation for this document


Copyright

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently
Contents

Guideline Development Group members vii
Preface ix

DEVELOPMENT OF THE GUIDELINE

1 Introduction 3
   1.1 Background 3
   1.2 Modern definition 3
   1.3 Health and resource implications 3
   1.4 How to use this guideline 4

2 Methodology 5
   2.1 Aim 5
   2.2 Scope 5
   2.3 Audience 5
   2.4 Involvement of people with Parkinson’s disease 6
   2.5 Guideline limitations 6
   2.6 Other work relevant to the guideline 6
   2.7 The process of guideline development 6
   2.8 Disclaimer 12
   2.9 Funding 12

THE GUIDELINE

3 Key messages 15
   3.1 Key priorities for implementation 15
   3.2 Audit criteria 17
   3.3 Parkinson’s disease algorithm 19

4 Communication with people with Parkinson’s disease and their carers 21
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>Diagnosing Parkinson's disease</td>
<td>29</td>
</tr>
<tr>
<td>5.1</td>
<td>Definition and differential diagnosis</td>
<td>29</td>
</tr>
<tr>
<td>5.2</td>
<td>Clinical versus post-mortem diagnosis</td>
<td>32</td>
</tr>
<tr>
<td>5.3</td>
<td>Expert versus non-expert diagnosis</td>
<td>33</td>
</tr>
<tr>
<td>5.4</td>
<td>Review of diagnosis</td>
<td>35</td>
</tr>
<tr>
<td>5.5</td>
<td>Single photon emission computed tomography</td>
<td>36</td>
</tr>
<tr>
<td>5.6</td>
<td>Positron emission tomography</td>
<td>39</td>
</tr>
<tr>
<td>5.7</td>
<td>Magnetic resonance imaging</td>
<td>40</td>
</tr>
<tr>
<td>5.8</td>
<td>Magnetic resonance volumetry</td>
<td>42</td>
</tr>
<tr>
<td>5.9</td>
<td>Magnetic resonance spectroscopy</td>
<td>43</td>
</tr>
<tr>
<td>5.10</td>
<td>Acute levodopa and apomorphine challenge tests</td>
<td>43</td>
</tr>
<tr>
<td>5.11</td>
<td>Objective smell testing</td>
<td>45</td>
</tr>
</tbody>
</table>
Parkinson’s disease

Appendix H: Deleted Text Appendix

6

Neuroprotection

6.1 Definitions
6.2 Vitamin E

6.3 Co-enzyme Q10
6.4 Dopamine agonists

6.5 Monoamine oxidase type B inhibitors

7

Symptomatic pharmacological therapy in Parkinson’s disease

7.1 Introduction
7.2 Early pharmacological therapy
7.2.1 Introduction
7.2.2 L-dopa
7.2.3 Dopamine agonists
7.2.4 Monoamine oxidase type B inhibitors
7.2.5 Beta-adrenergic antagonists (beta-blockers)
7.2.6 Amantadine
7.2.7 Anticholinergics

7.3 Comparisons of drug classes
7.3.1 Modified-release compared with immediate-release l-dopa
7.3.2 Dopamine agonists compared with l-dopa
7.3.3 Dopamine agonists plus l-dopa compared with l-dopa
7.3.4 Monoamine oxidase type B inhibitors compared with l-dopa
7.3.5 Monoamine oxidase type B inhibitors compared with dopamine agonists

7.4 Choice of initial pharmacological therapy in early PD
7.5 Later pharmacological therapy
7.5.1 Introduction
7.5.2 L-dopa
7.5.3 Dopamine agonists
7.5.4 Monoamine oxidase type B inhibitors
7.5.5 Catechol-O-methyl transferase inhibitors
7.5.6 Amantadine
7.5.7 Apomorphine
7.5.8 Intermittent subcutaneous apomorphine injections
7.5.9 Apomorphine infusions

7.6 Comparisons of drug classes
7.6.1 Dopamine agonists compared with monoamine oxidase type B inhibitors
7.6.2 Catechol-O-methyl transferase inhibitors compared with dopamine agonists
Parkinson's disease Appendix H: Deleted Text Appendix

7.6.3 Dopamine agonists compared with amantadine 99
7.7 Choice of pharmacological therapy in later PD 99

8 Surgery for Parkinson's disease 101
8.1 Introduction 101
8.2 Subthalamic nucleus stimulation 103
8.3 Globus pallidus interna stimulation 108
8.4 Comparison of different types of deep brain stimulation 108
8.5 Thalamic stimulation 110
Parkinson’s disease Appendix H: Deleted Text Appendix

<table>
<thead>
<tr>
<th></th>
<th>Non-motor features of Parkinson’s disease</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>Introduction</td>
<td>113</td>
</tr>
<tr>
<td>9.1</td>
<td>Mental health problems</td>
<td>114</td>
</tr>
<tr>
<td>9.2.1</td>
<td>Depression</td>
<td>114</td>
</tr>
<tr>
<td>9.2.2</td>
<td>Psychotic symptoms</td>
<td>117</td>
</tr>
<tr>
<td>9.2.3</td>
<td>Dementia</td>
<td>121</td>
</tr>
<tr>
<td>9.3</td>
<td>Sleep disturbance</td>
<td>124</td>
</tr>
<tr>
<td>9.3.1</td>
<td>Daytime hypersomnolence</td>
<td>125</td>
</tr>
<tr>
<td>9.3.2</td>
<td>Nocturnal akinesia</td>
<td>127</td>
</tr>
<tr>
<td>9.4</td>
<td>Falls</td>
<td>128</td>
</tr>
<tr>
<td>9.5</td>
<td>Autonomic disturbance</td>
<td>129</td>
</tr>
<tr>
<td>9.5.1</td>
<td>Gastrointestinal dysfunction</td>
<td>129</td>
</tr>
<tr>
<td>9.5.2</td>
<td>Orthostatic hypotension</td>
<td>132</td>
</tr>
<tr>
<td>9.5.3</td>
<td>Excessive sweating</td>
<td>132</td>
</tr>
<tr>
<td>9.5.4</td>
<td>Sialorrhoea</td>
<td>132</td>
</tr>
<tr>
<td>9.6</td>
<td>Pain</td>
<td>133</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Other key interventions</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Introduction</td>
<td>135</td>
</tr>
<tr>
<td>10.1</td>
<td>Psychological interventions</td>
<td>135</td>
</tr>
<tr>
<td>10.2</td>
<td>Parkinson’s disease nurse specialist</td>
<td>135</td>
</tr>
<tr>
<td>10.3</td>
<td>Physical therapy</td>
<td>138</td>
</tr>
<tr>
<td>10.4</td>
<td>Occupational therapy</td>
<td>142</td>
</tr>
<tr>
<td>10.5</td>
<td>Speech and language therapy</td>
<td>143</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Palliative care in Parkinson’s disease</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>Introduction</td>
<td>147</td>
</tr>
<tr>
<td>11.1</td>
<td>Art and culture</td>
<td>147</td>
</tr>
<tr>
<td>11.2</td>
<td>The palliative phase of PD</td>
<td>147</td>
</tr>
<tr>
<td>11.3</td>
<td>Ethical issues</td>
<td>150</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Research recommendations</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>Introduction</td>
<td>153</td>
</tr>
<tr>
<td>12.1</td>
<td>Future research recommendations</td>
<td>153</td>
</tr>
<tr>
<td>12.2</td>
<td>General research recommendations</td>
<td>159</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>APPENDICES</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Appendix A: The scope of the guideline</td>
<td>167</td>
<td></td>
</tr>
<tr>
<td>Appendix B: Details of questions and literature searches</td>
<td>171</td>
<td></td>
</tr>
</tbody>
</table>
## Guideline Development Group members

<table>
<thead>
<tr>
<th>Name</th>
<th>Job title</th>
<th>Employing organisation</th>
<th>Representing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carl Clarke</td>
<td>Clinical Advisor</td>
<td>City Hospital and University of Birmingham</td>
<td>NCC-CC</td>
</tr>
<tr>
<td>Tara Sullivan</td>
<td>Research Fellow and Project Manager</td>
<td>NCC-CC</td>
<td>NCC-CC</td>
</tr>
<tr>
<td>Alastair Mason</td>
<td>Chairman</td>
<td>NCC-CC</td>
<td>NCC-CC</td>
</tr>
<tr>
<td>Bernadette Ford</td>
<td>Information Scientist</td>
<td>NCC-CC</td>
<td>NCC-CC</td>
</tr>
<tr>
<td>Debbie Nicholl</td>
<td>Health Economist</td>
<td>NCC-CC</td>
<td>NCC-CC</td>
</tr>
<tr>
<td>Jill Parnham</td>
<td>Senior Research Fellow</td>
<td>NCC-CC</td>
<td>NCC-CC</td>
</tr>
<tr>
<td>Nicole Wilson</td>
<td>Project Manager</td>
<td>NCC-CC</td>
<td>NCC-CC (6 months)</td>
</tr>
<tr>
<td>David Anderson</td>
<td>John Hindle (GDG member)</td>
<td>Doug MacMahon (GDG member)</td>
<td>Consultant Psychiatrist</td>
</tr>
<tr>
<td>Angela Birkson</td>
<td>Brian Hurwitt (GDG member)</td>
<td>Advanced Practitioner in Occupational Therapy</td>
<td></td>
</tr>
<tr>
<td>David Burn</td>
<td>z (GDG member)</td>
<td>Consultant Neurologist</td>
<td></td>
</tr>
<tr>
<td>Michael Godfrey</td>
<td>Andrew Lear (GDG member)</td>
<td>Patient Representative</td>
<td></td>
</tr>
<tr>
<td>Jacqui Hazldey</td>
<td>(GDG member)</td>
<td>Parkinson's Disease Nurse Specialist</td>
<td></td>
</tr>
<tr>
<td>Position</td>
<td>Institution</td>
<td>Organization</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>--------------------------------------------------</td>
<td>---------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Consultant Physician, Care of the Elderly</td>
<td>Mosley Hill Hospital, Liverpool</td>
<td>Royal College of Psychiatrists</td>
<td></td>
</tr>
<tr>
<td>General Practitioner</td>
<td>Occupational Therapy, Clinical Support Services, South Tees Hospitals</td>
<td>College of Occupational Therapists</td>
<td></td>
</tr>
<tr>
<td>Professor of Neurology</td>
<td>Newcastle General Hospital, Newcastle upon Tyne</td>
<td>Parkinson's Disease Society</td>
<td></td>
</tr>
<tr>
<td>Consultant Physician (with special responsibility for the elderly)</td>
<td>Dorset County Hospital, Dorchester</td>
<td>British Geriatric Society</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Royal College of General Practitioners</td>
<td>Association of British Neurologists</td>
<td></td>
</tr>
<tr>
<td></td>
<td>North West Wales NHS Trust, Bangor</td>
<td>British Geriatrics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>King's College London</td>
<td>Society</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Royal Cornwall Hospitals</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NHS Trust</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Parkinson’s disease

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Organization/Institution</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Meadowcroft</td>
<td>Director of Policy</td>
<td>Parkinson’s Disease Society</td>
<td>Parkinson’s Disease Society (Attended ten meetings)</td>
</tr>
<tr>
<td>(GDG member)</td>
<td>Campaigns and Information</td>
<td></td>
<td></td>
</tr>
<tr>
<td>David McNiven</td>
<td>Policy and Campaigns Manager</td>
<td>Parkinson’s Disease Society</td>
<td>Parkinson’s Disease Society (Attended two meetings)</td>
</tr>
<tr>
<td>(GDG member)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bhanu Ramaswamy</td>
<td>Consultant Physiotherapist</td>
<td>Walton Hospital, Chesterfield</td>
<td>Chartered Society</td>
</tr>
<tr>
<td>(GDG member)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Julia Johnson</td>
<td>Speech and Language Therapist</td>
<td>King’s College Hospital London</td>
<td>Royal College of Speech and Language Therapists</td>
</tr>
<tr>
<td>(Expert advisor)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRK Varma</td>
<td>Consultant Neurosurgeon</td>
<td>Walton Centre for Neurology &amp; Neurosurgery, Liverpool</td>
<td>Society of British Neurological Surgeons</td>
</tr>
<tr>
<td>(Expert advisor)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ana Aragon</td>
<td>Occupational Therapist</td>
<td>Bath and North East Somerset PCT</td>
<td>College of Occupational Therapists (Attended one meeting)</td>
</tr>
<tr>
<td>(Deputy for Angela Bilson)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iris Leroi</td>
<td>Consultant in Old Age Psychiatry</td>
<td>Manchester Mental Health and Social Care Trust</td>
<td>Royal College of Psychiatrists (Attended one meeting)</td>
</tr>
<tr>
<td>(Deputy for David Anderson)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Karen Durrant</td>
<td>Superintendent Physiotherapist</td>
<td>Walton Hospital, Chesterfield</td>
<td>Chartered Society of Physiotherapy (Attended one meeting)</td>
</tr>
<tr>
<td>(Deputy for Bhanu Ramaswamy)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>David Stewart</td>
<td>Consultant Physician (medicine for the elderly)</td>
<td>Mansionhouse Unit, Victoria Infirmary Glasgow</td>
<td>British Geriatrics Society (Attended one meeting)</td>
</tr>
<tr>
<td>(Deputy for Doug MacMahon)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Preface

It is almost 200 years since James Parkinson described the major symptoms of the disease that came to bear his name. Slowly but surely our understanding of the disease has improved and effective treatment has been developed, but Parkinson's disease remains a huge challenge to those who suffer from it and to those involved in its management. In addition to the difficulties common to other disabling neurological conditions, the management of Parkinson's disease must take into account the fact that the mainstay of pharmacological treatment, levodopa, can eventually produce dyskinesia and motor fluctuation. Furthermore, there are a number of agents besides levodopa that can help parkinsonian symptoms, and there is the enticing but unconfirmed prospect that other treatments might protect against worsening neurological disability. Thus, a considerable degree of judgement is required in tailoring individual therapy and in timing treatment initiation.

It is hoped that this guideline on Parkinson's disease will be of considerable help to those involved at all levels in these difficult management decisions. The guideline has been produced using standard NICE methodology and is therefore based on a thorough search for best evidence. Because of the unique problems of Parkinson's disease, converting this evidence into recommendations for treatment might have been problematic, but we have been fortunate in having a very experienced and able Guideline Development Group who have interpreted the scientific papers in the light of their considerable clinical experience. I am grateful to them for their hard work and for their expertise.

The guideline includes many recommendations on the use of different classes of pharmaceutical agent, but the recommendations singled out as being of key importance also stress other aspects of management. This is not a negative emphasis based on the problems associated with anti-parkinsonian drugs, but reflects the major role of non-pharmacological aspects of care in this disabling chronic condition. Diagnosis is particularly highlighted. This can be difficult, and while swift assessment by someone with appropriate expertise is important when suspicion of Parkinson's disease first arises, so too is it vital to reconsider the diagnosis if atypical features develop later. The speed with which we have recommended that patients should be seen may seem aspirational, but reflects the importance the Development Group feel should be attached to this. Other key recommendations urge healthcare professionals to be aware throughout the course of the disease of the potential benefits of referral for specialist treatment such as physiotherapy, occupational or speech and language therapy. I would also commend to the reader the excellent section on communication, another area of particular difficulty in this disease.

One of the incidental benefits of producing an evidence-based guideline is that the process highlights those areas in which the evidence is particularly lacking. There are always more of these than we would wish. Towards the end of this document the Development Group has indicated
Parkinson's disease Appendix H: Deleted Text Appendix

those areas which they believe are particularly deserving of, and amenable to, further research efforts.

Two centuries since its first description, Parkinson's disease remains a huge challenge. We hope that this guideline will not only aid current treatment of the disease, but will also stimulate efforts to improve future management more quickly than has been possible to date.

Dr B Higgins MD FRCP
Director, National Collaborating Centre for Chronic Conditions
DEVELOPMENT OF THE GUIDELINE
1 Introduction

1.1 Background

Parkinson's disease (PD) is named after the London general practitioner (GP), James Parkinson, who vividly described many of the clinical features of the condition in his *Essay on the shaking palsy* (1817).5

In this work, Parkinson refers to the condition by its earlier name of *paralysis agitans*, a term that captures a peculiar characteristic of the disease, namely the combination of *movement loss* (ie hypokinesia) with *movement gain* (ie tremor at rest) which characterises the condition.6

*Shaking palsy* was named ‘maladie de Parkinson’ in 1888 by the French neurologist Jean-Martin Charcot. Charcot admired Parkinson's clinical acumen and powers of description, but criticised him for omitting mention of rigidity, which Charcot believed to be a typical feature of the condition.7

1.2 Modern definition

PD is a progressive neurodegenerative condition resulting from the death of the dopamine containing cells of the substantia nigra. There is no consistently reliable test that can distinguish PD from other conditions that have similar clinical presentations. The diagnosis is primarily a clinical one based on the history and examination.

People with PD classically present with the symptoms and signs associated with parkinsonism, namely hypokinesia (ie poverty of movement), bradykinesia (ie slowness of movement), rigidity and rest tremor.

Parkinsonism can also be caused by drugs and less common conditions such as: multiple cerebral infarction, and degenerative conditions such as progressive supranuclear palsy (PSP) and multiple system atrophy (MSA).

Although PD is predominantly a movement disorder, other impairments frequently develop, including psychiatric problems such as depression and dementia. Autonomic disturbances and
pain may later ensue, and the condition progresses to cause significant disability and handicap with impaired quality of life for the affected person. Family and carers may also be affected indirectly.

1.3 Health and resource implications

PD is a common, progressive neurological condition, estimated to affect 100–180 per 100,000 of the population (6–11 people per 6,000 of the general population in the UK)\(^*\) and has an annual incidence of 4–20 per 100,000.\(^*\) There is a rising prevalence with age and a higher prevalence and incidence of PD in males.\(^*\)

\(^*\)The size of the average general practice list in the UK.
PD can lead to extensive disability, which affects both the individual with the disease as well as indirectly family and carers. The economic impact of the disease includes:

- direct cost to the National Health Service (NHS)
- indirect cost to society
- personal impact of PD on individuals with the condition and their family and carers.

The direct costs of treatment to the NHS have been estimated at approximately £2,298 (£1 998) per patient per year.10 Significant cost drivers include the onset of motor fluctuations and dyskinesias.11 The condition is a frequent cause of falls and thus fractures and even death.12

The total annual cost of care including NHS, social services and private expenditure per patient in the UK has been estimated at approximately £5,993 (£1 998).10 This results in direct costs of approximately £599,300,000 per year in the UK for 100,000 individuals with PD.10

Total costs of care increase with age and disease severity.10 Costs to the NHS were approximately 38% of the total costs.10

1.4 How to use this guideline

The purpose of this guideline is to support clinical judgement, not to replace it. This means the treating clinician should:

- take into consideration any contraindications in deciding whether or not to administer any treatment recommended by this guideline
- consider the appropriateness of any recommended treatment for a particular patient in terms of the patient’s relevant clinical and non-clinical characteristics.

Wherever possible, before administering any treatment the treating clinician should follow good practice in terms of:

- discussing with the patient why the treatment is being offered and what health outcomes are anticipated
- highlighting any possible adverse events or side-effects that have been associated with the treatment
- obtaining explicit consent to administer the treatment.
For those recommendations involving pharmacological treatment, the most recent edition of the British National Formulary (BNF) should be followed for the determination of:

- indications
- drug dosage
- method and route of administration
- contraindications
- supervision and monitoring
- product characteristics

except in those cases where guidance is provided within the recommendation itself.
Methodology

2.1 Aim

The aim of the National Collaborating Centre for Chronic Conditions (NCC-CC) is to provide a user-friendly, clinical evidence-based guideline for the NHS in England and Wales that:

- offers best clinical advice for PD
- is based on best published evidence and expert consensus
- takes into account patient choice and informed decision making
- defines the major components of NHS care provision for PD
- indicates areas suitable for clinical audit
- details areas of uncertainty or controversy requiring further research
- provides a choice of guideline versions for different audiences.

2.2 Scope

The guideline was developed in accordance with a scope, which detailed the remit of the guideline originating from the Department of Health and specified those aspects of PD to be included and excluded.

Prior to the commencement of the guideline development, the scope was subjected to stakeholder consultation in accordance with processes established by NICE. The full scope is shown in Appendix A.

The guideline covers:

- diagnosis of PD and parkinsonism
- treatment of idiopathic PD
Parkinson’s disease Appendix H: Deleted Text Appendix

The scope excludes:

- juvenile onset PD (in people younger than 20 years of age)
- treatment of parkinsonism (a neurological disorder that manifests with hypokinesia, tremor or muscular rigidity) and other tremulous disorders (for example, essential tremor).

The guideline is relevant to primary, secondary and tertiary NHS care settings.

2.3 Audience

The guideline is primarily intended to provide guidance for NHS staff, but will also have relevance to the following people or organisations:

- all healthcare professionals
- people with the disease and carers of these people
- patient support groups
- commissioning organisations
- service providers.


2.4 **Involvement of people with Parkinson’s disease**

The NCC-CC was keen to ensure that the views and preferences of people with PD and their carers informed all stages of the guideline. This was achieved:

- by consulting the Patient Information Unit housed within NICE during the pre-development (scoping) and final validation stages of the guideline
- by having a person with PD and a user organisation representative on the Guideline Development Group (GDG).

The patient and/or a representative of the user organisation were present at every meeting of the GDG. They were involved at all stages of the guideline development process and were able to consult with their wider constituencies.

2.5 **Guideline limitations**

The limitations of the guideline are as follows:

- Clinical guidelines usually do not cover issues of service delivery, organisation or provision (unless specified in the remit from the Department of Health).
- NICE is primarily concerned with health services and so recommendations are not provided for social services and the voluntary sector. However, the guideline may address important issues in how NHS clinicians interface with these other sectors.
- Generally the guideline does not cover rare, complex, complicated or unusual conditions.

2.6 **Other work relevant to the guideline**

This guideline has been developed with the knowledge that other national work on PD and chronic neurological conditions has been completed or is in progress. This includes:

- the National Service Framework (NSF) for Long-term (Neurological) Conditions¹⁴
- the NSF for Older People¹⁵
- NICE Guideline on Falls¹⁶
- NICE Guideline on Dementia¹⁷
2.7 The process of guideline development

The development of this evidence-based clinical guideline draws upon the methods described by the NICE Guideline Development Methods manual\textsuperscript{1,13} and the methodology pack specifically developed by the NCC-CC for each chronic condition guideline.\textsuperscript{24} The developers' role and remit is summarised in Table 2.1.
Table 2.1 Role and remit of the developers

<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Collaborating Centre for Chronic Conditions (NCC-CC)</td>
<td>The NCC-CC was set up in 2001 and is housed within the Royal College of Physicians (RCP). The NCC-CC undertakes commissions received from the National Institute for Health and Clinical Excellence (NICE). A multi-professional partners' board inclusive of patient groups.</td>
</tr>
<tr>
<td>NCC-CC Technical Team</td>
<td>The Technical Team met and comprised the following members: GDG group leader, GDG clinical advisor, Information scientist, Research fellow, Project manager, Health economist.</td>
</tr>
<tr>
<td>Guideline Development Group (GDG)</td>
<td>The GDG met monthly for 13 months (2004 to 2006) and comprised a multidisciplinary team of professionals, service users (a person with PD), carers, and user organisation representatives who were supported by the Technical Team. The GDG membership details including patient representation and professional groups are detailed in the GDG Membership table at the front of the guideline.</td>
</tr>
<tr>
<td>Guideline Project Executive (PE)</td>
<td>The PE was involved in overseeing all phases of the guideline. It also reviewed the quality of the guideline and compliance with the Department of Health remit and NICE scope. The PE comprised: NCC-CC Director, NCC-CC Manager, NCC-CC Senior Research Fellow, NICE Commissioning Manager.</td>
</tr>
<tr>
<td>Sign-off workshop</td>
<td>At the end of the guideline development process the GDG met to review and agree all the guideline recommendations.</td>
</tr>
</tbody>
</table>

Members of the GDG declared any interests in accordance with the NICE technical manual. A register is available from the NCC-CC: ncc-cc@cuplondon.ac.uk

The basic steps in the process of producing a guideline are:
- developing clinical evidence-based questions
- systematically searching for the evidence
- critically appraising the evidence
- incorporating health economics advice
- distilling and synthesising the evidence and writing recommendations
- grading the evidence statements and recommendations
Parkinson's disease Appendix H: Deleted Text Appendix

agreeing the recommendations
structuring and writing the guideline
updating the guideline.
Parkinson's disease Appendix H: Deleted Text Appendix

Parkinson's disease

Developing evidence-based questions

The Technical Team drafted a series of clinical questions that covered the guideline scope. The GDG and Project Executive refined and approved these questions, which are shown in Appendix B.

Searching for the evidence

The information scientist developed a search strategy for each clinical question. In addition, the health economist searched for supplemental papers to inform models. Key words for the search were identified by the GDG. Papers that were published or accepted for publication in peer-reviewed journals were considered as evidence by the GDG. Conference paper abstracts and non-English language papers were excluded from all searches.

Each clinical question dictated the appropriate study design that was prioritised in the search strategy, but the strategy was not limited solely to these study types. The research fellow or health economist identified titles and abstracts from the search results that appeared to be relevant to the question. Exclusion lists were generated for each question together with the rationale for the exclusion. The exclusion lists were presented to the GDG. Full papers were obtained where relevant. Literature search details are shown in Appendix B.

Appraising the evidence

The research fellow or health economist, as appropriate, critically appraised the full papers. In general no formal contact was made with authors; however, there were ad hoc occasions when this was required in order to clarify specific details. Critical appraisal checklists were compiled for each full paper. One research fellow undertook the critical appraisal and data extraction. The evidence was considered carefully by the GDG for accuracy and completeness.

All procedures are fully compliant with the:

NICE methodology as detailed in Guideline development methods – information for National Collaborating Centres and guideline developers' manual

NCC-CC quality assurance document and systematic review chart, available at www.rcplondon.ac.uk/college/ceeu/nccce_index.htm.
Incorporating health economics advice

Due to the appointment of the health economist midway through the guideline development, the areas for health economic evidence were considered after the formation of the clinical questions. The health economist reviewed the clinical questions to consider the potential application of health economic evidence. Five key areas were separately identified by the clinical lead.

After agreement and selection of specific areas, the information scientist performed a literature search using economic filters on the related clinical questions. No study design criteria were imposed a priori. The searches were not limited to randomised controlled trials (RCTs) or formal economic evaluations. See the earlier section on ‘Searching for the evidence’ for details of the systematic search by the information scientist. The health economist reviewed titles and abstracts identified in the economic searches, and full papers were obtained as appropriate. The
health economist critically appraised the full papers and the relevant data were presented to the GDG at subsequent GDG meetings. See the previous section for information on critically appraising the evidence.

The health economist performed supplemental literature searches using key search terms in the York Centre for Review and Dissemination database, the NHS Economic Evaluation database, PubMed and the Google search engine to obtain additional information for modelling. Areas were modelled due to the limited amount of evidence in or relevance to the UK setting. Assumptions and designs of the models were explained and agreed by the GDG members during meetings and validated by an additional health economist.

Distilling and synthesising the evidence and writing recommendations

The evidence from each full paper was distilled into an evidence table and synthesised into evidence statements before being presented to the GDG. This evidence was then reviewed by the GDG and used as a basis upon which to formulate recommendations.

Evidence tables are available at:
www.cemlondon.ac.uk/pubs/online_home.htm

Agreeing the recommendations

The sign-off workshop employed formal consensus techniques to:

- ensure that the recommendations reflected the evidence base
- approve recommendations based on lesser evidence or extrapolations from other situations
- reach consensus recommendations where the evidence was inadequate
- debate areas of disagreement and finalise recommendations.

The sign-off workshop also reached agreement on the following:

- five to ten key priorities for implementation
- five key research recommendations
- algorithms.
In prioritising key recommendations for implementation, the sign-off workshop also took into account the following criteria:

- high clinical impact
- high impact on reducing variation
- more efficient use of NHS resources
- allowing the patient to reach critical points in the care pathway more quickly.

The audit criteria provide suggestions of areas for audit in line with the key recommendations for implementation.²

### Structuring and writing the guideline

The guideline is divided into sections for ease of reading. For each section the layout is similar and is described below.
Parkinson’s disease Appendix H: Deleted Text Appendix

### Table 2.2 Grading the evidence statements and recommendations

<table>
<thead>
<tr>
<th>Levels of evidence</th>
<th>Classification of recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Level</strong></td>
<td><strong>Type of evidence</strong></td>
</tr>
<tr>
<td>1++</td>
<td>High-quality meta-analysis (MA), systematic reviews (SR) of randomised controlled trials (RCTs), or RCTs with a very low risk of bias</td>
</tr>
<tr>
<td>1+</td>
<td>Well-conducted MA, SR or RCTs, or RCTs with a low risk of bias</td>
</tr>
<tr>
<td>1-</td>
<td>MA, SR of RCTs, or RCTs with a high risk of bias</td>
</tr>
<tr>
<td>2++</td>
<td>High-quality SR of case-control or cohort studies</td>
</tr>
<tr>
<td>2+</td>
<td>Well-conducted case-control or cohort studies with a low risk of confounding, bias or chance and a high probability that the relationship is causal</td>
</tr>
<tr>
<td>2-</td>
<td>Case-control or cohort studies with a high risk of confounding, bias or chance and a significant risk that the relationship is not causal</td>
</tr>
<tr>
<td>3</td>
<td>Non-analytic studies (for example case reports, case series)</td>
</tr>
<tr>
<td>4</td>
<td>Expert opinion, formal consensus</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>D</td>
<td>A good practice point (GPP) is a recommendation based on the experience of the GDG</td>
</tr>
</tbody>
</table>

Diagnostic study level of evidence and classification of recommendation was also included.1
Clinical introduction: sets a succinct background and describes the clinical context.
Methodological introduction: describes any issues or limitations that were apparent when reading the evidence base.
Evidence statements: provide a synthesis of the evidence base and usually describe what the evidence showed in relation to the outcomes of interest.
Health economics: presents, where appropriate, an overview of the cost-effectiveness evidence-base.
From evidence to recommendation: sets out the GDG decision-making rationale and provides a clear and explicit audit trail from the evidence to the evolution of the recommendations.
Recommendations: provides stand-alone, action-oriented recommendations.

Evidence tables

The evidence tables are not published as part of the full guideline but are available online at www.rcplondon.ac.uk/pubs/books/pd. These describe comprehensive details of the primary evidence that was considered during the writing of each section.

Writing the guideline

The first draft version of the guideline was drawn up by the Technical Team in accord with the decision of the GDG. The guideline was then submitted for two formal rounds of public and stakeholder consultation prior to publication.1,13 The registered stakeholders for this guideline are detailed in Appendix I. Editorial responsibility for the full guideline rests with the GDG.

<table>
<thead>
<tr>
<th>Table 2.3 Versions of this guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full version</td>
</tr>
<tr>
<td>NICE version</td>
</tr>
<tr>
<td>Information for the public</td>
</tr>
</tbody>
</table>
Updating the guideline

Literature searches were repeated for all of the evidence-based questions at the end of the GDG development process, allowing any relevant papers published up until February 2005 to be considered. Future guideline updates will consider evidence published after this cut-off date.

Two years after publication of the guideline, NICE will commission a National Collaborating Centre to determine whether the evidence base has progressed sufficiently to alter the guideline recommendations and warrant an early update. If not, the guideline will be updated approximately 4 years after publication.1,13
2.8 Disclaimer

Healthcare providers need to use clinical judgement, knowledge and expertise when deciding whether it is appropriate to apply guidelines. The recommendations cited here are a guide and may not be appropriate for use in all situations. The decision to adopt any of the recommendations cited here must be made by the practitioner in light of individual patient circumstances, the wishes of the patient, clinical expertise and resources.

The NCC-CC disclaims any responsibility for damages arising out of the use or non-use of these guidelines and the literature used in support of these guidelines.

2.9 Funding

The National Collaborating Centre for Chronic Conditions was commissioned by the National Institute for Health and Clinical Excellence to undertake the work on this guideline.
Parkinson's disease Appendix H: Deleted Text Appendix
THE GUIDELINE
3 Key messages

In this chapter three essential components of the guideline will be discussed:
key recommendations for implementation
  audit criteria
algorithm.

Recommendations for implementation consist of recommendations selected by the GDG that highlight the main areas likely to have the most significant impact on patient care and patient outcomes in the NHS as a whole.\textsuperscript{1,13}

Audit criteria are explicit statements developed from the recommendations for implementation, used to define the structure of care, process or outcome that is to be measured.\textsuperscript{1,13}

The algorithm is a flowchart of the clinical decision pathway described in the clinical chapters.\textsuperscript{1,13}

Another important section of the guideline is Chapter 12, 'Research recommendations'. This chapter discusses the GDG selected, priority areas for future PD research. Specific research questions are stated, the proposed trial structure is described and an explanatory paragraph is provided. General research recommendations are also included in this chapter.

3.1 Key priorities for implementation

\begin{itemize}
\item Referral to expert for accurate diagnosis
\end{itemize}

People with suspected PD should be referred quickly\textsuperscript{9} and untreated to a specialist with expertise in the differential diagnosis of this condition.

\begin{itemize}
\item Diagnosis and expert review
\end{itemize}
Parkinson's disease Appendix H: Deleted Text Appendix

The diagnosis of PD should be reviewed regularly** and reconsidered if atypical clinical features develop.

Acute levodopa and apomorphine challenge tests should not be used in the differential diagnosis of parkinsonian syndromes.

Regular access to specialist nursing care

People with PD should have regular access to the following:
   clinical monitoring and medication adjustment
   a continuing point of contact for support, including home visits, when appropriate

*The GDG considered that people with suspected mild PD should be seen within 6 weeks but new referrals in later disease with more complex problems require an appointment within 2 weeks.

**The GDG considered that people diagnosed with PD should be seen at regular intervals of 6 to 12 months to review their diagnosis.
a reliable source of information about clinical and social matters of concern to people with PD and their carers,

which may be provided by a Parkinson's disease nurse specialist (PDNS).

Access to physiotherapy

Physiotherapy should be available for people with PD. Particular consideration should be given to:
- gait re-education, improvement of balance and flexibility
- enhancement of aerobic capacity
- improvement of movement initiation
- improvement of functional independence, including mobility and activities of daily living
- provision of advice regarding safety in the home environment.

Access to occupational therapy

Occupational therapy should be available for people with PD. Particular consideration should be given to:
- maintenance of work and family roles, employment, home care and leisure activities
- improvement and maintenance of transfers and mobility
- improvement of personal self-care activities such as eating, drinking, washing and dressing
- environmental issues to improve safety and motor function
- cognitive assessment and appropriate intervention.

Access to speech and language therapy

Speech and language therapy should be available for people with PD. Particular consideration should be given to:
Palliative care

Palliative care requirements of people with PD should be considered throughout all phases of the disease.

People with PD and their carers should be given the opportunity to discuss end-of-life issues with appropriate healthcare professionals.
3.2 Audit criteria

The audit criteria shown in Table 3.1 are linked to the key priorities for implementation (see previous section). These are intended to be suggestions to aid and monitor the implementation of this guideline at the level of an NHS trust or similar scale healthcare provider.

<table>
<thead>
<tr>
<th>Table 3.1 Audit criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendation</strong></td>
</tr>
<tr>
<td>Referral to expert for accurate diagnosis</td>
</tr>
<tr>
<td>Diagnosis and expert review</td>
</tr>
<tr>
<td>Acute levodopa and apomorphine challenge tests should not be used in the differential diagnosis of parkinsonian syndromes.</td>
</tr>
<tr>
<td>Regular access to specialist nursing care</td>
</tr>
</tbody>
</table>

**Access to physiotherapy**
<table>
<thead>
<tr>
<th>Physiotherapy should be available for people with PD. Particular consideration should be given to:</th>
<th>For 100% of people with PD, at diagnosis and each regular review, physiotherapy is available and appropriate referral is activated. This is recorded in the patient’s notes.</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>- gait re-education, improvement of balance and flexibility</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- enhancement of aerobic capacity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- improvement of movement initiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- improvement of functional independence, including mobility and reduction of falls</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Parkinson’s disease Appendix H: Deleted Text Appendix
<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Audit criterion</th>
<th>Exceptions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Access to occupational therapy</td>
<td>For 100% of people with PD, at diagnosis and each regular review, OT is available and appropriate referral is activated. This is recorded in the patient’s notes.</td>
<td>None</td>
</tr>
<tr>
<td>Access to speech and language therapy</td>
<td>For 100% of people with PD, at diagnosis and each regular review, speech and language therapy is available and appropriate referral is activated. This is recorded in the patient’s notes.</td>
<td>None</td>
</tr>
<tr>
<td>Palliative care</td>
<td>100% of people with PD should be given opportunities to discuss and ask questions about their palliative care requirements with appropriate healthcare professionals.</td>
<td>None</td>
</tr>
</tbody>
</table>
Parkinson's disease Appendix H: Deleted Text

3 Key messages: Commented [SMS]: Do we wish to develop a new algorithm?
3.3 Parkinson's disease algorithm

**Disease progression**

**Interventions**

- **Disease progression**
  - Diagnosis and early disease:
    - Refer untreated to a specialist who makes and reviews diagnosis.
    - Use UK Parkinson's Disease Brain Bank Criteria.
    - Consider 17% FP-CIT SPECT.
    - Specialist should review diagnosis at regular intervals (6-12 months).

- **Throughout disease**
  - Consider management of non-motor symptoms in particular:
    - Depression
    - Psychosis
    - Sleep disturbance

- **Later disease**
  - It is not possible to identify a universal first choice drug therapy for people with later PD. The choice of drug prescribed should take into account clinical and lifestyle characteristics patient preference.
  - Provide regular access to specialist care.
  - Consider aripiprazole for clinical monitoring and medication adjustment.
  - Consider apomorphine in people with severe motor complications unresponsive to oral medication:
    - Intermittent injections to reduce off time.
    - Continuous subcutaneous infusion to reduce off time and dyskinesias.
  - Consider surgery: deep brain stimulation for suitable people refractory to best medical therapy.

- **Communication**
  - Reach collaborative care decisions by taking into account: patient preferences and choices after provision of information clinical characteristics, patient lifestyle and interventions available.
  - Provide communication and information about:
    - PD services and entitlements.
    - Falls, palliative care and end of life issues.

**Figure 3.1 Parkinson's disease algorithm: interventions for people with PD.**
7 Symptomatic pharmacological therapy in Parkinson’s disease

7.1 Introduction

Symptomatic therapies for PD treat the symptoms of the disease but do not necessarily slow the rate of progression of the condition. In this guideline the symptomatic pharmacological therapies have been classified on the basis of the clinical manifestations of a person with PD. Thus:

Early disease has been used to refer to people with PD who have developed functional disability and require symptomatic therapy.

Later disease has been used to refer to people on levodopa who have developed motor complications.

Clinical trials and regulatory authorities define the term ‘later disease’ in the same way. However, since motor complications can occur soon after starting levodopa, particularly if large doses are used, ‘later disease’ is something of a misnomer. The term is generally preferred to the alternative ‘advanced disease’.

7.1.1 Methodological limitations of symptomatic therapy studies

When reviewing the symptomatic therapy evidence, the following methodological issues should be considered:

- trial duration is often too short

- drug regimen variations between trials (type of drug, dose, frequency)

- small sample size which limits generalisability and sensitivity of tests to detect outcome differences between groups

- lack of reporting methods of randomisation and allocation concealment

- lack of washout periods between treatment arms in crossover studies

- lack of reporting results of first arm from crossover studies, which leads to risk of carry-over effect
lack of intention-to-treat analyses

lack of defining the clinical criteria for diagnosis
clinical versus statistical significance
over-representation of younger patients limiting generalisability.

Most of the poorly designed trials were performed in the 1970s and 1980s when trial design was in its infancy. Drugs evaluated in such trials may not have been found to be efficacious in this review. However, this does not mean that they are ineffective. In such cases, clinical experience may be the only appropriate judge of efficacy and safety.

The Cochrane reviews included in this chapter have received a 1++ grading for the methodology of the systematic review as applied by the Cochrane group, but this grading does not apply to the trials contained within these reviews. Although the methodologies of the systematic reviews were of good quality, the trials contained within the reviews sometimes suffered from
methodological limitations. The results of these trials should be treated with caution due to the inherent methodological limitations. In light of this, it was felt to be inappropriate to present evidence statements based on the individual trial data.

Efficacy outcome measures in later disease trials are considerably different from those in early disease. The people with PD in such trials have already developed motor complications and the aim of adjuvant therapy is to reduce the time the person with PD spends 'off' and to reduce the dose of levodopa, which has played some part in the generation of the complications in the first place. 'Off' time is measured from patient-completed 30 minute epoch 'on/off' diary cards, which are usually averaged over a 3-day period. Levodopa dose is recorded throughout the trial. Usually the UPDRS scale components are also noted during later disease trials.

7.2 Early pharmacological therapy

7.2.1 Introduction

It was evident from reviewing the evidence-base that there is no single drug of choice in the initial pharmacotherapy of early PD. Table 7.1 may help to guide the reader through the following section.

<table>
<thead>
<tr>
<th>Table 7.1 Options for initial pharmacotherapy in early PD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>Levodopa</td>
</tr>
<tr>
<td>Dopamine agonists</td>
</tr>
<tr>
<td>MAO-B inhibitors</td>
</tr>
<tr>
<td>Anticholinergics</td>
</tr>
<tr>
<td>Beta-blockers</td>
</tr>
<tr>
<td>Amantadine</td>
</tr>
</tbody>
</table>
7.2.2 Levodopa

The standard symptomatic therapy for PD for more than 30 years has been levodopa. This is the precursor of dopamine which is deficient in PD. Levodopa is readily converted into dopamine by dopa decarboxylase. To reduce peripheral metabolism of levodopa, it is combined with a peripheral dopa decarboxylase inhibitor (i.e. carbidopa or benserazide). This increases the amount of levodopa that crosses the blood-brain barrier.
However, levodopa preparations contribute to the development of motor complications in PD. These comprise abnormal involuntary movements or dyskinesias, such as athetosis and dystonia, along with response fluctuations in which people experience ‘wearing off’ of the drug’s effects and/or unpredictable switching between the ‘on’ and the ‘off’ state.

To avoid motor complications, the strategy of delaying the introduction of levodopa has developed. Most people with PD who commence therapy with another drug will eventually need levodopa therapy. This approach requires initial therapy with an alternative that is as effective as levodopa that does not cause motor complications. A number of drug classes have been examined for such properties.

Methodology

Only one RCT\(^2\) (ELLDOPA) was found which addressed the effectiveness of levodopa (plus a decarboxylase inhibitor) compared with placebo. The other trials found included studies on levodopa monotherapy compared with placebo and were published between 1969 and 1971. These were not reviewed, as levodopa is no longer used without a decarboxylase inhibitor.

The RCT\(^2\) was a large multi-centre study including 361 early PD people randomly assigned to four groups, consisting of three different doses of levodopa/carbidopa (150/37.5 mg/day, 300/75 mg/day or 600/150 mg/day) or placebo.

All people included in the trial had received a diagnosis of PD within the last 2 years and no one was on any anti-parkinsonian medication at the time of enrolment. The trial duration was 40 weeks, which was followed by a 2-week withdrawal period at the end of the trial.

There were two primary outcome measures: clinical assessment using UPDRS and measurement of the dopamine transporter with \(^{123}\)I- \(\text{CIT SPECT}\).

Evidence statements

With respect to clinical rating scales\(^2\)

Levodopa in a dose-dependent pattern reduced the worsening of symptoms of PD.

Changes in UPDRS scores from baseline to week 42 (versus placebo) were:
Parkinson's disease Appendix H: Deleted Text Appendix

- total score (p<0.001)
- ADL component (p<0.001)
- motor component (p<0.01)
- mental component (non-significant).

The UPDRS scores in the three levodopa groups worsened during the 2-week washout period but did not deteriorate to placebo levels.

The group receiving the highest dose of levodopa had the largest improvement in UPDRS. (1++)

With respect to $^{123}$I- -CIT (neuroimaging) outcomes.$^{62}$

The percentage decrease in striatal $^{123}$I- -CIT uptake over 40 weeks was greater among participants in the levodopa than the placebo group and, although this was non-significant, 15% of people had a putaminal uptake of more than 75% of that of age-matched controls.
Analysis of the results after exclusion of the 19 people without dopaminergic deficit on imaging showed a significantly greater decrease in uptake among those receiving levodopa than those receiving placebo (p=0.036). (I++)

With respect to adverse events.62

Side effects were more common in the 600 mg group than with placebo for dyskinesias (p<0.001), nausea (p=0.001), infection (p=0.01), hypertonia (p=0.03), and headache (p=0.03).

Other findings were non-significant between other levodopa doses and placebo. (I++)

With respect to withdrawal rates.62

Of the total of 361 participants enrolled, 317 (88%) took the study medication for 40 weeks and 311 (86%) completed the 2 weeks of washout.

The percentage of dropouts per group included: placebo (22%), 150 mg/d (15%), 300 mg/d (6%) and 600 mg/d (11%).

The main reasons for withdrawal were worsening of symptoms and adverse events. (I++)

From evidence to recommendations

The clinical impression that levodopa is a most effective treatment for PD has been confirmed in the large ELLDOPA trial. Short-term dopaminergic adverse effects are infrequent and usually settle with time. However, long-term levodopa therapy precipitates motor complications such as dyskinesias and motor fluctuations. Questions remain regarding the possibility that levodopa may be toxic or even protective to the remaining nigrostriatal dopaminergic neurones. Further work is required to clarify this issue.

RECOMMENDATIONS

R26 Levodopa may be used as a symptomatic treatment for people with early PD. A

R27 The dose of levodopa should be kept as low as possible to maintain good function in
7.2.3 Dopamine agonists

The dopamine receptor agonists mimic the effect of dopamine by binding directly with the post-synaptic dopamine receptors. They were introduced as adjuvant therapy to levodopa in later disease, but, more recently, trials have examined their effects as initial monotherapy in the hope that they may delay the onset of motor complications.

What is the effectiveness of dopamine agonists compared with placebo in the treatment of functionally disabled early PD?

≈ Methodology

Six randomised controlled trials\textsuperscript{122-127} were found which compared the effectiveness of dopamine agonists with placebo for the treatment of people with early PD who are functionally disabled. The sample size for most of these studies was quite large (range N=55–335, mean 177).
Evidence statements

The following outcomes were reported to be significantly in favour of dopamine agonists:
- UPDRS total score122,123
- UPDRS motor score122,124–127
- UPDRS > 30% reduction in motor scores122,124,127
- UPDRS ADL scores122,125,126
- Schwab and England ADL scores122
- CGI ‘very much improved’ score122,124,127
- requirement of levodopa supplementation124
- withdrawal rates124 (1+)

The following adverse events were found to be significantly increased (p<0.05) in the treatment group:
- nausea122,125,127
- somnolence122,125,127
- dizziness122,127
- insomnia, constipation, hallucinations125
- anorexia, vomiting122 (1+)

The following outcomes were reported as non-significant:
- incidence of reporting adverse events122–127
- incidence of withdrawals122,127 (1+)

From evidence to recommendation

Dopamine agonists are an effective treatment for the motor features of early PD. However, agonists generate significant dopaminergic adverse events. The latter do not lead to drug withdrawal, which suggests that they are mild and that tolerance develops. These conclusions apply to the relatively young people included in these studies. Further work on the efficacy and safety of dopamine agonists in older people is required.
Parkinson’s disease Appendix H: Deleted Text Appendix

Ergot-derived dopamine agonists (bromocriptine, cabergoline, lisuride and pergolide) are well known to cause rare serosal reactions such as pleural, pericardial and peritoneal effusion and/or fibrosis.\textsuperscript{128} Recently, two echocardiographic series have suggested that pergolide can also cause a cardiac valvulopathy.\textsuperscript{129,130} As a result of these reports, the pergolide Summary of Product Characteristics has been changed to include the following.

Pergolide is to be used as second line after a non-ergot dopamine agonist.

The dose of pergolide should not exceed 5 mg per day.

An echocardiogram must be obtained before initiating therapy and should be repeated regularly thereafter to monitor for valvulopathy.

Pergolide is contraindicated in anyone with anatomical evidence of cardiac valvulopathy.

Reports of serosal reactions with non-ergot dopamine agonists (pramipexole and ropinirole) are few and these are possibly due to previous exposure to ergot-derived agonists. However, the patient-years of exposure to these newer agonists is low, so firm conclusions cannot be reached.
RECOMMENDATIONS

R28 Dopamine agonists may be used as a symptomatic treatment for people with early PD. A

R29 A dopamine agonist should be titrated to a clinically efficacious dose. If side effects prevent this, another agonist or a drug from another class should be used in its place. D (GPP)

R30 If an ergot-derived dopamine agonist is used, the patient should have a minimum of renal function tests, erythrocyte sedimentation rate (ESR) and chest radiograph performed before starting treatment, and annually thereafter.* D (GPP)

R31 In view of the monitoring required with ergot-derived dopamine agonists, a non-ergot-derived agonist should be preferred in most cases. D (GPP)

7.2.4 Monoamine oxidase type B inhibitors

MAOB inhibitors block the metabolism of dopamine, thereby increasing its level in the striatum. MAOB inhibitors do not cause a reaction after consumption of tyramine-rich foods ('tyramine' or 'cheese' effect) and are therefore safer to use than non-selective inhibitors.

MAOB inhibitors were introduced as a symptomatic therapy in later PD. After encouraging pre-clinical and one retrospective clinical trial, they were used for a time in early PD in the hope that they might have a neuroprotective effect in addition to a symptomatic effect (see Chapter 6).

What is the evidence that MAOB inhibitors are an effective and safe symptomatic treatment in early PD?

Methodology

Two meta-analyses and two RCTs which addressed the effectiveness of MAOB inhibitors in treating people with early PD were included.

One meta-analysis included 3,525 people with PD from 17 randomised trials; 13 trials were
Parkinson’s disease Appendix H: Deleted Text Appendix

on selegiline, three trials were on lazabemide and one trial was on rasagiline therapy. Although only selegiline and rasagiline are licensed for use in the UK, the results of the lazabemide studies were consistent with the results of the other two therapies. Thus, the meta-analysis, which combined the results of all MAOB inhibitor trials, was included in the evidence base. All of the selegiline trials used the standard oral preparation rather than the lyophilised buccal preparation selegiline (Zelapar®). The other meta-analysis131 was a Cochrane review with a similar authorship. This included 2,422 people with PD from 10 trials where treatment duration or follow-up was 1 year or longer. Nine trials were on selegiline and one was on lazabemide. Several trials were included in both meta-analyses.

One RCT133 consisted of 15 people with PD. The small sample size could explain the non-significant results, when compared with the large meta-analysis. The other RCT132 consisted of 56 people with PD, divided into three rasagiline dose groups (1, 2 or 4 mg/d) and a placebo group. The authors of this study reported that the trial was inadequately powered for assessing anti-parkinsonian efficacy of the study drug.

*Full details of the restrictions on pergolide use and monitoring are available in the Summary of Product Characteristics.
Evidence statements

The large DATATOP study accounted for over 65% of the people with PD analysed for UPDRS scores and over 79% of people with PD in the MAOB inhibitor versus placebo comparison. The combined results from the other two studies of MAOB inhibitor compared with placebo were consistent with those from DATATOP and were significant independently (p=0.004).120 (I++)

With respect to clinical rating scales, one meta-analysis120 reported:

UPDRS scores at 3 months from six trials (all used selegiline for MAOB inhibitor intervention) were:
- total score: treatment difference 2.7 (95% CI 1.4 to 4.1, p=0.00009)
- motor score: treatment difference 1.8 (95% CI 0.8 to 2.7, p=0.0004)
- ADL score: treatment difference 0.9 (95% CI 0.5 to 1.4, p=0.00007).

All of the above quoted outcomes favoured selegiline over controls.

The Cochrane review121 also found that MAOB inhibitors significantly improved these UPDRS scores. (I++)

The randomised crossover trial133 reported no significant differences on the Webster rating scale (total scores) for people with PD on co-beneldopa/selegiline compared with people with PD on co-beneldopa/placebo. (I++)

The other RCT132 reported:

Total UPDRS score during 10-week period (p<0.05) for rasagiline 2 mg but not for 1 mg and 4 mg groups compared with placebo.

A responder analysis showed that 28% of people (12/43) receiving rasagiline had an improvement in total UPDRS score of more than 30%, compared with none of the people receiving placebo (p<0.05).

No evidence of drug effect was noted with respect to the Clinician’s Global Impression of Change (CGIC) scale, Hoehn and Yahr stage, Schwab and England ADL scale, or BDI. (I++)

With respect to need for levodopa therapy, the meta-analysis120 found the following:

Eight trials reported data on the need for levodopa (MAOB inhibitor versus placebo). The combination of these trial results showed a highly significant reduction in need for levodopa in people with PD randomised to a MAOB inhibitor compared with placebo.
The Cochrane review\textsuperscript{121} found a similar significant reduction in the requirement for levodopa, although it was noted that all patients were receiving levodopa after 4 years of follow-up. (I++)

With respect to motor complications, one meta-analysis\textsuperscript{120} found five trials. The combined results showed:

- 25\% reduction in motor fluctuations in MAOB inhibitor group, treatment difference 0.75 (95\% CI 0.59 to 0.95, p=0.02)
- No significant difference in the incidence of dyskinesia between treatment groups compared with non-MAOB inhibitor group.

The Cochrane review\textsuperscript{121} found very similar results. However, with regard to motor fluctuations, they found that the result was dependent on the adjusted results of one study (the UK-PDRG study) and if the unadjusted figures were used the overall result became insignificant. Additionally,
results were not reported for a number of patients in these studies and a modified worst-case sensitivity analysis also made the results non-significant. (1++)

The meta-analysis\textsuperscript{120} found more side effects were reported in people with PD randomised to an MAOB inhibitor, treatment difference 1.36 (95% CI 1.02 to 1.80, p=0.04).

The Cochrane review\textsuperscript{121} also found more adverse events with MAOB inhibitors; however, this was not a statistically significant difference. (1++)

The RCTs\textsuperscript{122,123} found minimal or no side effects reported in either treatment group. (1++)

One meta-analysis\textsuperscript{120} found more people in the MAOB inhibitor group withdrew due to adverse events than in the non-MAOB inhibitor group; treatment difference 2.16 (95% CI 1.44 to 3.23, p=0.0002). Similarly, the Cochrane review found significantly more withdrawals with MAOB inhibitors.\textsuperscript{121} (1++)

One meta-analysis\textsuperscript{120} found more deaths occurred in the MAOB inhibitor patients compared with controls but this was not a significant difference, while the Cochrane review\textsuperscript{121} found a non-significant increase in deaths among patients treated with MAOB inhibitors compared with controls. (1++)

\section*{From evidence to recommendation}

The trial evidence supports the ability of MAOB inhibitors in PD to improve motor symptoms, improve activities of daily living and delay the need for levodopa. The evidence on them delaying motor complications is unclear. This is at the expense of more dopaminergic adverse events and, as a result, more withdrawals from treatment. There was no conclusive evidence of any increase in mortality on selegiline.

It is not possible from the evidence available to decide whether the lack of amphetamine metabolites with rasagiline confers any clinical benefit compared with selegiline.

\section*{RECOMMENDATION}
R32 MAOB inhibitors may be used as a symptomatic treatment for people with early PD.

7.2.5 Beta-adrenergic antagonists (beta-blockers)

Beta-adrenergic antagonists (e.g., propranolol and oxprenolol) are well established in the treatment of the tremor seen in essential tremor and thyrotoxicosis.

Are beta-adrenergic antagonists effective in reducing the symptoms of PD?

Methodology

A Cochrane systematic review included four randomised controlled trials. Only 72 people with PD were included in these studies. All trials were randomised double-blind crossover studies.
Three of the crossover trials\textsuperscript{135,136,137} in the systematic review did not present data from the end of the first arms. Since there is a carry-over risk, the systematic review did not analyse the data from these trials. One trial did report data from the first arm\textsuperscript{138} however, the trial did not state baseline scores, numbers of patients in each group, or standard deviations.

Evidence statements

The systematic review was methodologically sound and hence it could technically be given a grading of 1+/1+. However, the methodological limitations of individual studies contained within the review meant that there were insufficient robust data from which to derive evidence statements.

The only evidence reported by the review was from a single trial\textsuperscript{138} which found no significant difference between oxprenolol and placebo in mean total score for tremor.

Details of the data analysis were not given so it was not possible for the systematic review to determine whether the non-significance was based on comparison between the first and second arms (which could have been affected by a possible crossover effect) or between the therapy and placebo groups at the end of each arm.

From evidence to recommendation

There is insufficient trial evidence for the efficacy or safety of beta-adrenergic antagonists in PD. However, the GDG felt that for selected people with PD with postural tremor they could be useful and safe.

**RECOMMENDATION**

**R33**  
Beta-adrenergic antagonists may be used in the symptomatic treatment of selected people with postural tremor in PD, but should not be drugs of first choice.  

D (GPP)
7.2.6 Amantadine

Amantadine was initially investigated as an anti-viral agent but found to be effective in PD by chance. The mechanism(s) of action of amantadine in PD are unclear.

What evidence is there to support the use of amantadine in early PD?

Methodology

A Cochrane systematic review\textsuperscript{139} was found which compared the effectiveness of amantadine versus placebo or levodopa in the treatment of people with early PD who are functionally disabled. The review included six studies, with a total sample size of 215 people with PD.

An additional randomised crossover trial\textsuperscript{140} was found but excluded due to the following methodological limitations: methods of randomisation and allocation concealment not stated, limited patient characteristics given, no intention-to-treat analysis, and no power calculations provided for the small sample size (N=29).
Parkinson’s disease Appendix H: Deleted Text Appendix

Parkinson’s disease

Due to inadequate reporting of trial data, only two of the six trials within the systematic review had results that could be examined. However, in these two trials\textsuperscript{141,142} only data for the trials’ ‘means’ were given and thus no statistical analysis of the significance of the changes due to amantadine could be undertaken.

\subsection*{Evidence statements}

The systematic review was methodologically sound and hence it could technically be given a grading of 1+/1+. However, the methodological limitations of individual studies contained within the review meant that there were insufficient robust data from which to derive evidence statements.

\subsection*{From evidence to recommendation}

There are limited trial data to document the efficacy and safety of amantadine in early PD. This can be explained by its development in the 1970s, when trial design was in its infancy. The GDG concluded that, while amantadine should be available for the treatment of mild PD symptoms, other drug classes (ie levodopa, dopamine agonists) are more appropriate treatments for the early stages of the disease.

\section*{RECOMMENDATION}

R34 Amantadine may be used as a treatment for people with early PD but should not be a drug of first choice. \hspace{1cm} \textbf{D (GPP)}

\subsection*{7.2.7 Anticholinergics}

Anticholinergics have been used to treat PD for over 100 years. They were introduced in the late 19th century after Charcot’s work with hyoscine (scopolamine). In the mid-20th century, the selective centrally active muscarinic receptor antagonists were developed which had fewer peripheral side effects. These agents proliferated in the absence of more effective pharmacotherapy, but the most commonly used for PD are trihexyphenidyl (benzhexol) and orphenadrine.
What is the evidence that selective muscarinic antagonists are effective and safe treatments for PD?

Methodology

A Cochrane review\textsuperscript{143} and an additional RCT\textsuperscript{144} were found which addressed the effectiveness of anticholinergics in early PD.

One study\textsuperscript{145} was excluded on the basis that the methodology did not constitute a randomised design between anticholinergic and levodopa treatment groups.

The Cochrane review included nine double-blind randomised crossover trials, with a total of 221 people. All of the trials compared the effectiveness of anticholinergics with placebo or no treatment. The RCT\textsuperscript{144} was a single-blind study with a total of 82 people randomised to three groups: anticholinergics, levodopa and bromocriptine.
The Cochrane review authors highlighted that the outcome measures varied widely among the trials and the scales used to measure effectiveness were either the authors' own or no longer in current clinical use. The numerous methodological issues associated with these trials included: rating scales not being defined in detail, incomplete reporting of methodology and results, and heterogeneous study designs which precluded any analysis of the results.

Evidence statements

The RCT\textsuperscript{144} showed that the three anti-parkinsonian medications (anticholinergics, bromocriptine and levodopa) did not have qualitatively different effects upon various parkinsonian symptoms. The authors suggested that this may have been due to low level of disease severity. (1+)

The systematic review was methodologically sound and hence it could technically be given a grading of 1++/1+. However, the methodological limitations of individual studies contained within the review meant that there were insufficient robust data from which to derive evidence statements.

The authors of the review conclude that as monotherapy or as an adjunct to other anti-parkinsonian drugs, anticholinergics are more effective than placebo in improving motor function in PD in short-term use.

From evidence to recommendation

There are insufficient data from RCTs on the efficacy and safety of anticholinergics in PD. This is particularly true of the claimed efficacy of this class in the treatment of tremor. However, the GDG concluded that anticholinergics should be available for the treatment of mild parkinsonian symptoms in people with no cognitive dysfunction. Their use should be regularly reviewed, but withdrawal can be difficult due to the re-emergence of motor impairments.

RECOMMENDATION

\textbf{R35} Anticholinergics may be used as a symptomatic treatment typically in young people with early PD and severe tremor, but should not be drugs of first choice due to limited
7.3 Comparisons of drug classes

While proving the efficacy and safety of a drug class in placebo-controlled trials is important, particularly from the regulatory point of view, clinicians are keen to know how each class compares with others so that evidence-based treatment recommendations can be made for individual people. Such active comparator trials are rare in PD.

Recommendations will be presented at the end of this section for all drug comparisons.
7.3.1 Modified-release compared with immediate-release levodopa

It has been suggested that levodopa induces motor complications because of its short duration of action and thus the pulsatile stimulation of dopamine receptors. To avoid this, modified-or slow-release formulations of levodopa were developed.

What is the evidence that modified-release levodopa preparations delay the onset of motor complications?

\[ \text{Methodology} \]

Four studies\textsuperscript{146-149} were found which addressed the effectiveness of modified-release levodopa compared with immediate-release levodopa in the treatment of early PD.

One study\textsuperscript{146} was excluded due to lack of important information on drug dosages, randomisation methods, method of outcomes measurement and clinical criteria for the patient group. Another study was excluded as it was an open-trial design and therefore had increased potential for bias.\textsuperscript{148}

One of the two included studies\textsuperscript{147} examined the efficacy of immediate-release co-beneldopa (Madopar\textsuperscript{®}; levodopa and benserazide) compared with modified-release (Madopar HBS/CR\textsuperscript{®}), while the other study examined immediate-release co-careldopa (Sinemet\textsuperscript{®}; levodopa and carbidopa) compared with modified-release (Sinemet CR\textsuperscript{®}) formulation.\textsuperscript{149}

\[ \text{Evidence statements} \]

With respect to clinical rating scales and quality of life:

the co-careldopa study\textsuperscript{149} (N=134) found:

- ADL scores (UPDRS scale) were in favour of the modified-release preparation
  (p=0.006 year 1; p=0.031 year 5).
- Nottingham Health Profile was in favour of modified-release for emotional reaction and social isolation (p<0.05). (++)

Both studies\textsuperscript{147,149} found no significant differences between the treatment groups for the
Parkinson's disease Appendix H: Deleted Text Appendix

following outcome measures of motor impairment:

- New York University Parkinson's Disease Scale (NYUPDS)
- Northwestern University Disability Scale (NUDS)
- UPDRS
- Hoehn and Yahr scales
- Schwab and England scores. (1+)

One study\textsuperscript{149} reported no significant difference between treatment groups for motor fluctuations (primary endpoint) either by diary data or by questionnaire. With respect to drug dosage, this study\textsuperscript{149} (N=618) found the average number of daily doses was in favour of the modified-release preparation (p<0.005), while the other study\textsuperscript{147} found no differences. (1+)

With respect to adverse effects, one study\textsuperscript{147} reported no significant differences between the two groups. (1+)
With respect to withdrawal rates, one study\textsuperscript{149} found the number of withdrawals was higher in the immediate-release group ($p=0.007$). (1+)

From evidence to recommendation

This evidence suggests that there is no value in using the existing modified-release levodopa preparations to delay the onset of motor complications.

**RECOMMENDATION**

**R36** Modified-release levodopa preparations should not be used to delay the onset of motor complications in people with early PD

**7.3.2 Dopamine agonists compared with levodopa**

How effective and safe are dopamine agonists compared with levodopa in the treatment of functionally disabled early PD?

Methodology

Twelve RCTs\textsuperscript{42,116,118,150–158} were found which addressed whether dopamine agonists were more effective than levodopa in treating people with early PD who are functionally disabled.

Eight of these papers were randomised double-blind studies.\textsuperscript{116,118,150–155,155,158} One of these studies\textsuperscript{154} was single blind and three were open-trial designs.\textsuperscript{42,156,157} Two of the papers\textsuperscript{116,153} included were by the same group of investigators; the more recent publication\textsuperscript{116} reported 10-year follow-up outcomes for the same cohort of people.

The sample sizes ranged from 18 to 782 (median 82) and the trial durations ranged from 5.8 months to 120 months (median 44.4 months or 3.7 years).
The results from the eight trials are summarised in Table 7.2.

| Quality of Life (PD QUALIF and Euro-Qol scores) | NS<sup>158</sup> |
| UPDRS total | NS<sup>150</sup>, PPX<sup>158</sup> |
| UPDRS motor (III) | NS<sup>151</sup>, PPX<sup>158</sup>, RP<sup>152</sup> |
| UPDRS ADL (II) | NS<sup>152,118</sup>, PPX<sup>158</sup> |
| Hoehn and Yahr | NS<sup>153,154</sup> |
| Columbia Score | NS<sup>151,155</sup>, BR<sup>153</sup> |

continued
7.3.3 Dopamine agonists plus levodopa compared with levodopa

What is the effectiveness of dopamine agonists plus levodopa compared with levodopa monotherapy in the treatment of functionally disabled early PD?

Methodology

Eight papers\textsuperscript{115,151,154,157,159–162} were found which addressed the effectiveness of dopamine agonists combined with levodopa compared with levodopa monotherapy. Five of these studies\textsuperscript{115,151,154,160,161} were included in a Cochrane review,\textsuperscript{163} but these papers were reviewed independently for additional outcomes and follow-up studies.
Five of the trials\textsuperscript{115,157,159,160,162} were open label for the majority of the follow-up, one trial\textsuperscript{154} was single blind and one trial\textsuperscript{151} was double blind.

The sample size ranged from 20 to 587 people (median 78) and the trial duration ranged from 12 months to 5 years.

Five articles were appraised (see Table 7.3) and met quality criteria.\textsuperscript{164–168} No UK studies were identified.
### Parkinson’s disease Appendix H: Deleted Text Appendix

#### 7 Symptomatic pharmacological therapy

**Table 7.3** Dopamine plus levodopa compared with levodopa monotherapy (14)

<table>
<thead>
<tr>
<th>Description</th>
<th>NS¹⁵²,¹⁶¹,¹⁶²,¹⁶³,¹⁶⁰,¹⁶⁴,¹⁶⁵</th>
<th>LD¹⁶⁴,¹⁶⁵,¹⁶⁶</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical rating scales</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UPDRS total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UPDRS II (activities of daily living)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UPDRS III (motor)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UPDRS IV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UPDRS addendum (motor complications) scores</td>
<td></td>
<td></td>
</tr>
<tr>
<td>On time during day</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hoehn and Yahr</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Webster score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Columbia University Rating Scale (CURS)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Modified CURS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schwab and England score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NUDS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse events</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All events</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mortality</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue/weakness</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hallucination/confusion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Withdrawal rates</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of drop-outs</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

¹¹PD is levodopa; NS is levodopa; 68 is levodopa plus rasagiline; 76 is levodopa plus selegiline; 19 is levodopa plus bromocriptine; 72 is levodopa plus amantadine; 17 is levodopa plus selegiline.

**Health economic methodology**
A US study assessed the cost-effectiveness of pramipexole compared with no pramipexole in early PD by estimating the cost per quality-adjusted life year (QALY) during a life-time horizon.\textsuperscript{164}

One study estimated the incremental cost (IC) per QALY of initial pramipexole treatment.
compared with initial levodopa treatment in early PD based on a 4-year US and Canadian multi-centre RCT.169

A Canadian study derived the costs per day per patient to substitute levodopa plus benserazide by ropinirole over a 5-year time horizon in a cost-minimisation analysis.166

A German study evaluated cabergoline compared with levodopa monotherapy by estimating the cost per decreased UPDRS score based on a Markov model with a 10-year time horizon and the ICs per additional motor complication-free patient.167

A Swedish study evaluated the cost-effectiveness of early cabergoline treatment compared with levodopa in the early treatment of PD by estimating the cost per year of motor complications over 5 years.168

A cost-minimisation analysis of dopamine agonist compared with levodopa in initial PD therapy was estimated from the perspective of the NHS over a 1-year period (Appendix E).

### Health economic evidence statements

In people with early PD, the incremental cost-effectiveness for pramipexole compared with no pramipexole is $8,840 in US$ 1997 (approximately £5,510) per QALY from a societal perspective and $34,420 (approximately £21,480) per QALY without including productivity gains from pramipexole.164 However, cost-effectiveness results were sensitive to changes in the model’s parameters, resulting in cost per QALYs of $3,880 (approximately £2,420) when direct medical costs are 50% higher, $46,470 (approximately £28,990) when the rate of change of UPDRS after levodopa is 0.5 (versus 1.375 baseline) and $908,310 (approximately £566,720) when no-pramipexole treatment includes pergolide as adjunct.

One study estimated the incremental cost-effectiveness of initial pramipexole treatment compared with initial levodopa treatment in patients with early PD over a 4-year time period. The incremental cost-effectiveness ratio for pramipexole was $43,000 in US$ (approximately £24,700) per QALY, using the EQ-5D health-related quality of life measure. However, the pramipexole strategy is dominated by the levodopa strategy when using the EQ-VAS to derive the health utilities.165

Assuming equivalent clinical effectiveness, the cost of replacing levodopa plus benserazide with ropinirole in a Canadian setting gives a net IC of $4.14 (£2.38) per patient day. From a societal perspective, productivity and caregiver utilisation savings offset the drug acquisition cost for
Parkinson’s disease Appendix H: Deleted Text Appendix

ropinirole. Varying the key parameters (nursing home admission rates, cost of caregiver time and proportion of people with disabling dyskinesias who lost their jobs) by 15–20%, did not change the direction of the results.166

In people aged 60 years or over, cabergoline monotherapy was estimated to cost approximately an additional €1,030 in Euro 2002 (approximately £718) per unit decrease in UPDRS score. This value was robust to changes in the discount rate, cost data and mortality assessed in the sensitivity analysis. Levodopa monotherapy dominated cabergoline monotherapy in people under 60 years of age. Incremental costs per additional motor complication-free patient were estimated at €104,400 (approximately £72,710) in people under 60 years of age and €57,900 (approximately £40,330) in people aged 60 years or over based on subsamples of the clinical trial used for data analysis.167
7 Symptomatic pharmacological therapy

One study estimated an incremental cost-effectiveness of £13,869 (approximately £9,660) per year of motor complications avoided with cabergoline treatment.\textsuperscript{168}

The baseline estimates result in an IC of £2,390 for pramipexole treatment over a 1-year period. The unit cost of pramipexole had the most impact on the IC's and resulted in the widest range of all the IC estimates (£1,880 to £2,640). On the basis of equivalent quality of life between the treatments, the levodopa strategy is the less costly option (see Appendix E).

From evidence to recommendation

There is a wealth of evidence from dopamine agonist compared with levodopa trials that agonists delay the onset of motor complications. However, there is some evidence that levodopa treats motor impairments and disability better. Agonists also lead to more adverse events such as somnolence, oedema and hallucinations, but this does not lead to an excess of withdrawals from the trials.

It is more difficult to interpret the generally older dopamine agonist combined with levodopa compared with levodopa monotherapy trials. There is some suggestion of combination therapy treating motor impairments and disability better than levodopa but at the expense of more adverse events such as nausea, vomiting, fatigue, hallucinations and confusion. There are few data on motor complications.

The implication is that to delay motor complications, dopamine agonists should be used initially without levodopa. However, patients’ motor function will not be treated as well and they may suffer more side effects. This issue requires further clarification in trials using patient-rated quality of life as the primary outcome measure. The GDG acknowledged that the ongoing PD MED trial might provide additional data on the cost benefits of the various agents. Although useful for economic evaluations, the EQ-5D is a relatively insensitive measure of health-related quality of life. Given that no difference was detected in the PDQUALIF or EQ-VAS scales, the GDG concluded that there was no clear evidence of a clinically important difference in overall quality of life between the two treatment strategies (see Appendix E). This assumption was used in the economic model that indicated the levodopa strategy is the less costly short-term option.

7.3.4 Monoamine oxidase type B inhibitors compared with levodopa

How effective are MAOB inhibitors compared with levodopa in managing people with
Methodology

Two meta-analyses\textsuperscript{120,121} and a randomised crossover trial\textsuperscript{133} which addressed the effectiveness of MAOB inhibitors in treating people with early PD were included.

The meta-analyses\textsuperscript{120,121} compared MAOBs with controls (and did not differentiate between levodopa and placebo controls). In many of the included trials, the MAOB inhibitors were not given alone but were in combination with levodopa therapy. The RCT\textsuperscript{133} also compared people on levodopa plus selegiline with levodopa plus placebo.
One meta-analysis\textsuperscript{120} included 3,525 people with PD from 17 randomised trials while the other (a Cochrane review) included 2,422 people with PD from 10 trials.\textsuperscript{121} The randomised crossover trial consisted of 15 people with PD. The small sample size may have underpowered the study and could be reflective of the non-significant results, when compared with the large meta-analysis.

\section*{Evidence statements}

With respect to clinical rating scales:

Only one study\textsuperscript{42} in the meta-analyses\textsuperscript{120,121} reported mean Webster disability scores. The trial reported that the difference was non-significant between groups on levodopa plus selegiline compared with levodopa alone (no \textit{p} values given). (1+)

The randomised crossover trial\textsuperscript{133} reported no significant differences between scores for the Webster rating scale (total scores) in people with PD on levodopa plus selegiline compared with levodopa alone. (1++)

With respect to motor complications, only one study\textsuperscript{156} from one meta-analysis\textsuperscript{120} reported the following:

Motor fluctuations were more frequent among levodopa-treated people (29.7\%) than selegiline-treated people (18.7\%).

People assigned to selegiline were significantly less likely to experience motor fluctuations (non-significant, no \textit{p} value stated).

Dyskinesias occurred less frequently in the selegiline group (20.7\%) than the levodopa group (27.1\%). (1+)

With respect to need for levodopa therapy, the combined trials in the meta-analysis\textsuperscript{120} found:

The dose of levodopa required for adequate symptom control was 67 mg lower in the selegiline arm (95\% CI 14 to 119, \textit{p}=0.01).

All studies showed higher levodopa doses in the control groups than in patients treated with MAOB inhibitors (meta-analysis not performed for this outcome).\textsuperscript{121} (1+)

With respect to withdrawal rates:

Only one study\textsuperscript{156} from one meta-analysis\textsuperscript{120} reported data on withdrawal rates. The trial found the probability of people ceasing treatment in the selegiline group was about threefold higher than in those assigned to levodopa.
Parkinson’s disease Appendix H: Deleted Text Appendix

Most of these withdrawals occurred after the first 6 months and were due to peoples’ or physicians’ determination of inefficacy (two people stopped because of sleep disturbance side effects). (I+)

With respect to mortality:

One study\textsuperscript{42} in the meta-analysis\textsuperscript{120,121} reported the following between levodopa monotherapy and levodopa plus selegiline therapy:

- for all deaths, unadjusted hazard ratio of 1.22 (95% CI 0.95 to 1.55, no p value stated)
- first 5 years of study, unadjusted hazard ratio of 1.41 (95% CI 0.92 to 2.17, p=0.27).

Another study\textsuperscript{156} in one meta-analysis found no difference between rates of mortality. (I+)
From evidence to recommendation

Selegiline delays the onset of motor complications and the need for levodopa but at the expense of more withdrawals due to lack of efficacy. There are few trial data on selegiline's effect on motor impairments and none on quality of life. The clinical experience of the GDG suggests that selegiline is less effective than levodopa in the treatment of functional impairments and disability in PD. There are no trial data or clinical experience on the comparative efficacy and safety of rasagiline. Further trials to compare MAO-B therapy with levodopa are required.

7.3.5 Monoamine oxidase type B inhibitors compared with dopamine agonists

How effective are MAO-B inhibitors compared with dopamine agonists in the treatment of early PD?

Methodology

Only two RCTs\(^1\)\(^2\)\(^4\)\(^2\) were found which compared the effectiveness of MAO-B inhibitors and dopamine agonists in the treatment of early PD.

Both studies included a third levodopa therapy arm. Most of the disability and motor function analysis in the UK-PDRG study\(^2\)\(^4\)\(^2\) involved the comparison of bromocriptine with levodopa. Similarly, the other trial\(^1\)\(^5\) used the levodopa group as the reference group and did not provide statistical analysis of the results for the comparison of selegiline and dopamine agonists.

The UK-PDRG study\(^2\)\(^4\)\(^2\) consisted of 782 people with PD, and compared the effectiveness of levodopa, levodopa and selegiline and bromocriptine. The other study\(^1\)\(^5\)\(^6\) consisted of 473 people with PD, and compared the effectiveness of selegiline, levodopa and dopamine agonists (bromocriptine and lisuride). It is important to note that selegiline in the UK-PDRG trial\(^2\)\(^4\)\(^2\) was combined with levodopa therapy, whereas the other study\(^1\)\(^5\)\(^6\) used selegiline as a monotherapy (levodopa could be added if physician deemed selegiline alone to be ineffective).

Evidence statements
Parkinson's disease Appendix H: Deleted Text Appendix

In the UK-PDRG study, after 9 years of follow-up, there was a non-significant difference in Webster scores (adjusted for baseline score) between the bromocriptine group and the levodopa plus selegiline group. (1+)

With respect to motor complications, one study found no significant differences in:
- mean time to motor fluctuation
- frequency of dyskinesias
- difference in time to dyskinesia between dopamine agonist and MAOB inhibitor groups. (1+)

With respect to mortality, the UK-PDRG study found non-significant differences in mortality between levodopa plus selegiline and bromocriptine groups:
- unadjusted hazard ratio for overall deaths (non-significant)
- unadjusted hazard ratio in first 5 years was (p=0.27). (1+)
Parkinson's disease Appendix H: Deleted Text Appendix

Parkinson's disease

The other study\textsuperscript{156} found no significant difference in mortality between the dopamine agonist groups and the selegiline group. (1+)

With respect to withdrawal rates, one study\textsuperscript{156} reported the following.

Most people with PD withdrew from dopamine agonists because of nausea/vomiting or postural hypotension or both (43/53 people).

Most of the withdrawals in the selegiline group occurred in the first 6 months of treatment and were due to lack of efficacy.

Combination therapy was started in 40.7\% of people on dopamine agonists and 63.9\% of people on selegiline.

The initiation of levodopa therapy was delayed for a median of 30 months in dopamine agonist group and 15 months in selegiline group. (1+)

\begin{itemize}
\item From evidence to recommendation
\end{itemize}

While there was no difference in the delaying of motor complications between MAOB inhibitors and dopamine agonists, there is a suggestion that agonists are more effective than MAOB inhibitors in delaying the need for levodopa. More people with PD withdraw from MAOB inhibitors because of lack of efficacy; however, this evidence is based on just two studies and all of the data relates to selegiline.

7.4 Choice of initial pharmacological therapy in early Parkinson's disease

7.4.1 From evidence to recommendation

See Table 7.1 for a summary of the drugs covered within this section.

It was evident from reviewing the evidence base that there is no single drug of choice in the
Further trials are required to compare the initial treatment of PD with levodopa, dopamine agonists and MAOB inhibitors, preferably using quality-of-life and health economics outcome measures. The UK PD MED trial will attempt to address these comparisons. More information can be found from [www.pdmed.bham.ac.uk](http://www.pdmed.bham.ac.uk)

**RECOMMENDATION**

**R37** It is not possible to identify a universal first-choice drug therapy for people with early PD. The choice of drug first prescribed should take into account:

- clinical and lifestyle characteristics

  patient preference, after the patient has been informed of the short- and long-term benefits and drawbacks of the drug classes.

  D (GPP)
7.5 Later pharmacological therapy

“Off” is unmedicated. At my stage, it can get to where I can’t really speak that well and I can’t really use my face. I’ll be shaking. And that’s “off”. And then “on” is a version of this, which is when the medication’s working. I have “on” plus, because I have a little bit of dyskinesia, which is a function of the medication.

(patient)³

7.5.1 Introduction

It was evident from reviewing the evidence base that there is no single drug of choice in the pharmacotherapy of later PD. Table 7.4 may help to guide the reader through the following section.

<table>
<thead>
<tr>
<th>Table 7.4 Options for adjuvant pharmacotherapy in later PD</th>
</tr>
</thead>
<tbody>
<tr>
<td>First-</td>
</tr>
<tr>
<td>Dopamine agonists</td>
</tr>
<tr>
<td>COMT inhibitors</td>
</tr>
<tr>
<td>MAO-B inhibitors</td>
</tr>
<tr>
<td>Amantadine</td>
</tr>
<tr>
<td>Apomorphine</td>
</tr>
</tbody>
</table>

+++ = Good degree of symptom control.
++ = Moderate degree of symptom control.
+ = Limited degree of symptom control.
= Evidence of increased motor or nonmotor side effects.

7.5.2 Levodopa
Parkinson’s disease Appendix H: Deleted Text Appendix

Since most people with PD will eventually need levodopa, they will all with time develop motor complications. While the latter can be mild and not interfere with a person’s quality of life, for some they can be severely incapacitating. Adjuvant drugs to take with levodopa have been developed with the aim of reducing these complications and improving quality of life.

The previous section contains a statement about the methodological limitations of symptomatic therapy studies and recommendations about symptomatic pharmacological therapies for both early and later disease.

The GDG was concerned that the old practice of withdrawing PD patients from medication in the hope of improving motor complications is dangerous. Such ‘drug holidays’ can lead to severe immobility with secondary chest infection, neuroleptic malignant syndrome and death. This practice is rarely performed now and, because of the dangers, it should be abandoned.
Modified-release levodopa

Wearing off of the effects of levodopa and peak dose dyskinesia is largely caused by pulsatile stimulation of dopamine receptors, which is related to the intermittent administration of exogenous immediate-release levodopa. One potential way to overcome this is to prolong the effect of each dose of levodopa by administering controlled or modified-release levodopa preparations. Such preparations of co-careldopa (Sinemet CR®) and co-beneldopa (Madopar HBS/CR®) have been developed.

Can modified-release preparations of levodopa reduce motor complications compared with immediate-release preparations?

Methodology

Eleven randomised controlled trials\(^\text{170–180}\) comparing the effect of controlled-release 50/500 mg levodopa with immediate-release 25/100 levodopa in later PD were found. The sample size (range 19–202, mean 57) and mean age of people (range 58–67 years, mean 62.8) varied between trials.

Most of the included studies\(^\text{170–178,180}\) used the co-careldopa formulation of either 25/100 or 50/200 for the immediate-release and controlled-release tablets, respectively. Only one trial\(^\text{179}\) used 25/200 for the immediate-release dosage, but administered 50/200 for controlled release. None of the included trials used the co-beneldopa formulation.

Only one trial reported a washout period between trials\(^\text{179}\); all other trials analysed data from either the end of the trial arms or at week 2 or later in each arm.

All of the included trials started with an open-label titration phase in which the optimal antiparkinsonian dose and inter-dose interval for each treatment were determined. In many of the trials a large percentage of people withdrew (35%\(^\text{179}\), 31%\(^\text{175}\), 26%\(^\text{170}\), 24%\(^\text{173}\), 18%\(^\text{180}\), 17%\(^\text{171}\)) during the open phase because of inconsistencies with response, delayed onset of drug action or adverse events. Due to the already small sample size (average 60), lack of power calculations and intention-to-treat analysis, these studies were highly biased towards a pre-selected patient population. The trial duration was also very short with a range of 8–24 weeks.

Evidence statements
The results of the trials are summarised in Table 7.5.

With respect to adverse events:

Most common adverse events for both treatments included dizziness, dyskinesia,

dystonia, headache, hallucinations, nausea, vomiting, hypotension and confusion.171,176,177

There was no significant difference in the reported incidence of adverse events between the two treatment groups.171,174,180

One study177 reported people treated with controlled-release levodopa had a higher incidence of self-reported adverse events (p<0.05) but not a higher frequency. (1+)
Table 7.5 Controlled-release compared with immediate-release levodopa

<table>
<thead>
<tr>
<th>Parameter</th>
<th>CR 173, 175, 178, 179</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of trials</td>
<td>11</td>
</tr>
<tr>
<td>Total sample size (N)</td>
<td>646</td>
</tr>
<tr>
<td>Clinical rating scales</td>
<td></td>
</tr>
<tr>
<td>UPDRS motor score</td>
<td>CR 173</td>
</tr>
<tr>
<td>Hoehn and Yahr score</td>
<td>CR 175</td>
</tr>
<tr>
<td>NYUPDS score (after 6 months’ treatment)</td>
<td>CR 177</td>
</tr>
<tr>
<td>SEALD score</td>
<td>CR 171</td>
</tr>
<tr>
<td>Patient-rated global improvement</td>
<td>CR 175</td>
</tr>
<tr>
<td>Physician-rated global improvement</td>
<td>CR 175</td>
</tr>
<tr>
<td>Patient-reported helpfulness of medication and</td>
<td>CR 171</td>
</tr>
<tr>
<td>improvement in clinical fluctuations</td>
<td></td>
</tr>
<tr>
<td>Motor complications</td>
<td></td>
</tr>
<tr>
<td>On time</td>
<td>CR 173, 175, 178, 179</td>
</tr>
<tr>
<td></td>
<td>IR 173</td>
</tr>
<tr>
<td>Off time</td>
<td>CR 173, 177, 179</td>
</tr>
<tr>
<td>Dyskinesia duration</td>
<td>IR 178</td>
</tr>
<tr>
<td>Levodopa dose</td>
<td></td>
</tr>
<tr>
<td>Mean doses per day</td>
<td>CR 170, 172, 173, 175, 180</td>
</tr>
<tr>
<td></td>
<td>NS 177</td>
</tr>
<tr>
<td>Mean interdose interval</td>
<td>CR 170, 173, 180</td>
</tr>
<tr>
<td>Mean daily levodopa dose (mg/d)</td>
<td>IR 171–174, 176, 178–181</td>
</tr>
</tbody>
</table>

CR = controlled release - favour IR (p<0.05); CR: IR = immediate release - favour IR (p<0.05); NS = non-significant

With respect to withdrawal rates:

Two studies171,172 found 52–54% of people preferred controlled release over 27–33% of people who preferred immediate release.

Two studies found high numbers of people continuing controlled-release therapy after the completion of their trials (100%179 and 87%180).
Common reasons for withdrawal include adverse events, insufficient therapeutic response, lack of compliance and missing follow-up appointments.176,177 (I+)

- From evidence to recommendation

The trial evidence suggests that modified-release levodopa preparations can satisfactorily reduce motor fluctuations. However, the GDG had considerable reservations about the design
Parkinson’s disease Appendix H: Deleted Text Appendix

Parkinson’s disease

of many of the trials. Subsequent clinical practice has found that switching directly from immediate- to modified-release levodopa leads to an increase in off time. This is probably due to poorer absorption of modified-release preparations from the gut. As a result, modified-release levodopa is rarely used to manage motor complications. Modified-release preparations are also more expensive than immediate-release formulations. The GDG concluded that combinations of modified- and immediate-release levodopa could be useful in a small number of people with motor complications.

RECOMMENDATION

R38  Modified-release levodopa preparations may be used to reduce motor complications in people with later PD but should not be drugs of first choice.

7.5.3 Dopamine agonists

While recent trial work has concentrated on the use of dopamine agonists as initial therapy in PD, these agents were originally introduced as adjuvant therapy to reduce motor complications in later disease.

How effective and safe are dopamine agonists as adjuvant therapy in later PD?

Methodology

Nine papers, which included six Cochrane reviews\textsuperscript{182–187} and three additional RCTs,\textsuperscript{188–190} were found that addressed the effectiveness of adding dopamine agonists compared with placebo in the treatment of motor complications in people with later PD. Sample sizes of these trials are listed in Table 7.6. No RCTs were found on lisuride’s effectiveness.

There were several issues for consideration with the trials included in the Cochrane reviews\textsuperscript{182–187} such as:

- inclusion of phase II and III studies and unpublished papers

- additional unpublished data obtained from investigators or manufacturers sought by the Cochrane authors.
The three RCTs\textsuperscript{188-190} that were published since the Cochrane reviews were well designed and had sound methodologies.

Evidence statements

With respect to quality of life:

two trials, one\textsuperscript{191} included in the Cochrane review\textsuperscript{186} and another published after the review,\textsuperscript{198} reported the following outcomes in favour of pramipexole:

\begin{itemize}
  \item Functional Status Questionnaire Basic ADL
  \item mental health scales
  \item EuroQol Scale
  \item patient diaries (impairment of daily living and severity of tremor (p<0.0001). (1++)
\end{itemize}

With respect to clinical rating scales, motor complications and levodopa dose reduction, improvement was found to be in favour of the dopamine agonists (bromocriptine, cabergoline, pergolide, pramipexole and ropinirole) in most of the included trials (Table 7.6).
### Table 7.6 Dopamine agonists compared with placebo in later PD

<table>
<thead>
<tr>
<th>Number of trials</th>
<th>Sample size (N)</th>
<th>Clinical rating scales</th>
<th>Global rating</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>7</td>
<td>3</td>
<td>1</td>
</tr>
</tbody>
</table>

#### Motor complications

<table>
<thead>
<tr>
<th>Complication</th>
<th>Basal</th>
<th>Pramipexole</th>
<th>Bromocriptine</th>
<th>Amantadine</th>
<th>Pramipexole</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dyskinesia</td>
<td>L618</td>
<td>–</td>
<td>–</td>
<td></td>
<td>–</td>
</tr>
<tr>
<td>Off time</td>
<td>NS199,197</td>
<td>NS199,200</td>
<td>DA202</td>
<td>DA191,203,205,189</td>
<td>DA207</td>
</tr>
<tr>
<td>Impairment</td>
<td>DA195,196</td>
<td>NS199,198</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Wearing-off</td>
<td>DA198</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Levodopa dose reduction</td>
<td>NS196</td>
<td>DA201</td>
<td>DA202</td>
<td>DA191,203,205</td>
<td>DA207</td>
</tr>
</tbody>
</table>

#### Adverse events

<table>
<thead>
<tr>
<th>Complication</th>
<th>Basal</th>
<th>Pramipexole</th>
<th>Bromocriptine</th>
<th>Amantadine</th>
<th>Pramipexole</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hallucinations</td>
<td>NS199,201</td>
<td>p202</td>
<td>–</td>
<td>p191,203,204</td>
<td>–</td>
</tr>
<tr>
<td>Dyskinesia</td>
<td>NS199</td>
<td>p202</td>
<td>–</td>
<td>DA191,203,204</td>
<td>p207</td>
</tr>
<tr>
<td>Hypotension</td>
<td>NS199</td>
<td>DA199-201</td>
<td>–</td>
<td>NS191,203-205</td>
<td>–</td>
</tr>
<tr>
<td>Withdrawal rate</td>
<td>NS199</td>
<td>NS202</td>
<td>DA191</td>
<td>NS207</td>
<td>–</td>
</tr>
<tr>
<td>Adverse events</td>
<td>NS199</td>
<td>NS202</td>
<td>DA191</td>
<td>NS207</td>
<td>–</td>
</tr>
</tbody>
</table>
DA = favouring dopamine agonist (p<0.05); P = favouring placebo (p<0.05); = not reported; NS = non-significant (p>0.05).
From evidence to recommendation

In people with PD and motor complications, adjuvant dopamine agonist therapy reduces off time and levodopa dose and improves motor impairments and activities of daily living. This is at the expense of increased dopaminergic adverse events including dyskinesia, hallucinations and postural hypotension. These conclusions are based on short-term trials and the long-term acceptability of adjuvant agonist therapy remains to be evaluated.

Concerns regarding serosal reactions with ergot-derived dopamine agonists have been considered earlier in this chapter.

RECOMMENDATIONS

R39 Dopamine agonists may be used to reduce motor fluctuations in people with later PD. A

R40 If an ergot-derived dopamine agonist is used, the patient should have a minimum of renal function tests, ESR and chest radiograph performed before starting treatment and annually thereafter.* D (GPP)

R41 A dopamine agonist should be titrated to a clinically efficacious dose. If side effects prevent this, then another agonist or a drug from another class should be used in its place. D (GPP)

R42 In view of the monitoring required with ergot-derived dopamine agonists, a non-ergot-derived agonist should be preferred in most cases. D (GPP)

7.5.4 Monoamine oxidase type B inhibitors

The MAOB inhibitor selegiline was first used as a symptomatic treatment for PD before it was evaluated as a possible neuroprotective therapy (Chapter 6). More recently, rasagiline has become available as another MAOB inhibitor with symptomatic effects in PD.
How effective and safe are these MAOB inhibitors in treating the motor complications of later PD?

Methodology

Ten randomised double-blind placebo-controlled trials were found which addressed the effectiveness of MAOB inhibitors as an adjunct to levodopa treatment in people with later PD and motor complications. Of these nine trials, six were parallel group studies and three were crossover trials.

All of the trials apart from three investigated the effectiveness of conventional selegiline treatment. Two RCTs investigated the effectiveness of rasagiline, while the other assessed the effectiveness of Zelapar® selegiline, a formulation that dissolves on contact with saliva and undergoes pregastric absorption.

*Full details of the restrictions on pergolide use and monitoring are available in the Summary of Product Characteristics.
A common methodological issue in all the conventional selegiline trials was the lack of sample size calculations. Most of these trials failed to demonstrate a significant difference in many of the outcomes measures investigated between active treatment and placebo. The small sample sizes (range 19–96, mean 54.6) and the short-term duration (range 3–8 weeks, mean 6.7 weeks) need to be taken into consideration.

One large (N=687) RCT (LARGO)\textsuperscript{217} compared rasagiline with entacapone and placebo over 18 weeks. Another RCT (PRESTO)\textsuperscript{218} with a large sample size (N=472) and duration of 26 weeks compared two different doses of rasagiline (0.5 or 1 mg) with placebo.

The Zelapar\textsuperscript{8} selegiline study\textsuperscript{209} was a (N=140) study of 12 weeks’ duration. The only shortcoming of this trial was the lack of a conventional selegiline arm to directly compare the two formulations.

Most of the studies using conventional selegiline used a dose of 10 mg/day. One study\textsuperscript{214} used a dosing sequence of 0–5–10 mg/day in a random order, another study\textsuperscript{211} started with 5 mg/day in the first 4 weeks and increased to 10 mg/day for the final 4 weeks, and only one study\textsuperscript{218} used 5 mg/day for the entire trial duration of 8 weeks. The rasagiline study administered a dose of 1 mg/day for 18 weeks. The study on Zelapar\textsuperscript{8} selegiline used a dose of 1.25–2.5 mg/day for 12 weeks.

Evidence statements

Outcomes that favoured (p<0.05) conventional selegiline were:

- Physician preference\textsuperscript{211}
- Webster Rating Scale\textsuperscript{211}
- Modified Columbia Rating Scale: 5/22 items (dressing, dysarthria, hypomimia, salorrhoea, tremor)\textsuperscript{212}
- Disability Scale: 2/22 items (facial expression and resting tremor)\textsuperscript{213}
- Investigator’s Global Subjective Opinion: more likely to have experienced improvement than worsened or no change\textsuperscript{213} (I+)

With respect to patient observations of conventional selegiline:

At the end of the 6-week treatment period 76% of people reported themselves to be
improved in the selegiline group and only 26% in the placebo group.212

People reported the following while on selegiline treatment: dose of levodopa lasted longer, transitions between on and off periods were less abrupt, on periods were better, off periods were less severe.216 (1+)

With respect to long-term follow-up:

One study215 performed a long-term blinded follow-up. People selected the treatment period they preferred during the randomized short-term trial and they were maintained on that preferred treatment for about 16 months on average. The follow-up study found:

- The average levodopa dose was significantly lower (p<0.001) in selegiline-treated people.

- The average dosing frequency was also lower in the selegiline group (p<0.01). (2+)
<table>
<thead>
<tr>
<th>Variable</th>
<th>Conventional</th>
<th>1</th>
<th>2</th>
<th>7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of trials</td>
<td>7</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Sample size (N)</td>
<td>169</td>
<td>1,159</td>
<td>140</td>
<td></td>
</tr>
<tr>
<td>Quality of life</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDQUALIF scores</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical rating scales</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UPDRS total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UPDRS motor (on)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UPDRS motor (off)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UPDRS subscores</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schwab and England ADL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient diaries: proportion of people with improvement</td>
<td>SEL\textsuperscript{212,213}</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinician Global Impression Scale</td>
<td></td>
<td></td>
<td></td>
<td>SEL\textsuperscript{209}</td>
</tr>
<tr>
<td>Patient Global Impression Scale</td>
<td></td>
<td></td>
<td></td>
<td>SEL\textsuperscript{209}</td>
</tr>
<tr>
<td>Motor complications</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>On-off episodes</td>
<td>SEL\textsuperscript{210}</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>On time</td>
<td>SEL\textsuperscript{214}</td>
<td>SEL\textsuperscript{209}</td>
<td>SEL\textsuperscript{209}</td>
<td></td>
</tr>
<tr>
<td>Off time</td>
<td>SEL\textsuperscript{214}</td>
<td>SEL\textsuperscript{209}</td>
<td>SEL\textsuperscript{209}</td>
<td></td>
</tr>
<tr>
<td>On time with dyskinesia (increased)</td>
<td>p\textsuperscript{216}</td>
<td>N.S\textsuperscript{217,218}</td>
<td>N.S\textsuperscript{217,218}</td>
<td></td>
</tr>
<tr>
<td>Tremor</td>
<td>SEL\textsuperscript{215}</td>
<td>SEL\textsuperscript{217}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Daily levodopa dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levodopa dose reduction</td>
<td>SEL\textsuperscript{211,215,216}</td>
<td>SEL\textsuperscript{217}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse events and withdrawal rates</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any adverse events</td>
<td>N.S</td>
<td>N.S\textsuperscript{217}</td>
<td>N.S\textsuperscript{209}</td>
<td></td>
</tr>
<tr>
<td>All-cause withdrawal rates</td>
<td>N.S</td>
<td>N.S\textsuperscript{217,218}</td>
<td>N.S\textsuperscript{209}</td>
<td></td>
</tr>
</tbody>
</table>

N.S = favouring placebo (p<0.05); R = favouring rasagiline (p<0.05); P = favouring placebo (p<0.05).
One rasagiline RCT\textsuperscript{118} reported a significant (p<0.05) increase in adverse events in the treatment group:

- Dyskinesias were reported as an adverse event by 10% receiving placebo and by 18% receiving either dose of rasagiline.
- Weight loss, vomiting and anorexia were reported in 1.0 mg/day group.
- Balance difficulty and depression were reported in 0.5 mg/day group. (I++)

\textbf{RECOMMENDATION}

**R43** MAOB inhibitors may be used to reduce motor fluctuations in people with later PD. A

### 7.5.5 Catechol-O-methyl transferase inhibitors

Levodopa is now always combined with carbidopa (co-carbidopa) or benserazide (co-benêdopa) to block its metabolism by dopa decarboxylase. This increases levodopa bioavailability by twofold to threefold and reduces peripheral side effects. However, only 5–10% of each levodopa dose crosses the blood-brain barrier, the rest being metabolised to 3-O-methyl(dopa by catechol-O-methyl transferase (COMT). The aim of COMT inhibitors is to further reduce the metabolism of levodopa and thus increase the amount crossing into the brain.

Two COMT inhibitors are available. entacapone and tolcapone. These lead to a 30–50% increase in levodopa half-life and a 25–100% increase in the levodopa concentration versus time curve (area under the curve); they do not increase the maximum plasma concentration of levodopa.\textsuperscript{219} Most of this occurs because of peripheral inhibition, but tolcapone also has a central effect in the brain.
Toicapone was the first COMT inhibitor to enter clinical practice in England and Wales but its European product licence was withdrawn in November 1998 after three cases of fatal hepatic toxicity. However, after further clinical experience in other markets and a forced switch from entacapone to toicapone study, it has recently been reintroduced in Europe. It is currently licensed, at a dose of 100 mg three times per day, for people who have failed on entacapone, and requires mandatory liver function test monitoring at 2-week intervals for the first year of treatment followed by less stringent monitoring ad infinitum.

Entacapone has been combined with the levodopa plus carbidopa combination (co-carbidopa) as a triple combination called Stalevo®. One study has shown that Stalevo® simplifies the taking of medication, which is more acceptable to patients.220

How effective are these COMT inhibitors in reducing the motor complications of later PD?
Methodology

A Cochrane review was found which addressed the effectiveness of the COMT inhibitors tolcapone and entacapone compared with placebo in people with PD suffering from motor complications.

Two additional RCTs were found after the Cochrane search date. One RCT compared entacapone (200 mg) with placebo (LARGO). The study had a large \( N=456 \) sample size and a trial duration of 18 weeks. The other RCT compared entacapone (200 mg) with levodopa monotherapy. The study sample size was large \( N=270 \) and the trial duration was 13 weeks. The methodological limitations of this study were lack of reported methods of randomisation and allocation concealment.

An additional RCT was also found but excluded on the basis of patient characteristics. The people included in this trial could not experience end-of-dose wearing off within 4 hours of levodopa use, and had an average disease duration of 4.5 years. The results of this trial were not included due to the absence of motor complications.

The Cochrane review consisted of 14 trials (13 phase III, one phase II) and 2,566 patents with PD and motor fluctuations. Eight trials examined entacapone compared with placebo \( N=1560 \) and six trials examined tolcapone compared with placebo \( N=1006 \). Two of the included entacapone papers were abstracts; however, the results were consistent with the full publications. The level of evidence for the Cochrane review is graded as 1++, which is based on the review’s methodology and not that of the individual trials.

Issues for consideration with the Cochrane entacapone studies included: lack of randomisation and allocation concealment methods, lack of methodological detail available from the abstracts, and two studies did not state the method of data analysis. In addition, one of the entacapone studies was a crossover design \( N=26 \) without a washout period, and the results were presented as a combination of the two trial arms. The review did not use the results of this study in the meta-analysis.

Evidence statements

Table 7.8 summarises the evidence for the effectiveness of COMT inhibitors compared with placebo.

The additional RCT which compared entacapone with levodopa monotherapy reported the
following significant (p<0.05) results in favour of combined therapy:

- improvement in UPDRS II (ADL) score, treatment difference −1.6 (95% CI −2.4 to −0.8, p=0.0001)
- UPDRS III (motor) scores decreased, treatment difference −1.9 (95% CI −3.7 to −0.2, p=0.03)
- mean UPDRS total score decreased, treatment difference −3.6 (95% CI −6.0 to −1.2, p=0.004)
- fluctuation sum score (UPDRS IVb) decreased, treatment difference −0.3 (95% CI −0.5 to −0.1, p=0.02)

Global Assessment scores by study investigator increased (p<0.001) and the proportion of participants who improved was greater (1+)
Table 7.8 Meta-analysis of COMT inhibitors compared with placebo222 (++)

<table>
<thead>
<tr>
<th></th>
<th>Combined</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number of trials</td>
</tr>
<tr>
<td></td>
<td>Sample size (N)</td>
</tr>
<tr>
<td><strong>Efficacy</strong></td>
<td></td>
</tr>
<tr>
<td>Levodopa dose reduction</td>
<td>COMT217,224-227,230 COMT232-237 COMT</td>
</tr>
<tr>
<td>Off time (hours)</td>
<td>COMT217,224-227 COMT232,233,236 COMT</td>
</tr>
<tr>
<td>On time (hours)</td>
<td>COMT217,224-227 COMT232,233,236 COMT</td>
</tr>
<tr>
<td>UPDRS ADL</td>
<td>COMT217,224-227,231 COMT232-234 --</td>
</tr>
<tr>
<td>UPDRS motor score</td>
<td>COMT217,224-227,231 COMT232-233 --</td>
</tr>
<tr>
<td><strong>Adverse events</strong></td>
<td></td>
</tr>
<tr>
<td>Dyskinesia</td>
<td>p224-227,231, Ns217</td>
</tr>
<tr>
<td>Nausea</td>
<td>p224-227,231, Ns217</td>
</tr>
<tr>
<td>Vomiting</td>
<td>p223-224, Ns217</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>p224-227, Ns217</td>
</tr>
<tr>
<td>Constipation</td>
<td>p224-226, Ns217</td>
</tr>
<tr>
<td>Hallucinations</td>
<td>Ns217,224-227</td>
</tr>
<tr>
<td><strong>Withdrawal rates</strong></td>
<td></td>
</tr>
<tr>
<td>Due to adverse events</td>
<td>p224-227,231, Ns217</td>
</tr>
<tr>
<td>Due to all causes</td>
<td>p224-227,231, Ns217</td>
</tr>
</tbody>
</table>

COMT = favouring COMT inhibitor (p<0.05); P = favouring placebo (p<0.05); -- = not reported; NS = non-significant (p>0.05); ** = significant for 50, 100, 200 and 400 mg tds doses; *** = significant for 200 mg tds doses.

The RCT222 also reported the following non-significant outcomes between treatment groups:

- Parkinson's Disease Questionnaire 39 (PDQ-39) summary index scores and subscores
- SF-36 variables and EQ-5D self-rating questionnaire utility score
- Patient home diaries: mean 'off' time and mean 'on' time
- UPDRS I (mentation, behaviour and mood) scores
- Dyskinesia sum score (UPDRS IVA)
Parkinson’s disease Appendix H: Deleted Text Appendix

severity of PD (UPDRS part V, Hoehn and Yahr staging)
UPDRS IV (Schwab and England)

mean daily dose of levodopa. (1+)
The RCT\textsuperscript{222} reported the following in relation to adverse events.

113 (65\%) entacapone and 47 (49\%) levodopa monotherapy people reported adverse events.

A total of 311 adverse events occurred in entacapone (2.8 events per participant) and 104 in levodopa monotherapy group (2.2 events per participant).

The most frequently reported adverse events significantly (p≤0.05) in favour of levodopa monotherapy were nausea, diarrhoea, aggravated parkinsonism and constipation.

A frequently reported adverse event was also dyskinesia, but there was no significant difference between treatment groups. (1+)

The RCT\textsuperscript{222} reported the following results in relation to withdrawal rates.

45 (17\%) of participants discontinued prematurely (27/174 entacapone and 18/96 levodopa monotherapy).

Reported reasons for discontinuation were adverse events for 26 (10\%) of people; an unsatisfactory response to treatment for 14 (5\%) of people; a wish to discontinue for three participants (1\%); and other reasons for two participants (1\%). (1+)

From evidence to recommendation

The placebo-controlled COMT inhibitor trials document the efficacy of these agents in reducing off time and levodopa dose, while improving on time, motor impairments and disability. This is at the expense of increased dopaminergic adverse events such as nausea, vomiting and dyskinesia.

Tolcapone has caused rare cases of fatal hepatic toxicity and neuroleptic malignant syndrome. As a result, it can only be used in England and Wales after a patient has failed on entacapone and its use requires intensive monitoring of hepatic function (see Summary of Product Characteristics).

RECOMMENDATIONS

R44 Catechol-O-methyl transferase inhibitors may be used to reduce motor fluctuations in people with later PD. A

R45 In view of problems with reduced concordance, people with later PD taking entacapone
should be offered a triple combination preparation of levodopa, carbidopa and entacapone.*

**R46** Tolcapone should only be used after entacapone has failed in people with later PD due to lack of efficacy or side effects. Liver function tests are required every 2 weeks during the first year of therapy, and thereafter in accordance with the Summary of Product Characteristics.

**7.5.6 Amantadine**

When originally introduced, amantadine was used as an early therapy for PD. It fell into disuse as more effective agents such as levodopa and dopamine agonists became available. In the last few years, amantadine has had a revival after several small trials suggested it might have an antidysskinetic effect in people with later PD and motor complications.

How effective and safe is amantadine in managing the motor complications of later PD?

*Trade name Stalevo® (Orion).*
Methodology

A Cochrane review\textsuperscript{238} and an RCT\textsuperscript{239} (published after the review) were found which compared the effectiveness of adding amantadine versus placebo in the treatment of people with later PD and motor complications.

The Cochrane review\textsuperscript{238} included three studies with a total of 53 people, while the RCT\textsuperscript{239} included a total of 40 people.

Issues for consideration included a lack of reporting: allocation concealment, washout periods in crossover design trials, clinical criteria for PD diagnosis, and intention-to-treat analysis. The trials were generally of small sample size (range 11–40) and short trial duration (range 4–6 weeks). A dose of 100–400 mg/day of amantadine was used.

The three trials\textsuperscript{240–242} included in the review\textsuperscript{238} were all crossover designs, in which none had reported the results of the first treatment arms. Two of the trials\textsuperscript{241,242} did not incorporate a washout period; thus, data from these trials were not reported.

Evidence statements

The RCT\textsuperscript{239} found the results of key outcome measures changed over time (Table 7.9). (I+)

<table>
<thead>
<tr>
<th>Table 7.9 Amantadine compared with placebo at different time points\textsuperscript{239}</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical rating scale</td>
</tr>
<tr>
<td>UPDRS items 32–34 (self-assessment)</td>
</tr>
<tr>
<td>Motor complications</td>
</tr>
<tr>
<td>NIA scores of dyskinesia</td>
</tr>
<tr>
<td>DRS total scores</td>
</tr>
</tbody>
</table>

\textsuperscript{1} A = favour amantadine (well-tolerated); NS-B = non-significant improvement in amantadine; NS = no differences between groups.
With respect to motor complications:

Only one trial from the systematic review\textsuperscript{240} reported the outcome of dyskinesia severity following levodopa challenge. This trial reported that dyskinesia was reduced after oral amantadine treatment by 6.4 points (41\%) when compared with placebo arm (after 2 weeks of amantadine treatment). (1++)

With respect to adverse events:

Only one trial\textsuperscript{240} from the systematic review\textsuperscript{238} reported adverse events for patients while on amantadine medication; these included: confusion, worsening of hallucinations, reappearance of palpitations, nausea, reversible oedema, dry mouth and constipation. (1++)
Only one trial\textsuperscript{239} from the review reported adverse events following amantadine withdrawal; these included: an abrupt increase of dyskinesia to 100\% of daily time, hypothermia, and severe confusion (amantadine was reintroduced).\textsuperscript{(1+)}

With respect to withdrawal rates:

Reasons for withdrawal from amantadine treatment included: mild and transient adverse events,\textsuperscript{242} tachycardia (N=1),\textsuperscript{239} psychosis and livedo reticularis (N=2).\textsuperscript{239} (1++) Reasons for withdrawal from placebo group included: dizziness,\textsuperscript{239} somnolence,\textsuperscript{239} poor compliance.\textsuperscript{241} (1++)

\section*{From evidence to recommendation}

While there is some encouraging trial evidence that amantadine can be used as an anti-dyskinesia agent, data on its long-term effects are lacking. The evidence from one small trial suggests that amantadine's anti-dyskinetic effect is substantially reduced after 8 months of therapy. Further work is required in this area.

\section*{RECOMMENDATION}

\begin{itemize}
  \item \textbf{R47} Amantadine may be used to reduce dyskinesia in people with later PD.
\end{itemize}

\subsection*{7.5.7 Apomorphine}

Apomorphine is a dopamine agonist that is not effective orally due to extensive first-pass metabolism in the liver. Early studies in PD lead to severe emesis and pre-renal failure. Its further development was facilitated by the availability of the antiemetic domperidone, which in doses of 10–30 mg tds for 72 hours before apomorphine can prevent most peripheral dopaminergic side effects.

There are currently two distinct methods of administering apomorphine: subcutaneous bolus doses and continuous infusion. People with a maximum of five or six off periods per day are suitable for intermittent bolus injections. Initially, the threshold dose of apomorphine (usual range 2–4 mg) is established as an inpatient using clinical examination and motor rating scales.
Parkinson’s disease Appendix H: Deleted Text Appendix

The patient is then trained to use a pre-filled apomorphine injection system in which the agreed threshold dose can be dialled up more easily by the patient when in the off state.

Subcutaneous infusions of apomorphine are appropriate for PD people with many off periods that repeated bolus injections are inappropriate. Apomorphine is administered by a portable syringe driver connected via a butterfly cannula sited in the abdominal wall or subcutaneous tissue of the thighs. The programmable pump delivers 50–120 mg of apomorphine over the waking day or the whole 24-hour period. Usually, oral medication can be reduced according to the patient’s response. Considerable adjustment of the infusion dose is required once the patient is in the home environment. This can be facilitated by a PDNS.

What is the evidence that apomorphine injections and infusions are effective and safe treatments for motor complications in later PD?
7.5.8 Intermittent subcutaneous apomorphine injections

Methodology

Three randomised controlled trials\textsuperscript{243,244,245} were found which addressed the effectiveness of subcutaneous injections of apomorphine compared with placebo. The people included in these trials were all classified as later PD and had mean disease duration of 9–12 years.

All three studies\textsuperscript{243,244,245} were placebo controlled. One was an 8-day crossover design\textsuperscript{244} (4 days per arm), while another was a 4-week parallel design.\textsuperscript{245} The third consisted of five $N=1$ trials conducted over 10 consecutive ‘off periods’ with each person acting as their own control\textsuperscript{245}. The sample sizes of all three trials were relatively small ($N=29,243,244$ $N=22,243,244$ and $N=5$\textsuperscript{245}).

No controlled trials were found which looked at apomorphine compared with standard oral treatment, and no controlled trials were found of continuous subcutaneous apomorphine infusions.

Evidence statements

Table 7.10 summarises the evidence for subcutaneous apomorphine injections.

With respect to a correlation analysis\textsuperscript{243}

Levodopa dose (the single dose that produced the effect to which apomorphine responses were matched) was not predictive of the required apomorphine dose.

Total daily levodopa dose was also not predictive of apomorphine dose ($p=0.32$).

Inpatient response was correlated with and predictive of outpatient efficacy ($p=0.001$). (I+)

With respect to clinical global impressions\textsuperscript{244}

86\% of people who completed the apomorphine 8-week follow-up (maintenance phase) reported ‘much’ or ‘very much’ improvement at the last visit.

No people reported to have worsened during the follow-up. (I+)
With respect to withdrawal rates: 243, 244

Reasons for withdrawal included: failure to demonstrate a significant response to the levodopa challenge, adverse events (nausea and vomiting, hypotension, exanthema), lack of motivation. (1+)

With respect to adverse events:

Common events included: injection site complaints, drowsiness, yawning, dyskinesias, nausea or vomiting, chorea, sweating and warmth, dizziness, headache, rhinitis. 243, 244

Other events included: nausea, dyskinesia, short-lasting twinkling (sic) in legs, short-lasting worsening of tremor, warmth and sweating, lower level of motor functioning at end of clinical effect compared with baseline level before the test. 245

There were no significant changes in other safety measures (blood tests, electrocardiography, physical examination). 243 (1+)
### Table 7.10 Effectiveness of subcutaneous apomorphine injections (1+)

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Before versus after</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical rating scales</td>
<td></td>
</tr>
<tr>
<td>UPDRS (I, II, III, IV) scores</td>
<td>NS244</td>
</tr>
<tr>
<td>UPDRS motor (II) score</td>
<td>APO243</td>
</tr>
<tr>
<td>Columbia individual item (tremor, rigidity, gait, hypokinesia, stability) scores</td>
<td>APO245s</td>
</tr>
<tr>
<td>Columbia total score</td>
<td>APO245</td>
</tr>
<tr>
<td>Timed finger/foot tapping, walking and pinboard combined test scores</td>
<td>APO246</td>
</tr>
<tr>
<td>Patient diaries for hand-tapping test</td>
<td>APO243</td>
</tr>
<tr>
<td>Patient diaries for Webster step-seconds scores</td>
<td>p243</td>
</tr>
<tr>
<td>Motor complications</td>
<td></td>
</tr>
<tr>
<td>Mean daily duration of off periods (minutes/day)</td>
<td></td>
</tr>
<tr>
<td>Staff rating</td>
<td>APO244</td>
</tr>
<tr>
<td>Patient rating</td>
<td>APO244</td>
</tr>
<tr>
<td>Mean daily numbers of off periods</td>
<td></td>
</tr>
<tr>
<td>Staff rating</td>
<td>p244</td>
</tr>
<tr>
<td>Patient rating</td>
<td>NS244</td>
</tr>
<tr>
<td>Distribution of severity of off periods</td>
<td>APO244</td>
</tr>
<tr>
<td>Patient diaries (out of 10 parameters):</td>
<td></td>
</tr>
<tr>
<td>Off-state events aborted per patient</td>
<td>APO243</td>
</tr>
<tr>
<td>Onset latency (minutes)</td>
<td>APO243</td>
</tr>
<tr>
<td>Total time off per day</td>
<td>APO243</td>
</tr>
<tr>
<td>Incidence of dyskinesia</td>
<td>p243</td>
</tr>
<tr>
<td>Adverse events</td>
<td></td>
</tr>
<tr>
<td>Yawning</td>
<td>p243</td>
</tr>
<tr>
<td>Mean daily duration of involuntary movements</td>
<td>p244</td>
</tr>
<tr>
<td>Mean daily numbers of involuntary movements</td>
<td>p244</td>
</tr>
</tbody>
</table>

APO: not specified; NS: not significant; p: p < 0.05

---
Parkinson’s disease Appendix H: Deleted Text Appendix
7.5.9 Apomorphine infusions

Methodology

There were no randomised or controlled trials, which assessed the effectiveness of chronic apomorphine infusion in people with later PD. Ten studies, nine retrospective and one prospective, were found which investigated the benefit of chronic apomorphine treatment compared with pre-treatment evaluations.

Most of the included retrospective studies used a hospital/clinic database to identify people who had received apomorphine for the treatment of severe motor fluctuations or dyskinesia, but who were refractory to optimal oral medication. One prospective study enrolled people with motor fluctuations and dyskinesias at two sites if they were refractory to oral medication and scheduled to start continuous apomorphine infusion. For included studies, the follow-up ranged from 3 months to 5 years, the sample size ranged from seven to 64 people, and the average age ranged from 56 to 65 years.

The methodological limitations of these studies included: lack of prospective protocols in most instances, non-randomisation of people, lack of control groups, small sample sizes, and lack of patient and/or investigator blinding.

Evidence statements

Table 7.11 summarises the evidence for continuous apomorphine infusions.

With respect to clinical global rating scales:

Patient rating: no patient described overall worsening; three felt unchanged; six experienced slight improvement; and 16 had a clear improvement.

Physician rating: no patient worsened; two people were unchanged (the same who described themselves as unchanged); seven slightly improved; and 16 had clearly improved.

With respect to drug dosage:

Larger doses of apomorphine produced a longer duration of anti-parkinsonian effect.
Parkinson’s disease Appendix H: Deleted Text Appendix

(p<0.001). (3)

Two studies253,254 looked at the anti-dyskinetic effect of monotherapy, which means these people received no oral anti-parkinsonian drug treatment from the time when the apomorphine pump was started in the morning to when it was turned off at night. There was an overlap in the patient populations included in these studies; therefore, only the results of one 255 will be reported below.

With respect to motor complications:253

There was a mean maximum reduction of dyskinesia per patient of 64% (p<0.005). The mean time to achieve maximum dyskinesia improvement was 12.1 months. There was an increase in on time of 55% (p<0.005). (3)

With respect to treatment management:253

25% of people managed treatment independently, 50% managed with family help, 25% required nurse input.

The success rate was greater (p<0.05, 81%) among people managing the pump system independently or with help from family than those requiring outside help (eg nurse). (3)
Table 7.11 Effectiveness of continuous apomorphine infusions (3)

<table>
<thead>
<tr>
<th>Clinical rating scales</th>
<th>APO247</th>
</tr>
</thead>
<tbody>
<tr>
<td>UPDRS total and subscores</td>
<td>APO253</td>
</tr>
<tr>
<td>UPDRS 32 (dyskinesia duration)</td>
<td>APO253*</td>
</tr>
<tr>
<td>UPDRS 33 (dyskinesia severity)</td>
<td>APO255</td>
</tr>
<tr>
<td>Lang and Fahn</td>
<td>APO255</td>
</tr>
<tr>
<td>Hoehn and Yahr scores (off and on states)</td>
<td>APO250</td>
</tr>
<tr>
<td>Schwab and England scale (off and on states)</td>
<td>APO250</td>
</tr>
<tr>
<td>Severity and duration in diaries</td>
<td>APO255*</td>
</tr>
<tr>
<td>Motor complications</td>
<td></td>
</tr>
<tr>
<td>Decrease in off time</td>
<td>APO248-248,250-253, 255</td>
</tr>
<tr>
<td>Increase in on-time duration (% waking day)</td>
<td>APO253*</td>
</tr>
<tr>
<td>Dyskinesias</td>
<td>NS247,248,250</td>
</tr>
<tr>
<td>Levodopa</td>
<td></td>
</tr>
<tr>
<td>Daily dose of levodopa</td>
<td>APO246-250,252,255</td>
</tr>
<tr>
<td>Number of levodopa doses per day</td>
<td>APO252</td>
</tr>
</tbody>
</table>

With respect to neuropsychiatric problems:253

There was 40% improvement (especially in people with depressive-type symptoms) (p<0.05). (3)

With respect to adverse events:246-253,255

The majority of people developed subcutaneous nodules.

Other effects were: rhinorrhea, nausea and hiccups, recurrent diarrhoea, confusion and emotional lability, euphoria and dystartha, worsening of dyskinesia, orthostatic hypotension, psychosis, hallucinations, intermittent illusions, confusion, sleepiness, vertigo, osinophilia, increased appetite, increased libido, visual delusions, diurnal agitation, immune haemolytic anaemia, mild self-limiting leg oedema, positive direct
Parkinson's disease Appendix H: Deleted Text Appendix

anti-globulin test without associated haematological changes. (3)

With respect to withdrawal rates,246,248,250–253

People withdrew due to side effects (psychiatric effects, insufficient therapeutic effects or adverse effects). (3)

With respect to effects of single-dose levodopa and apomorphine challenges before and after continuous apomorphine infusion on dyskinesias.255
Levodopa reduced dyskinesias after continuous apomorphine infusion by at least 40% (AIMS and Goetz scales; both \( p < 0.01 \)).

Apomorphine reduced dyskinesias after continuous apomorphine infusion by at least 36% (AIMS and Goetz scales; both \( p < 0.01 \)). (3)

From evidence to recommendation

The evidence base for the use of both intermittent injections and continuous infusions of apomorphine is relatively poor but both techniques are licensed for use in England and Wales. The GDG considers these to be useful treatment modalities for people with severe off periods that are not responsive to changes in oral medication. However, there is a risk of triggering serious side effects such as confusion and hallucinations. In addition, the risk of injection site reactions is considerable.

Long-term continuous apomorphine infusions can dramatically reduce both off periods and dyskinesia and allow withdrawal of oral medication.

The initiation of apomorphine should be restricted to expert units with the availability of a home monitoring system by a suitably trained health professional such as a PDNS.

RECOMMENDATIONS

R48 Interim intermittent apomorphine injections may be used to reduce off time in people with PD with severe motor complications. B

R49 Continuous subcutaneous infusions of apomorphine may be used to reduce off time and dyskinesia in people with PD with severe motor complications. Its initiation should be restricted to expert units with facilities for appropriate monitoring. D

7.6 Comparisons of drug classes
While it is valuable to know that various drug classes are effective agents in managing the motor complications seen in later PD, clinicians are particularly keen to know whether one class or combination of classes is better than another so that clinicians can make rational decisions about the order in which adjuvant therapies are used.

7.6.1 Dopamine agonists compared with monoamine oxidase type B inhibitors

How effective are dopamine agonists compared with MAOB inhibitors in the management of later PD?

Methodology

No trials were found which compared dopamine agonists with MAOB inhibitors in the treatment of people with later PD and motor complications.
From evidence to recommendation

In the absence of any evidence, no firm conclusions on the comparative efficacy and safety of dopamine agonists versus MAOB inhibitors can be made. Further trials are required to compare these two drug classes.

7.6.2 Catechol-O-methyl transferase inhibitors compared with dopamine agonists

How effective are dopamine agonists compared with COMT inhibitors in the management of later PD?*

Methodology

One Cochrane review** was found which compared the effectiveness of dopamine agonists versus COMT inhibitors.

Two RCTs were included in the review. One trial*** (N=205) compared tolcapone with pergolide and the other trial**** (N=146) compared tolcapone with bromocriptine.

Evidence statements

With respect to quality of life:**

PDQ-39 improved more with tolcapone than pergolide (p=0.005).
Sickness Impact Profile was non-significant. (I++)

With respect to clinical rating scales:**

Both studies found a non-significant difference in UPDRS ADL scores and UPDRS motor scores. (I++)
Parkinson’s disease Appendix H: Deleted Text Appendix

With respect to levodopa dose reduction:

One trial\textsuperscript{258} found the total daily levodopa dose decreased significantly with tolcapone compared with bromocriptine (124 mg versus 30 mg, \(p<0.01\)).

The other trial\textsuperscript{257} found a non-significant difference between tolcapone and pergolide (mean of 108 mg versus 92 mg). (I++)

With respect to total on and off time:

One trial\textsuperscript{258} found a non-significant difference in off and on time between tolcapone and bromocriptine. (I++)

With respect to adverse events:

The combined results of both trials showed more nausea (OR=0.42, \(p=0.0003\), constipation (OR=0.26, \(p=0.00007\)) and orthostatic complaints (OR=0.24, \(p=0.0002\)) in pergolide and bromocriptine groups than in tolcapone groups. (I++)

With respect to withdrawal rates:

One of the studies\textsuperscript{257} reported, due to adverse events, a trend towards more pergolide withdrawals (Peto OR=0.34, \(p=0.02\)). Neither study showed any significant differences for all-cause withdrawal. (I++)
From evidence to recommendation

While there is some evidence of the superiority of tolcapone over bromocriptine and pergolide, this is insufficient to recommend the use of COMT inhibitors ahead of dopamine agonists. Further trials are required to compare these classes of adjuvant therapy.

7.6.3 Dopamine agonists compared with amantadine

How effective are dopamine agonists compared with amantadine in the management of later PD?

Methodology

No trials were found which compared adding dopamine agonists versus amantadine to levodopa therapy in the treatment of people with later PD and motor complications.

From evidence to recommendation

In the absence of any evidence, no conclusions on the comparative efficacy and safety of dopamine agonists compared with amantadine can be made. Further trials are required to compare these two drug classes.

7.7 Choice of pharmacological therapy in later Parkinson’s disease

7.7.1 From evidence to recommendation

A summary of the drugs covered in this section can be found in Table 7.4.
Parkinson’s disease Appendix H: Deleted Text Appendix

It was evident from reviewing the evidence base that there is no single drug of choice in the pharmacotherapy of later PD.

Further trials are required in later PD with motor fluctuations to compare adjuvant therapy with dopamine agonists, COMT inhibitors and MAOB inhibitors, preferably using quality-of-life and health economics outcome measures. The PD MED trial in the UK is just such a trial and is scheduled to continue recruitment until November 2006 (www.pdmed.bham.ac.uk).

7.7.2  **Generic therapeutic issues in later Parkinson’s disease**

There are a number of generic issues concerning the prescription and administration of anti-parkinsonian medication that are crucial to good concordance. Sudden increases in off time can occur if people with later PD are not given their medication often enough when they are admitted to hospital or care homes. This may require administration at times other than the normal ‘drug rounds’. This is often best achieved by allowing patients to self-medicate. It is also advisable that the anti-parkinsonian regimen of patients admitted to hospital is reviewed and, if necessary, adjusted by an expert.

In addition, there are concerns over the dangers of sudden withdrawal or changes in medication and the overuse of such medication by a minority of people with PD.
RECOMMENDATIONS

R50  It is not possible to identify a universal first-choice adjuvant drug therapy for people with later PD. The choice of adjuvant drug first prescribed should take into account:

   clinical and lifestyle characteristics

   patient preference, after the patient has been informed of the short- and long-term benefits and drawbacks of the drug classes.

D (GPP)

R51  Anti-parkinsonian medication should not be withdrawn abruptly or allowed to fail suddenly due to poor absorption (for example gastroenteritis, abdominal surgery) to avoid the potential for acute akinesia or neuroleptic malignant syndrome.

D (GPP)

R52  The practice of withdrawing patients from their anti-parkinson drugs (so-called 'drug holidays') to reduce motor complications should not be undertaken because of the risk of neuroleptic malignant syndrome.

D (GPP)

R53  In view of the risks of sudden changes in anti-parkinsonian medication, people with PD who are admitted to hospital or care homes should have their medication:

   given at the appropriate times, which in some cases may mean allowing self-medication adjusted by, or adjusted only after discussion with, a specialist in the management of PD.

D (GPP)

R54  Clinicians should be aware of dopamine dysregulation syndrome, an uncommon disorder in which dopaminergic medication misuse is associated with abnormal behaviours, including hypersexuality, pathological gambling and stereotypic motor acts. This syndrome may be difficult to manage.

D (GPP)
Parkinson's disease Appendix H: Deleted Text Appendix
8 Surgery for Parkinson’s disease

8.1 Introduction

Recognition of the limitations of dopaminergic therapy and the need to treat motor complications were the prime movers in the revival of functional stereotactic surgery for PD. This was aided by technological advances in the fields of imaging and computing. The introduction of CT and MRI scanning allowed surgeons to visualise and directly target deep brain structures without the need for indirect calculations from atlases based on cadaveric dissections. Modern engineering methods and computer technology resulted in easily used and reliable stereotactic hardware. Further advances came with the development of technology for deep brain stimulation (DBS), which has become the mainstay of movement disorder surgery.

Better understanding of the pathophysiology of movement disorders and of the basal ganglia circuitry has refined the surgical targets used in movement disorder surgery.

The ventrolateral nucleus of the thalamus has been one of the commonly used target sites for surgery in PD. Cells firing at tremor frequency can be identified in the ventralis intermedialis (Vim) part of the thalamus and lesions or stimulators placed at this target can dramatically improve tremor.\textsuperscript{259}

The serendipitous observation\textsuperscript{260} of the effects of accidental ligation of the anterior choroidal artery focused attention on the globus pallidus interna (GPI) as a target for surgery. One group\textsuperscript{261} identified the ventral and posterior parts of the internal segment (GPI) as the optimal site for surgical ablation. This group\textsuperscript{262} revived this procedure and it was in widespread use in the early 1990s. While pallidotomy significantly reduced dyskinesia, it had a lesser effect on tremor and akinesia. The morbidity of bilateral lesions and the introduction of subthalamic nucleus (STN) DBS reduced the use of pallidotomy. However, DBS of the pallidum has a role in dystonia and some patients with PD.
Figure 8.1 Structures of the basal ganglia [8] (reproduced with permission from publisher).
Experimental studies using the MPTP primate model showed increased cellular activity in the STN, and lesions or stimulation of the STN can reverse the cardinal features of parkinsonism.\cite{26,264} However, surgeons were reluctant to lesion the STN in humans because of the risk of inducing hemiballismus. It was then shown that electrical stimulation of the STN-DBS\cite{263} produced dramatic improvement in parkinsonian symptoms in PD. STN-DBS has since become the most widely undertaken surgical procedure for PD.

Surgical techniques vary between centres, but it is generally performed in three stages: radiological localisation, physiological localisation, and then either an ablation or a stimulation procedure.

Radiological localisation involves the rigid fixation to the skull under local anaesthesia of a stereotactic base ring onto which a fiducial array can be mounted. In the past, ventriculography (ie outlining the ventricles of the brain by instilling air or contrast medium) was the radiological technique used, but this has been largely replaced by CT and MRI. It is now possible to identify most of the targets on MRI, and their position in stereotactic space is calculated using sophisticated computer programs.

When the radiological data have been acquired and analysed, the patient is moved to the operating theatre and the radiological localiser is replaced with a stereotactic arm system that allows the surgeon to pass electrodes through a small opening in the skull with a high degree of precision. This is usually undertaken under local anaesthesia to allow the surgeon to evaluate responses from the patient, though some centres now carry this out under general anaesthesia and depend on recording of cellular activity for final localisation of the target. Microelectrode recording of cellular activity is widely used for physiological localisation, but there is no consensus on the added value of this technique. Evaluating the patient’s response to electrical stimulation of the target usually makes further confirmation of accurate identification of the target.

When the target has been identified the options are of either using radiofrequency current for thermal ablation of the area or introducing a system for chronic electrical stimulation. Ablation has the advantage of being an inexpensive single procedure that does not require long-term follow-up for maintenance of implanted hardware. These advantages are largely negated by the irreversibility of the procedure and higher morbidity. Ablation has therefore largely been replaced by chronic DBS.

For DBS, the initial target localization is similar to that used for ablative procedures. Once the target has been identified the test electrode is replaced with an implantable quadripolar electrode, which is anchored to the skull. A period of stimulation using an external stimulator is sometimes used and when the efficacy has been confirmed the system is internalised. Under general anaesthesia fine cables are connected to the electrodes and tunnelled subcutaneously to a programmable pulse generator usually placed in the chest wall. The pulse generator is similar
Parkinson’s disease Appendix H: Deleted Text Appendix

to a cardiac pacemaker with a high degree of programmability by an external device. It is possible to provide the patient with a degree of control of the stimulator. The pulse generator has a battery within it and depending on usage will have to be replaced in a simple surgical procedure every 3–5 years.

In view of the relative safety of stimulation procedures compared with lesioning, most surgery for people with PD today uses the former approach. The GDG felt therefore that it should confine its recommendations to STN, Gpi and thalamic stimulation.
8.1.1 **Methodological limitations of surgery trials**

The included trials all had methodological limitations common to non-analytical study designs. Firstly, none of the included trials were randomised into surgical or non-surgical intervention groups. Secondly, none of the trials were performed under blinded conditions, either single or double. None of the trials were controlled with a cohort of non-surgical patients for longitudinal comparison over time.

There was also a general lack of inclusion/exclusion criteria, which could lead to pre-selected patient populations, lack of multi-centre comparative results analysis, and lack of sample size calculations. The mean follow-up of most trials was 7–12 months and the patient population tended to be younger with an average age of approximately 60 years.

What is the effectiveness and safety of any DBS procedure versus standard medical therapy in the treatment of motor complications in patients with PD?

8.2 **Subthalamic nucleus stimulation**

8.2.1 **Methodology**

No randomised or controlled trials were found on the effectiveness of any DBS procedure versus standard medical therapy. Therefore, the GDG agreed that large case series studies with a minimum sample size of 40 patients were to be accepted for review.

Nine papers were found which reported the effectiveness of STN-DBS versus standard medical therapy.

8.2.2 **Health economic methodology**

Four health economic studies met our quality criteria.\textsuperscript{266–269} One study\textsuperscript{267} evaluated the incremental cost-effectiveness of bilateral DBS of the STN or GPI versus best medical management. The study\textsuperscript{267} estimated the cost per QALY of bilateral DBS of the STN or GPI
Another study evaluated the incremental cost-effectiveness of STN-DBS versus drug treatment. This study estimated the extra cost per additional UPDRS point gained from bilateral high-frequency STN-DBS by comparing STN-DBS and drug treatment with drug treatment alone in the German healthcare context.

One study evaluated the costs of STN-DBS. The study estimated the total health service cost per patient including preoperative assessment, STN-DBS and postoperative management over a 5-year period in the UK healthcare context.

Another study evaluated the change in medication costs after bilateral STN-DBS. This study estimated the anti-parkinsonian medication costs pre- and post-operatively at 1 and 2 years after bilateral STN-DBS in a US healthcare context.

A simplified cost-effectiveness analysis of bilateral DBS-STN was estimated from the perspective of the NHS over 5-year period (Appendix F).
8.2.3 Evidence statements

With respect to quality of life\textsuperscript{270}

Parkinsonian symptoms, systemic symptoms, emotional functioning and social functioning all improved post-operatively (p<0.001).

The improvement in the score of UPDRS II correlated with the improvement in total Parkinson's Disease Quality of Life (PDQ-L) score (p<0.001). (3)

With respect to efficacy, see Table 8.1.

<table>
<thead>
<tr>
<th>Table 8.1 Bilateral STN stimulation (stimulator 'on')</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Motor complications</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
**Parkinson’s disease Appendix H: Deleted Text Appendix**

<table>
<thead>
<tr>
<th>Medication</th>
<th>g274</th>
<th>g271,272</th>
<th>g270,272,274-276</th>
<th>g272,274</th>
<th>g276</th>
<th>g276</th>
</tr>
</thead>
</table>

S = improvement in favour of STN stimulation (p<0.05); NS = not significant; B = worsening of symptoms after surgery (p<0.05); – = not reported; * = patients >70 years of age; ^ = axial symptoms: speech, postural stability and gait (items 18, 29, 29 and 10 of UPDRS III); = off medication.
With respect to predictive factors, the following results were observed (Table 8.2):

One study\(^{274}\) found: ‘the younger the age at the moment of operation and the shorter the duration of disease, the better the clinical outcome’. Another study\(^{277}\) reported: no significant correlation between age at time of surgery or disease duration and post-operative clinical outcome. (3)

One study\(^{275}\) found: UPDRS motor scores off medication were improved but less so in patients over 70 (<70 vs >70, p<0.02), and changes in UPDRS motor scores (on medication) worsened in patients over 70 and improved in patients under 70 (p<0.05). Another study\(^{274}\) found: no significant difference between patients older and younger than 60 years of age for UPDRS II, III and IV scores, and no significant difference in mean daily levodopa dosage at follow-up. (3)

<table>
<thead>
<tr>
<th>Table 8.2 Correlations between pre-operative and post-operative factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (^{275}) - Improvement from stimulation (p&lt;0.01)</td>
</tr>
<tr>
<td>Age of patients(^{273}) - Fine motor score (p&lt;0.001) and initiation subset of Mattis DRS (p=0.007)</td>
</tr>
<tr>
<td>Age of patients(^{273}) - Item 2 of UPDRS thought disorders (p=0.023)</td>
</tr>
<tr>
<td>Age or disease duration (p&lt;0.005 and p=0.007 respectively)(^{271}) + Motor disability score in the 'on' stimulation and 'on' drug conditions</td>
</tr>
<tr>
<td>Younger patients and shorter disease duration(^{271}) + Residual ADL, motor disability and axial scores</td>
</tr>
<tr>
<td>Low motor disability and high neuropsychological status(^{271}) + Improvement in motor disability Please note: low motor disability predicting level of improvement in motor disability after surgery may be a statistical artifact (increased t's mean)</td>
</tr>
<tr>
<td>Less severe axial motor symptoms(^{271}) + Improvement in axial motor disability</td>
</tr>
<tr>
<td>Levodopa challenge(^{275}) + Results from STN-DBS (p&lt;0.02)</td>
</tr>
<tr>
<td>Improvement from levodopa(^{275}) + Improvement from STN-DBS (p=0.00001)</td>
</tr>
<tr>
<td>Levodopa response in an individual symptom(^{275}) + Simulation response for that same symptom (akinesia, tremor, rigidity, postural instability, gait and null test (p&lt;0.001))</td>
</tr>
<tr>
<td>Improvement from levodopa in Hoehn and Yahr and Schwab and England clinical rating(^{275}) + Improvement from stimulation in the same rating (p&lt;0.001)</td>
</tr>
</tbody>
</table>

\( + \) = Positively correlated (i.e. increase in factor 1 leads to an increase in factor 2); \( - \) = Negatively correlated (i.e. increase in factor 1 leads to a decrease in factor 2).
With respect to adverse events, the following were reported following STN-DBS:

Neuropsychological events including: confusion, mania, delusion, depression, hypomania, aggressive behaviour, hallucinations, attentional and cognitive deficit, dementia, panic attack and apathy, which in some impaired activities of daily living.

Other adverse events including: hypophonia, transitory eye opening apraxia, thrombophlebitis, subcutaneous infection, haematomas, focal cerebral contusions, infections of the system (sic) ('the system relates to the actual equipment used), dysarthria, disequilibrium, dystonia, weight gain, connection wound dehiscence, lead repositioning, air embolus, seizure and dyskinesias.

Stimulator-induced events including: electrode replacement due to unsatisfactory results, local pain at the implantation site of the pulse generator, reversible stimulation-induced dyskinesias after an increase in voltage, minor intracerebral bleeding at the site of the trajectory lead, dislocation of the impulse generator from site of implantation, transient paraesthesias associated with adjustment of stimulation parameter. (3)

With respect to withdrawal rates:

Two studies reported suicide attempts: one study reported patients with depression (three) who then attempted suicide (two)270 and the other study reported four patients who attempted suicide post-operatively (one died).273

In a third study,277 three patients died from causes unrelated to surgery or stimulation, and in a fourth study,276 three deaths were reported (from intracerebral haemorrhage, myocardial infarction and suicide). (3)

### 8.2.4 Health economic evidence statements

Bilateral STN- or GPi-DBS costs an additional $49,194 in US$2000 (approximately £31,112) per QALY in comparison to best medical management.267 The study's results suggest DBS may therefore be cost-effective if the quality of life after the procedure is improved by 18% or more compared with best medical management.

Bilateral STN-DBS costs approximately an additional DM1,800 (UK£580) in 2002 prices per unit improvement in UPDRS total score, derived from German costs and patient data.266 However, the costs will decrease further over the long term (> 1 year study period) from reduced drug expenditure and improved patient functioning. Therefore, the direct and indirect costs need to be assessed over the long term to sufficiently evaluate the cost-effectiveness of DBS.

The total health service costs of DBS of the STN, including pre-operative assessment, surgery
and post-operative management over a 5-year period, was recently evaluated in the UK.\textsuperscript{268} The estimated total cost per patient was £32,526 for the bilateral procedure and £30,447 for the unilateral procedure (€ 2002).\textsuperscript{268}

A US study evaluated the change in anti-parkinsonian medication costs 2 years after bilateral STN-DBS. The study found the medication costs had significantly decreased by 32\% (p < 0.01) from the 1-year pre-operative costs and there was 39\% reduction after 2 years.\textsuperscript{269} Pre-operatively, the average daily cost of PD medication was $19.53 \pm 10.41 in US$ 2002 (approximately £11.92 \pm 6.35) per patient. Post-operatively, this fell to $13.25 \pm 5.41 (approximately £8.08 \pm 3.30) per patient.\textsuperscript{269}

The economic modelling performed for this guideline (Appendix F) suggests that STN-DBS costs approximately £19,500 per QALY over a 5-year period in comparison to standard PD care in the UK (£ 1998). The results are relatively robust based on one-way sensitivity analysis.
8.2.5 From evidence to recommendation

In the absence of RCTs, any conclusions on the efficacy and safety of bilateral STN stimulation must be tentative. Most of the patients in the open-label non-controlled trials described above were relatively young (aged around 60 years) so the results may not be generalisable to all those with the condition. Follow-up was for around 12 months only, which may not record later complications.

Despite these limitations, what evidence is available supports the efficacy of this technique in reducing off time, dyskinesia and levodopa dose, improving motor impairments and disability, and improving quality of life.

There is a small but significant risk of permanent neurological disability as a consequence of this operation, due mostly to cerebral infarction or haemorrhage. In a small number of patients, this can lead to death. Most other adverse effects of surgery were transient but concern remains regarding the incidence of neuropsychiatric complications, particularly depression and suicide. It is difficult to comment reliably on such issues in the absence of a control group.

The procedure requires an experienced, well-trained multidisciplinary team.

The high cost of this type of functional neurosurgery in PD is well recognised. No long-term data from clinical trials are available. However, economic modelling over a 5-year period performed as part of this guideline suggests that bilateral STN-DBS costs £19,500 per QALY in comparison to standard PD care in the UK (£ 1998).

The National Institute for Health and Clinical Excellence (NICE) published an Interventional Procedure Statement on bilateral STN stimulation in November 2003. This supported the use of the procedure provided normal arrangements for consent, audit and clinical governance are in place.

The PD SURG trial is evaluating the clinical and cost-effectiveness of STN surgery and recruitment is ongoing (www.pdsurg.bham.ac.uk/). The NICE Interventional Procedure Statement encouraged clinicians to consider randomising patients in this trial.

RECOMMENDATION

R55 Bilateral STN stimulation may be used in people with PD who:
Parkinson's disease Appendix H: Deleted Text Appendix

have motor complications that are refractory to best medical treatment,
are biologically fit with no clinically significant active comorbidity,
are levodopa responsive and

have no clinically significant active mental health problems, for example depression

or dementia.
8.3 Globus pallidus interna stimulation

8.3.1 Methodology

No randomised or controlled trials were found on the effectiveness of any GPI-DBS procedure versus standard medical therapy. Therefore, large case series designs with a minimum sample size of 40 people were accepted for review.

8.3.2 Evidence statements

No trials were found which assessed the effectiveness of GPI stimulation in a case series with a minimum sample size of 40 people with PD.

8.3.3 From evidence to recommendation

While no RCTs or large case series have evaluated GPI-DBS, there are a small number of case series and comparative trials that suggest the procedure is effective (see section 8.4). However, it is likely to suffer from the same concerns regarding adverse events and costs as STN-DBS.

GPI-DBS is rarely performed for PD in the UK at present, though it is sometimes undertaken when STN-DBS is not possible.

RECOMMENDATION

R56 Bilateral GPI stimulation may be used in people with PD who:

- have motor complications that are refractory to best medical treatment,
- are biologically fit with no clinically significant active comorbidity,
- are levodopa responsive and

- have no clinically significant active mental health problems, for example
8.4 Comparison of different types of deep brain stimulation

What is the most effective form of DBS procedure in the treatment of motor fluctuations and complications in patients with PD?

8.4.1 Methodology

There were no randomised or controlled trials reporting the most effective form of DBS in the treatment of patients with PD. The majority of trials were retrospective case series, which compared the results of different techniques. Due to the lack of comparative trials in this area, the GDG agreed studies with a sample size minimum of 10 patients per arm should be reviewed.

Five trials278–282 were found which compared the before and after surgery results of STN-, GPi- and Vim thalamic DBS.
The majority of the patient population received bilateral implantation, though results were not reported separately from the unilateral implantation results.

### 8.4.2 Evidence statements

With respect to clinical efficacy

The following criteria were significantly (p<0.05) in favour of both STN- and GPi-DBS:
- UPDRS I, II (off and on), III (off and on), IV,278,279,281,282
- time in off state (UPDRS item 39)282
- Hoehn and Yahr scores281
- levodopa equivalent daily dose278,279,281
- dyskinesia scores278,279
- patient and physician global assessments
- Schwab and England scale282
- home diary scores (% of time with good mobility and without dyskinesia during the waking day). 279 (3)

The following criteria were improved in only one DBS technique versus another:
- Motor score improvement was more pronounced in STN patients than GPi patients (no p values stated).281
- Medication could be reduced only in STN patients and not in GPi patients (no p values stated).281
- Levodopa dose equivalent, though unchanged in the GPi group, was significantly reduced in the STN group (p=0.017).282
- Trail making test (p=0.0013), test B (p=0.0015) and BDI (p<0.0001) improved under STN stimulation and not GPi.281
- Literal (p=0.0018) and total (p=0.0002) fluency decreased under STN-DBS and not GPi-DBS.281
- Core Assessment Program for Intracerebral Transplantations dyskinesia rating scale favoured GPi (p=0.046) in absolute scores but percentage changes were not
Parkinson’s disease Appendix H: Deleted Text Appendix
significant.282 (3)

Thalamic nucleus stimulation could not be compared directly to other techniques, as the
outcome measures used to assess its efficacy are different from other techniques. The
main outcome, tremor suppression, was found to be significantly improved with the
procedure.283 (3)

With respect to adverse events, the following was reported:
No GPi-specific adverse events were reported.
See thalamic stimulation and STN stimulation sections for events specific to these
procedures. (3)

8.4.3 From evidence to recommendation

There is no evidence from RCTs to compare STN with GPi stimulation. However, observational
studies suggest that STN stimulation may lead to greater improvement in motor scores and
more reduction in levodopa dose and depression scores. In comparison, GPi stimulation may
lead to less cognitive impairment. Further work is required in this area.
It is recognised that pallidal stimulation for PD is rarely performed at present, though it is sometimes undertaken when STN-DBS is not possible.

**RECOMMENDATION**

R57 With the current evidence it is not possible to decide if the STN or GPi is the preferred target for DBS for people with PD, or whether one form of surgery is more effective or safer than the other. In considering the type of surgery, account should be taken of:

- clinical and lifestyle characteristics of the person with PD
- patient preference after the patient has been informed of the potential benefits and drawbacks of the different surgical procedures.  

**8.5 Thalamic stimulation**

How effective and safe is thalamic stimulation for the control of tremor in PD?

**8.5.1 Methodology**

Three papers284,283,285 reported the effectiveness of chronic stimulation to the Vim thalamic nuclei. The methodological limitations of these papers are similar to those of STN stimulation (see Section 8.2).

**8.5.2 Evidence statements**

With respect to tremor suppression:

All three studies284,283,285 showed a benefit of thalamic stimulation.
Only one study\textsuperscript{283} reported statistical analysis and stated that the following outcomes were significantly (p<0.05) improved: face tremor and observed tremor, hypokinesia, rigidity and ADL score. (3)

With respect to adverse events, the following were reported:

Post-operative events included: venous infarction with temporary aphasia, intraventricular haemorrhage and cardiovascular problems intra-operatively.

Stimulation-related events that occurred considerably more frequently in patients with bilateral implants (52\%) as compared with unilateral (31\%)\textsuperscript{285} included: dystonia, diplopia, sleepiness, altered mental status, paraesthesias, mild disturbance of gait and balance, mild dysarthria, increased drooling, nausea, insomnia, dysphagia, depression, wire tightness and dysarthria. (3)

No mortality was reported in any of the trials.

With respect to withdrawal rates:

Most withdrawals were due to adverse events. (3)
8.5.3 From evidence to recommendation

There is no evidence from RCTs of the benefit of thalamic stimulation in PD. Data from observational studies suggest that this is an effective method of reducing tremor. The operation carries a risk of serious complications such as cerebral infarction and haemorrhage. The GDG recognised that this form of surgery is rarely performed for tremor in people with PD in England and Wales, having been superseded by STN stimulation.

RECOMMENDATION

R58 Thalamic DBS may be considered as an option in people with PD who predominantly have severe disabling tremor and where STN stimulation cannot be performed.
Parkinson's disease Appendix H: Deleted Text Appendix
Non-motor features of Parkinson’s disease

*I feel trapped inside my body . . . as if I’m not in control . . . almost as if someone or something else is running my life.* (patient)

9.1 Introduction

The spectrum of PD includes many problems that do not directly affect motor function. These non-motor features are of crucial importance to people since they have a major impact on quality of life.

Non-motor features comprise:
- mental health problems
- depression and dementia
- falls and potential fractures
- sleep disturbance
- autonomic disturbance and pain.

While most people are troubled by these problems in the later stages of their PD, certain non-motor conditions can develop throughout the course of the condition (eg depression, anxiety, hypersomnia) or even precede it (eg sleep disturbance, depression, anxiety).

A recent study reported on the non-motor problems experienced by a group of 149 people with PD followed for 15–18 years. They found the occurrence rates were: falls 81% (with 23% suffering fractures), cognitive decline 84% (48% fulfilling criteria for dementia), hallucinations 50%, depression 50%, choking 50%, symptomatic postural hypotension 35%, and urinary incontinence 41%.

There have previously been few therapeutic studies examining the effects of treatments for non-motor disorders. However, there is now a real desire to increase research into the non-motor features of PD as their effect on people’s well-being has been recognised.
The non-motor features of PD considered in the scope of this guideline and thus undergoing literature review were:

- mental health problems:
  - depression
  - dementia
  - psychosis

- sleep disturbance:
  - hypersomnia
  - rapid eye movement sleep behaviour disorder (RBD)
  - restless legs syndrome (RLS)

- inverted sleep-wake cycle
- nocturnal akinesia.
Although the following non-motor features of PD were not considered within the scope of this guideline, it is recognised that they are important and should always be considered in patient care. These non-motor features include:

- mental health problems
  - anxiety
  - apathy
- falls
- autonomic disturbance
  - bowel dysfunction including constipation
  - dysphagia
  - weight loss
  - dribbling of saliva
- bladder dysfunction
- sexual dysfunction
  - postural hypotension
  - excessive sweating
  - pain.

Depression, dementia and psychosis are frequent problems in PD and some research has been performed on their treatment. Therefore, these topics were included in the scope of this guideline.

Other important mental health issues in PD include anxiety and apathy, but little work has been done in these areas specific to PD so they were not included in the scope. Standard treatment therefore applies in these areas; see NICE guidance entitled: ‘Anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care.’

### 9.2 Mental health problems

#### 9.2.1 Depression
Depression affects around 40–50% of people with PD. It is usually mild to moderate but can be severe, and symptoms of depression can predate motor manifestations.

The relationship of depression to the pathology of PD is unclear but the inconsistent relationship between mood changes and the severity of motor symptoms indicates that depression should not simply be considered a reaction to motor disability.

There are difficulties in diagnosing mild depression in people with PD as the clinical features of depression overlap with the motor features of PD.

The characteristic features of depression are low mood, loss of interest and enjoyment, and fatigue. This is accompanied by various combinations of:

- slowed mental and physical function
- motor agitation
- poor appetite and sleep
- weight loss
other somatic symptoms

disturbance of cognitive function and thought processes.

The disturbance of cognitive functions and thought processes may result in poor concentration and memory, excessive worry, feelings of worthlessness, hopelessness and guilt, negative views of self and life, and thoughts of suicide. Psychological and physical symptoms of anxiety are also common.

The development of depression creates an added burden for people with PD and their carers and has been shown to be an important determinant of quality of life.

Factors relevant to the aetiology of depression that need to be considered are:
- previous susceptibility to depression
- neurotransmitter disturbances of PD
- effects of drug treatments
- relationship to on-off motor fluctuations
- the person's adjustment to the diagnosis of PD and their symptoms and life factors, including losses
- other stressors
- interpersonal relationships.

What is the effectiveness of antidepressant therapies versus placebo or active comparator in the treatment of depression in PD?

Methodology

A Cochrane review and two randomised controlled trials (published after the review's search date) were found which addressed the effectiveness of antidepressant therapies versus placebo or active comparator. No controlled trials were found on electroconvulsive therapy or behavioural therapy for the treatment of depression in PD people.

The Cochrane review included three trials: one trial compared a selective serotonin re-uptake inhibitor (SSRI) with placebo; another study compared a tricyclic antidepressant
(TCA) with placebo; and the third trial compared the effectiveness of an SSRI versus a TCA.

These trials included small sample sizes (range 22–47). There were several methodological limitations of the included studies: lack of power calculations, lack of baseline characteristics, and no details on methods of randomisation and allocation concealment. The duration of the included trials varied from 16 to 52 weeks (with one study not reporting the trial duration).

One of the independent RCTs compared the effectiveness of an SSRI with placebo. The methodological limitations of this study included unclear methods of randomisation and allocation concealment, small sample size (N=12, six in each arm) and lack of power calculations. The study reported that, because of the low recruitment, the study was terminated after 10 weeks.

The second independent RCT compared repetitive transcranial magnetic stimulation (rTMS) versus an SSRI as an effective antidepressant therapy. The methodological limitations included: short trial duration (8 weeks), small sample size (N=42, 21 in each arm) and lack of power calculation.
Evidence statements

The Cochrane review[^291] reported the following non-significant results:

- Nortriptyline (TCA) improved depressive symptoms in the first half of a crossover trial with no deterioration in parkinsonian symptoms.
- Citalopram (SSRI) provided no additional benefit over placebo in the treatment of depressive symptoms in a parallel trial design.
- Fluvoxamine (SSRI) and amitriptyline (TCA) showed similar efficacy in an open-label trial.

Confusion and visual hallucination were infrequently reported in people taking fluvoxamine and amitriptyline; otherwise, no other major adverse events were reported. (I++)

One of the independent RCTs[^293] reported no significant difference between sertraline (SSRI) and placebo in terms of 'response' to treatment (defined as at least 50% reduction of the pretreatment Montgomery-Asberg Depression Rating Scale), or UPDRS motor scores. (I+)

One of the independent RCTs[^292] reported that the following outcomes were improved in both rTMS and fluoxetine-treated groups: the Hamilton Depression Rating Scale and BDI, ADL scores, and the Mini-Mental State Examination (MMSE), with no significant differences between groups. However, adverse events were found more frequently in the fluoxetine-treated group than the rTMS group (p=0.03). (I++)

From evidence to recommendation

There is insufficient evidence from RCTs of the efficacy or safety of any antidepressant therapy in PD. This includes cognitive behavioural therapy, all classes of antidepressant medication and electroconvulsive therapy.

NICE has recently published guidelines[^18] for the management of depression which include people with physical disorders. While it is tempting to adopt these guidelines for people with PD, there are a number of factors that suggest that the management of depression in PD may require different strategies:

There are case reports suggesting that some antidepressants may make PD motor symptoms worse[^297]
There are established, but rare, interactions between some antidepressants and dopaminergic therapy for PD (e.g. MAO-B inhibitors and antidepressants).298

Cognitive behavioural therapy is not widely available to secondary care teams looking after people with PD.

There is an urgent need for further research to establish effective and safe treatments for depression in PD.
RECOMMENDATIONS

R59 Clinicians should have a low threshold for diagnosing depression in PD.  
D (GPP)

R60 Clinicians should be aware that there are difficulties in diagnosing mild depression in people with PD because the clinical features of depression overlap with the motor features of PD.  
D (GPP)

R61 The management of depression in people with PD should be tailored to the individual, in particular, to their co-existing therapy.  
D (GPP)

9.2.2 Psychotic symptoms

Psychotic symptoms indicate a loss of reality testing; that is, the formation of beliefs and sensations without a basis in reason or external sensory stimulus. Delusions (false unshakeable beliefs that cannot be understood from the individual’s sociocultural context) and hallucinations (perceptions in any sensory modality occurring without external sensory stimulus) are the most common symptoms of psychosis.

Psychotic symptoms may occur at any stage in PD. Up to 50% of people with the condition may develop psychotic symptoms²⁹⁹ and 30% may experience hallucinations within the first 5 years.³⁰⁰ Although visual hallucination is the most frequent psychotic symptom, a degree of auditory hallucination is found in 40%.³⁰ⁱ Delusions may involve themes of persecution, infidelity and jealousy but these are much less common.

The aetiology of psychotic symptoms in PD is complex. They may arise from the neurotransmitter disturbances of PD but can be caused by any of the drugs used to treat motor symptoms.

The appearance of psychotic symptoms requires careful evaluation. Psychotic symptoms may also occur as part of delirium (caused by other physical illness or drug treatments) or dementia, or may indicate the development of a co-morbid mental illness.

Psychotic symptoms are distressing and may be frightening to people with PD and their carers who may not appreciate that they are symptoms of illness. It is essential to explain the nature
of these symptoms to people with PD and their carers.

What is the effectiveness of atypical antipsychotic therapies versus placebo or active comparator in the treatment of psychotic symptoms in PD?

**Methodology**

Five RCTs\textsuperscript{301–305} were found which addressed the effectiveness of atypical antipsychotic therapies versus placebo or active comparator in the treatment of psychosis.

Three trials\textsuperscript{306–308} were found that compared two atypical antipsychotic drugs, and these were excluded as within drug class comparisons.

The methodological limitations for some of the included studies involved: lack of randomisation and allocation concealment methods, lack of multi-centre comparative results analysis, lack of power calculations, small sample sizes (\( N=31 \)\textsuperscript{309}, 160\textsuperscript{303}, 30\textsuperscript{302} and 60\textsuperscript{304}), short trial duration and no intention-to-treat analysis protocols.
Evidence statements

With respect to psychiatric outcomes:

Trials which looked at the effectiveness of clozapine versus placebo found the following outcomes in favour of active drug treatment:

- CGI scale (p=0.002)\textsuperscript{301}, (p=0.001)\textsuperscript{304}
- Brief Psychiatric Rating Scale (BPRS) score (p=0.002)\textsuperscript{301}
- BPRS-Modified score (p=0.003)\textsuperscript{301}
- Scale for the Assessment of Positive Symptoms (p=0.01)\textsuperscript{301}
- Positive and Negative Syndrome Scale positive subscore (p<0.001).\textsuperscript{304} (1+)

Trials which looked at the effectiveness of olanzapine versus placebo found no significant differences between groups on a battery of neuropsychological tests.\textsuperscript{302,303} (1+)

One trial which looked at quetiapine versus placebo found no significant difference between groups on the Baylor PD Hallucination Questionnaire, the BPRDS, and a battery of neuropsychological tests.\textsuperscript{307} (1+)

With respect to motor outcomes:

One trial which looked at clozapine versus placebo reported a beneficial effect of clozapine on UPDRS tremor subscore (p=0.02).\textsuperscript{301} (1+)

Other trials which looked at olanzapine versus placebo reported that the following outcomes worsened with drug treatment:

- UPDRS total (p=0.007 and p=0.024)\textsuperscript{303}
- UPDRS motor scores (p=0.023 and p=0.039),\textsuperscript{303} (p<0.05)\textsuperscript{302}
- subscores gait (p<0.001) and hypokinesia (p<0.05)\textsuperscript{302}
- timed tapping scores (p<0.05)\textsuperscript{302}
- UPDRS ADL scores (p=0.004 and p=0.009).\textsuperscript{303} (1+)

The trial that looked at quetiapine found no differences between placebo and active drug...
Parkinson’s disease Appendix H: Deleted Text Appendix

groups on UPDRS ADL or motor scores. There was also no difference found on the Goetz Dyskinesia Rating Scale scores.505 (1+)

With respect to adverse events:

The following events were reported as significantly increased in people receiving clozapine treatment:

- increased mean resting heart rate (p=0.046)501
- increased body weight (p=0.005)501
- increased somnolence (53% vs 18%) and worsening of parkinsonism (21.8% vs 4%) (p values not stated)504 (1+)

The following events were reported as significantly increased in people receiving olanzapine treatment:

- extrapyramidal syndrome (p=0.003)503
- hallucinations (p=0.013)503
- increased salivation (p=0.026)503
- no case of agranulosyosis reported504 (1+)

There were no significant differences in adverse events reported in the study on quetiapine versus placebo. The study did report that no people on the active drug dropped out secondary to related adverse events, which included sedation (N=9, 43%), and subjective worsening in PD (N=4, 19%).505 (1+)
With respect to withdrawal rates:

Trials on clozapine efficacy reported that most withdrawals were due to either treatment failure or adverse events.\(^{304}\) (1+)

Trials which assessed the effectiveness of olanzapine reported:

- significantly more people receiving olanzapine discontinued (p=0.029), and mostly due to adverse events (p=0.003), compared with placebo.\(^{307}\) (1+)

The trial that assessed quetiapine effectiveness reported no significant differences in withdrawal rates. The study found that 81% of the active drug group completed the study, with four patients withdrawing due to serious unrelated illness or lack of effect and poor compliance. In the placebo group 80% of the participants completed the trial; reasons for withdrawal included unrelated serious illness, resulting in death.\(^{305}\) (1+)

From evidence to recommendation

Psychosis is a common problem in later PD and can be difficult to manage (Figure 9.1). It may be precipitated by intercurrent illnesses (eg infections), addition of new anti-parkinsonian medication or dementia. Correspondingly, the initial treatment of psychosis should include general medical assessment and treatment of any potential causative factor. Consideration should be given to withdrawal of any recently added medication that may have triggered a psychotic reaction. Drugs that are particularly prone to trigger psychosis, such as anticholinergics, selegiline and amantadine, should be withdrawn first. The patient should be evaluated for a fixed cognitive deficit that might suggest the development of dementia.

For psychosis which does not respond to the above measures, no treatment may be required if psychotic features are not troublesome to the patient or their carers.

In more severe psychosis, antipsychotic medication should be considered. Typical antipsychotics (eg phenothiazines and butyrophenones) are well known to exacerbate PD and should not be used. Various atypical antipsychotics have been evaluated in PD, but only clozapine has a licence for this indication in England and Wales:

Several randomised placebo-controlled trials have shown that clozapine can reduce psychotic symptoms in PD without exacerbating parkinsonian features. However, the use of clozapine requires intensive monitoring to detect the uncommon but potentially life-threatening complication of agranulocytosis. As a result, it is rarely used in PD.
Limited trial evidence suggests that olanzapine is not effective against psychotic features and makes parkinsonian symptoms worse.

There are concerns about the safety of olanzapine and risperidone in elderly people with dementia and risk factors for stroke.\textsuperscript{310}

There is no evidence from RCTs of the efficacy and safety of quetiapine as an antipsychotic in PD. However, several trials are ongoing in this area. Quetiapine is thought to be relatively safe and does not require haematological monitoring. As a result, quetiapine has been widely used in PD psychosis.
Figure 9.1 Management of psychosis in PD
RECOMMENDATIONS

R62 All people with PD and psychosis should receive a general medical evaluation and
treatment for any precipitating condition.  

D (GPP)

R63 Consideration should be given to withdrawing gradually anti-parkinsonian
medication that might have triggered psychosis in people with PD.  

D (GPP)

R64 Mild psychotic symptoms in people with PD may not need to be actively treated if
they are well tolerated by the patient and carer.  

D (GPP)

R65 Typical antipsychotic drugs (such as phenothiazines and butyrophenones) should
not be used in people with PD because they exacerbate the motor features of the
condition.  

D (GPP)

R66 Atypical antipsychotics may be considered for treatment of psychotic symptoms in
people with PD, although the evidence base for their efficacy and safety is limited.  

D (GPP)

R67 Clozapine may be used in the treatment of psychotic symptoms in PD, but registration
with a mandatory monitoring scheme is required. It is recognised that few specialists
caring for people with PD have experience with clozapine.  

B
9.2.3 Dementia

PD is associated with impairment of cognitive function. Compared with people without PD, deficits in visuospatial abilities, category learning, verbal fluency, set switching and executive functions are typically reported.

Particular attention has focused on deficits of executive function that may mediate many of the other impairments. Executive functions include working memory, mental flexibility, and the ability to initiate and suppress responses.

Dementia (the progressive loss of global cognitive function) is also common in PD; 48%\(^{205}\) to 80%\(^{211}\) of people may develop dementia at some point in the course of the condition.

In addition to cognitive decline, dementia leads to impairment in activities of daily living and disturbance of behaviour and other psychological functions. Dementia in PD is accompanied by reduced quality of life for people with PD and their carers.\(^{290,312}\)

Other pathologies commonly causing dementia include Alzheimer’s disease, vascular brain disease and dementia with Lewy bodies.

Traditionally, dementia developing more than 1 year after the onset of the motor features of PD is referred to as PD with dementia (PDD). Dementia developing within 1 year of the onset of motor features is classified as dementia with Lewy bodies. The relationship between PDD and dementia with Lewy bodies is unclear, but many consider them to be a continuum rather than discrete entities.

Since people with dementia with Lewy bodies may not develop parkinsonism, we have not considered the treatment of this type of dementia in this guideline. The GDG acknowledges that this decision may need to be revisited in the future if new evidence proves that a continuum exists between PDD and dementia with Lewy bodies.

Rarely, dementia may arise due to a treatable illness. All people with dementia require careful evaluation of their medical condition, treatment and investigations to clarify the diagnosis with attention to potentially treatable conditions. In this context, cognitive decline due to depression, often referred to as depressive ‘pseudodementia’, should be considered.

The assessment and management of dementia will require a range of clinical expertise that can be provided only by a multidisciplinary team.
Are cholinesterase inhibitors effective cognitive enhancement therapies in PD?

**Methodology**

Seven papers were found which addressed the effectiveness of cholinesterase inhibitors as cognitive enhancement therapies in PD. All levels of evidence (RCTs and case series) were selected in order to provide a comprehensive body of evidence upon which to analyse the cost-effectiveness of these treatments in people with PDD. In addition, the literature search cut-off date, for this particular section of the guideline, was August 2005 instead of February 2005.

In addition to the seven papers selected, a Cochrane review which included only one RCT on rivastigmine versus placebo was excluded. This paper was excluded as the patient population was defined as people suffering from dementia with Lewy bodies and not PDD.
Evidence statements

| Table 9.1 Effectiveness of cholinesterase inhibitors for people with PDD (1++) |
|-----------------------------|-------------------|------------------|-----------------|
| Study design | RCT | CS | RCT | CS |
| Level of evidence | 1++ | 3 | 1+ | 3 |
| Number of trials | 1 | 1 | 3 | 1 |
| Sample size (N=) | 341 | 287 | 2230 | 1637, 1534 | 1931 |
| Trial duration (weeks) | 24 | 34 | 1637, 1634 | 1639 |

Key cognitive outcomes

- ADAS-cog: C111, C118, NS116, NR117, NR114, NR119
- MMSE: C111, NS118, C116, C117, NS114, NS119
- UPDRS total: NR113, NS118, NS116, NS117, NR114, NR119
- UPDRS motor: NS113, NS118, NS116, NS117, NR114, NR119

Other cognitive outcomes reported to be in favour (p<0.05) of cholinesterase inhibitor treatment:
- Neuropsychiatric Inventory 10113
- Alzheimer's disease assessment scale (ADAS-cog)1113
- Alzheimer's Disease Cooperative Study (ADCS)-CGIC1113
- ADCS ADL113
- Cognitive Drug Research power of attention tests1113
- Delis-Kaplan Executive Function System1113
- Ten-point clock-drawing test1113
- Dementia Rating Scale memory subscore114
- CGI116 (1++)
- Clinical impression of change at weeks 12 and 26118
- UPDRS subscore part I (mental)118
Clock-drawing test.319 (3)

Other cognitive outcomes reported to be improved in people treated with galantamine.319
Hallucinations improved in 78% of people who experienced hallucinations at baseline.
Cognition improved in 62% of people and declined in 31%.319 (3)

*Because executive function tests were not performed at all sites, these tests included only people who actually took these tests (74% and 18% of patient population respectively).
A third case series study\(^\text{315}\) reported the following outcomes specific to the trial’s PDD population: In people diagnosed with PDD there was an association with increased probability of an MMSE response (p=0.02).

PDD patients improved by a mean of 2.3 MMSE points. \(^3\)

With respect to adverse events:

In the rivastigmine-treatment group:

- More adverse events were experienced (p<0.001).\(^\text{313}\)
- Parkinsonian symptoms were more frequent (p=0.002).\(^\text{313}\)
- The most common events included: tremor (p=0.01), nausea and vomiting (p<0.001). \(^1++\)
- 40% of people had to decrease the daily dose.\(^3\)\(^18\) \(^3\)

In the donepezil-treatment group:

- There was a non-significant difference in incidence.\(^\text{314}\)
- Events leading to withdrawal included: constipation, nausea and vomiting, hypersalivation, worsening of motor symptoms (gait impairment, increased number of falls, increased tremor).\(^\text{314,317}\) \(^1+\)

In the galantamine-treatment group.\(^\text{319}\)

- Three people withdrew prematurely due to vomiting, worsening tremor, anorexia and nausea. \(^3\)

With respect to withdrawals:

There was no significant difference in rivastigmine trials.\(^\text{313,320}\) \(^1+\)

The donepezil-treatment group remained in the trial 4.2 weeks longer on average (p<0.05).\(^\text{314}\)

57% of donepezil group versus 11% of placebo group withdrew due to adverse events.\(^\text{314}\) \(^1++\)
From evidence to recommendation

There is evidence from randomised placebo-controlled trials of the effectiveness and safety of cholinesterase inhibitors in the treatment of PDD. They are effective in treating both cognitive decline and psychosis in this context. However, not all patients respond, so regular review of the need for these agents is required.

At the time of writing, only one of the cholinesterase inhibitors has a product licence in the UK. The GDG considers that these are useful agents that are commonly used in clinical practice and that they should be available.

NICE has commissioned the guideline ‘Dementia: management of dementia, including use of antipsychotic medication in older people’. NICE is developing this guideline in collaboration with the Social Care Institute for Excellence. This guideline will cover all major forms of dementia, including Alzheimer’s disease, vascular dementia, Lewy body dementia, subcortical dementia, frontotemporal dementias, and mixed cortical and subcortical dementia. Dementia encountered in the course of PD will be addressed. The guidelines will, where appropriate, address the differences in treatment and care for people with mild, moderate and severe dementia.
RECOMMENDATION

R68 Although cholinesterase inhibitors have been used successfully in individual people with PD dementia, further research is recommended to identify those patients who will benefit from this treatment. D (GPP)

9.3 Sleep disturbance

‘He has lots and lots of nightmares when he goes to sleep, and he comes to and doesn’t know where he is...’ (care)²

Sleep problems are common in PD and comprise:
- daytime hypersomnolence
- nocturnal akinesia
- restless leg syndrome (RLS) (Ekberg’s syndrome)
- periodic leg movements of sleep
- REM sleep behaviour disorder (RBD)
- sudden onset of sleep
- vivid dreams and/or hallucinations
- nocturia (passing of urine frequently – three times or more – at night)
- sleep fragmentation.

They are particularly taxing to people with PD and their bed-partners because of their mixed nature comprising motor, sensory and sleep issues. In addition, if inadequate rest is gained by night, there is a high prevalence of excessive daytime somnolence that may have serious consequences on social functioning and safety.³²²

Assessment should include a thorough sleep history including:
- enquiry about the three phases of sleep: initiation, maintenance and awakening
Parkinson’s disease Appendix H: Deleted Text Appendix

enquiry about leg movements – periodic leg movements in sleep, RLS
hallucinations and vivid dreams
questioning whether dreams are acted out, sometimes violently, indicative of RBD, which occurs in up to 15% of people with PD and may precede the diagnosis of PD.

Drug-induced hallucinations and/or vivid dreams may occur, and should be distinguished from RBD. Many centrally acting drugs may disturb sleep patterns, mainly by inducing sedation, but some may cause nocturnal alertness (eg selegiline).

One of the most common sleep disorders seen in PD is RLS. The International RLS Study Group323 criteria for the diagnosis of RLS are:

desire to move the extremities, usually associated with discomfort or disagreeable sensations in the extremities
motor restlessness – people move to relieve the discomfort (eg walking, or providing a counter-stimulus to relieve the discomfort such as rubbing the legs)
symptoms are worse at rest with at least temporary relief by activity
symptoms are worse later in the day or at night.
Vivid dreams and nightmares may be provoked by many of the commonly used drugs in PD. A review of medication and reduction/avoidance of suspected causes is usually effective. However, RBD may also occur in which dreams are so vivid that they are acted out. When pharmacotherapy is required, a response may be seen to low doses of clonazepam.122

’Sudden onset of sleep’ without warning has recently been described in PD people, with the potential to cause road traffic accidents.324 While certain dopamine agonists were initially incriminated, current opinion is that all PD medications can cause daytime hypersomnia and that all people with PD are liable to hypersomnia and should be warned of the possibility of falling asleep at the wheel. This may be more likely in people with later PD on multiple medications and also during upwards dose titration, particularly with dopaminergic agonists. Any person so affected should not drive.

**RECOMMENDATIONS**

R69 A full sleep history should be taken from people with PD who report sleep disturbance. D (GPP)

R70 Good sleep hygiene should be advised in people with PD with any sleep disturbance and includes:

- avoidance of stimulants (for example coffee, tea, caffeine) in the evening
- establishment of a regular pattern of sleep
- comfortable bedding and temperature

- provision of assistive devices, such as a bed lever or rails to aid with moving and turning, allowing the person to get more comfortable
- restriction of daytime siestas

- advice about taking regular and appropriate exercise to induce better sleep

- a review of all medication and avoidance of any drugs that may affect sleep or alertness, or may interact with other medication (for example, selegiline, antihistamines, H₂ antagonists, antipsychotics and sedatives). D (GPP)

R71 Care should be taken to identify and manage restless leg syndrome (RLS) and rapid
Parkinson's disease Appendix H: Deleted Text Appendix

eye movement (REM) sleep behaviour disorder in people with PD and sleep disturbance. D (GPP)

R72 People with PD who have sudden onset of sleep should be advised not to drive and to consider any occupational hazards. Attempts should be made to adjust their medication to reduce its occurrence. D (GPP)

9.3.1 Daytime hypersomnolence

It has been recognised in recent years that daytime hypersomnolence is a major issue for people with PD. This may even lead to the sudden onset of sleep, which can be dangerous.

How effective is modafinil in treating daytime hypersomnolence in PD?
Methodology

Three placebo-controlled, double-blind RCTs\textsuperscript{325,326,327} were found which investigated the effectiveness of modafinil treatment for sleep disorders in people with PD. Two of the studies used a 200 mg/d dose\textsuperscript{325,326} while the third increased the dose to 400 mg/d after 1 week.\textsuperscript{327}

All studies were small (N=15, 21 and 40)\textsuperscript{325,326,327} and of short duration (between 4 and 8 weeks). The mean age of the people included in these studies was 65 years, with mean disease duration of 7 years.

No RCTs were found on the specific treatment of RBD and RLS in PD.

Evidence statements

With respect to the Epworth Sleepiness Scale (ESS):

One study\textsuperscript{325} demonstrated the change in ESS was statistically significant in favour of modafinil treatment (95\% CI –8.6 to –0.2, \( p = 0.039 \)). (1+)

Another study\textsuperscript{327} found no significant change in ESS between modafinil and placebo groups. (1++)

With respect to patient-rated scales:

The patient-rated CGI scale improved significantly on modafinil (\( p = 0.07 \)).\textsuperscript{325} (1+)

There was no difference between modafinil and placebo groups in terms of change in sleepiness ‘much or very much improved’.\textsuperscript{327} (1++)

With respect to other outcome measures:

There were no significant differences between modafinil and placebo in the largest study\textsuperscript{327} for the following:

– UPDRS ADL and motor scores
– Multiple sleep latency test
Parkinson’s disease Appendix H: Deleted Text Appendix

- SF-36
- Fatigue Severity Scale
- Hamilton depression scale
- adverse events
- withdrawal rates. (1++)

There were no significant differences between modafinil and placebo for the following in the two smaller studies:525,526
- Maintenance of Wakefulness Test526
- mean changes in sleep latency526
- sleep logs (similar amounts of sleep)526
- Beck depression scores526
- physician-rated CGIC525
- worsening/improvement of PD signs525
- UPDRS scores, Hoehn and Yahr scores, timed tapping tests or patient diaries525
- percentage on time525
- adverse events525,526
- withdrawal rates. 525,526 (1+)
9 Non-motor features of Parkinson’s disease

From evidence to recommendation

While there is little evidence from RCTs of the efficacy and safety of modafinil in the treatment of daytime hypersomnia in PD, it has a product licence for use in hypersomnia in chronic diseases. Members of the GDG have little experience in its use but acknowledged that modafinil can be useful in this clinical context.

RECOMMENDATION

R73 Modafinil may be considered for daytime hypersomnia in people with PD. D (GPP)

9.3.2 Nocturnal akinesia

Turning over in bed (nocturnal akinesia) may become difficult in PD due to truncal rigidity. This can have a major impact on people with PD and can interfere with sleep and thus lead to daytime hypersomnia.

Treatment has traditionally been with either small doses of immediate-release levodopa or controlled-release levodopa last thing at night. There is insufficient experience with dopamine agonists and COMT inhibitors in this area.

Are controlled-release levodopa preparations effective in the management of nocturnal akinesia in PD?

Methodology

A double-blind RCT\(^{25}\) was found which compared controlled-release levodopa and immediate-release levodopa in the treatment of nocturnal and early-morning disability.

The RCT was a multi-centre trial including 103 people from 11 centres in the UK. The mean age of people included in the study was 68 years, with average disease duration of 8 years. Controlled-release co-beneldopa or immediate-release co-beneldopa was given at a dose of 125 mg/day immediately before going to bed.
Methodological limitations included: lack of randomisation and allocation concealment methods, no washout period or first-arm results, and intention-to-treat analysis was not stated. However, carry-over effects and differences between centres were statistically analysed and produced no significant differences.

Evidence statements

With respect to controlled-release levodopa versus immediate-release levodopa, one study reported the following outcomes:

There were no significant differences in nocturnal and early morning disability. (I+)

From evidence to recommendation

There is insufficient evidence from RCTs to support the use of controlled-release levodopa preparations in the treatment of nocturnal akinesia in PD. However, the GDG had considerable experience of their use in this context and were able to support their value.
There is also some experience in using long-acting dopamine agonists, especially cabergoline, for nocturnal akinesia, although such ergot-derived agonists are used less frequently in view of the risk of serosal reactions.

**RECOMMENDATION**

**R74** Modified-release levodopa preparations may be used for nocturnal akinesia in people with PD. D (GPP)

### 9.4 Falls

Falls are common in PD; two-thirds of people with PD fall each year, with most eventually becoming fallers.12,329,330

Early onset of falls may indicate an alternative diagnosis to idiopathic PD such as PSP.531

Predictors of falls specific to PD include:12,329,330,332

- longer disease duration
- more advanced disease
- dyskinesia
- motor fluctuations
- atypical parkinsonism
- postural instability
- small steps
- freezing
- stride-to-stride variability
- altered step and stance width
- loss of arm swing.
Parkinson’s disease Appendix H: Deleted Text Appendix

Predictors of falls in PD similar to those in the general population include:\textsuperscript{12,333}
old age
previous falls
use of sedative drugs
depression
dementia.

The clinical impact of falls is considerable, often leading to injury requiring healthcare services, an incapacitating fear of renewed falls, anxiety and depression.\textsuperscript{334} The associated costs for society are substantial in terms of finances as well as stress on the patient and their support network.

\subsection{9.4.1 Assessment and prevention of falls}

People with PD require a multidisciplinary assessment of the specific and non-specific predictors of falls together with the intrinsic and extrinsic factors that contribute to falls. In common with other people with repeated falls the assessment and prevention of falls in PD
requires multifactorial assessment and intervention by a professional with understanding of PD. The NICE clinical guideline no. 21 ‘Falls: assessment and prevention of falls in older people’ provides a framework for this process. The ‘Quick Reference Guide’ (Appendix D) of this guideline is applicable to all people with PD.

**RECOMMENDATION**


### 9.5 Autonomic disturbance

Autonomic dysfunction is common in PD due to the underlying pathophysiology of the condition affecting the catecholaminergic neurones of the autonomic nervous system.

While symptoms due to autonomic disturbance are common, and while this area has not undergone a systematic search for treatment trials, several crucial issues specific to PD were identified by the GDG as Good Practice Points.

#### 9.5.1 Gastrointestinal dysfunction

**Weight loss**

Unintended weight loss is common in PD, occurring in over 50% of individuals, with 20% losing over 12 kg in one study. A larger proportion of women than men with PD may experience weight loss. Moderate or severe dyskinesia is the strongest correlate of under-nutrition in PD, although the reasons for weight loss are likely to be more complex than simply ‘burning off’ more calories. Similarly, the weight gain commonly observed after bilateral DBS has not yet been adequately explained.
When significant weight loss occurs, the following general points should be considered:
other medical causes for weight loss (eg malignancy, endocrine causes)
investigation of swallow338
review of anti-parkinsonian medications if dyskinesias are problematic
dietary supplements
referral to a dietitian.

Dysphagia

Dysphagia is an impairment of swallowing. It is a complex process with risks of asphyxiation, aspiration pneumonia, malnutrition and dehydration. Swallowing difficulties in PD usually relate to disease severity and may affect all phases of the swallow process (oral, pharyngeal and oesophageal). Abnormalities are often detected on video fluoroscopy (modified barium swallow).

One group339 studied 75 people at different stages of PD and showed that up to 94% had problems with swallowing. In Hoehn and Yahr stages I–III the problems were often not noticed
by the person with PD. However, abnormalities are often detected on modified barium swallow testing. In advanced PD, swallowing difficulties can be severe and are usually obvious to patients and their carers. There is a high incidence of silent aspiration in PD, putting the person at risk of developing recurrent chest infections if not properly investigated. Infected oral secretions are a prime cause of pneumonia and this may be caused by poor oral hygiene due to reduced motor movement in the mouth. Pneumonia is a leading cause of death in later stages of PD.

Dysphagia in PD results from catecholaminergic degeneration and Lewy body formation in the brainstem and within the pharyngeal muscles. It does not respond fully to optimisation of dopaminergic medication.

Dysphagia poses a major problem to the taking of medications which are critical in the successful management of PD. Reduced tongue control leads to difficulty manipulating and clearing tablets from the mouth. Pharyngeal pooling and dysmotility may lead to retention of pills in the valleculae and pyriform fossae; consequently, delivery of medications may be erratic.

The management of dysphagia in PD may involve the following generic issues:
There should be early referral to a speech and language therapist for assessment, swallowing advice and, where indicated, further instrumental investigation (eg videofluoroscopy or fibreoptic endoscopic examination of swallow safety (FEES)).

Videofluoroscopy/FEES should be considered to exclude silent aspiration.

The problems associated with eating and swallowing should be managed on a case-by-case basis. Problems should be anticipated and supportive measures employed to prevent complications where possible.

Enteral feeding options may need to be considered. This may involve short-term nasogastric tube feeding to re-establish a suitable drug regimen, or placement of a longer-term feeding system such as a percutaneous endoscopic gastrostomy.

Cricopharyngeal (CP) myotomy has been reported to be successful in some cases with specific CP deficits. However, treatment must be based on physiology, which is best revealed with videofluoroscopy. CP myotomy may put people with PD at high risk of laryngeal penetration and pulmonary aspiration if oral and pharyngeal dysphagia is present.

CP myotomy also puts people at high risk of aspiration of reflux from the stomach.
Colonic dysmotility and anorectal dysfunction are common in PD, occurring in up to 30% and 60% of cases, respectively. Lewy body degeneration occurs within the myenteric plexus of the colon in PD, leading to slow transit times and, occasionally, megacolon, intestinal pseudo-obstruction and volvulus. A combination of disordered contraction and relaxation of the muscles of defecation, which may in part be dystonic, leads to excessive straining, pain, and a sense of incomplete evacuation. Faecal incontinence, when it occurs in PD, is usually due to overflow around faecal impaction.

The management of constipation due to colonic dysmotility in PD should follow a staged, or stepladder, approach. Increasing dietary fibre and fluid intake (at least eight glasses of water per day) and avoiding bananas...
increasing exercise

fibre supplements such as psyllium\textsuperscript{346} or methylcellulose

stool softener (eg docusate)

osmotic laxative (eg lactulose)

polyethylene glycol electrolyte-balanced solutions\textsuperscript{347}

occasional enemas when required.

For further details on nutrition support in adults, please refer to the NICE guideline on ‘Nutrition support in adults’ available from www.nice.org.uk/page.aspx?o=292900

Genitourinary dysfunction

Urinary dysfunction

Up to 75\% of people with PD develop bladder problems. Nocturia is the earliest and most common urinary problem, although daytime urgency and frequency may also be troublesome. Urinary incontinence is common in PD. Detrusor overactivity of neurogenic origin appears to result from disinhibition of the ponto-mesencephalic micturition centre.\textsuperscript{348}

Where there are refractory or persistent bladder problems, referral to a person with urological expertise should be considered.

Other management approaches include:

excluding urinary tract infection where there is an abrupt change in voiding pattern

excluding diabetes mellitus where frequency and polyuria are prominent

use of anticholinergic agents (tolterodine, oxybutynin, propiverine, solifenacin), although, since these drugs cross the blood-brain barrier, they must be used with caution as they may induce a toxic confusional state. Other drugs may be available which do not cross the blood-brain barrier (eg trospium chloride).

Sexual dysfunction
Erectile dysfunction is more common in PD (60–70%) than in age-matched controls (38%). Men with PD may also experience sexual dissatisfaction and premature ejaculation. In women, difficulties with arousal, low sexual desire and anorgasmia are common.

Dopaminergic therapy may also induce hypersexuality, even when there is erectile dysfunction.

In the management of erectile dysfunction the following should be considered:

- co-morbid endocrine abnormalities (eg hypothyroidism, hyperprolactinaemia)
- ‘latent’ depression
- discontinuation of drugs associated with erectile dysfunction (eg alpha-blockers) or anorgasmia (eg SSRIs)
- type V cGMP-specific phosphodiesterase inhibitors (eg sildenafil)
- intracavernous injections or transurethral suppositories of alprostadil (a synthetic prostaglandin E1).
9.5.2 Orthostatic hypotension

Orthostatic hypotension (OH) occurs in 48% of people with PD in the community but is asymptomatic in up to 60%.\(^{351}\) It may be defined as a drop in systolic blood pressure after standing greater than or equal to 20 mmHg or to less than 90 mmHg.\(^{353}\) The aetiology of OH in PD is multifactorial and includes Lewy body degeneration in the hypothalamus, brainstem and peripheral nervous system. Symptoms of OH include fatigue, pre-syncope and syncope, while OH may also contribute to falling. Persisting or troublesome OH may warrant referral to a unit with expertise in falls and syncope.

The management of OH in PD should follow a stepladder approach

- eliminate or reduce antihypertensive medications; reduce or change anti-parkinsonian drugs
- increase dietary salt and fluid intake, avoid caffeine at night, eat frequent, small meals and avoid alcohol
- elevate head of bed by 30–40°
- salt-retaining steroid (e.g. fludrocortisone)
- direct-acting sympathomimetic (e.g. midodrine, only available on named-patient basis).

9.5.3 Excessive sweating

Severe sweating may occur as an end-of-dose off phenomenon or while in the on motor state, usually associated with dyskinesias.

The management approach to excessive sweating should exclude a comorbid medical problem (e.g. chronic infection, thyrotoxicosis), or the post-menopausal state.

9.5.4 Sialorrhoea

Excessive saliva or drooling occurs in 70–80% of people with PD and may be more common in men.\(^{354,355}\) It may result from oropharyngeal dysfunction, including reduced swallow
frequency. Apart from social embarrassment and soiling of clothing, sialorrhea may also be associated with perioral infection.

General management measures may include:

- referral to a speech and language therapist for full assessment of swallowing ability
- advice and trial of behavioural management techniques to encourage regular saliva swallows
- use of a portable metronomic brooch as a reminder for saliva swallows\(^{356}\)
- lip seal and swallow exercises
- sublingual 1% atropine ophthalmic solution twice daily\(^{357}\)
- injection of salivary glands with botulinum toxin A\(^{358}\)
RECOMMENDATION

P76 People with PD should be treated appropriately for the following autonomic disturbances:

- urinary dysfunction
- weight loss
- dysphagia
- constipation
- erectile dysfunction
- orthostatic hypotension
- excessive sweating
- sialorrhoea.

9.6 Pain

Pain is defined as an unpleasant or distressing sensory experience. Pain occurs in around 40% of people with PD but is rarely a major feature of the disorder.

Pain in PD has been classified as:

- musculoskeletal – often secondary to parkinsonian rigidity and hypokinesia (e.g. frozen shoulder)
- dystonic – associated with dystonic movements and postures which often occur in the off period in the feet
- primary or central – burning or paraesthetic pain outwith a dermatome or root territory which is not explained by a musculoskeletal or dystonic cause
- neuropathic – pain in the distribution of a root or nerve with associated signs
- akathisia-related – inner feeling of restlessness leading to inability to keep still.

Little research has been done in this area and the management of many of these types of pain is generic rather than being specific to PD. Therefore, the GDG elected not to undertake a literature search in this area. The GDG did recognise the importance of dystonic pain which is
Parkinson's disease Appendix H: Deleted Text Appendix

often responsive to dopaminergic medications (see Chapter 7).
10 Other key interventions

'Never has anybody said to us, 'Do you think you need a physiotherapist, a speech therapist, or an occupational therapist – do you need these services?' That’s something we have gone out to find ourselves and I think too late.'

10.1 Introduction

In previous chapters, consideration has been given to the evidence for pharmacological treatments and surgical interventions. People with PD may also benefit from interventions provided by a range of health disciplines. This chapter addresses the effectiveness of specific interventions that are part of:

- PD specialist nursing
- physiotherapy occupational therapy
- speech and language therapy.

Because service issues lie outside the scope of this guideline, evidence has been sought for the effectiveness of the interventions that are part of a discipline and recommendations made accordingly. It should be noted that some interventions, particularly those related to maintaining independence, may, in practice, be carried out by professionals from a number of disciplines.

10.1.1 Methodological limitations

When reviewing the evidence of the interventions delivered by health professionals the following methodological limitations should be considered:

- variations in location of therapy (home, outpatient clinic, in hospital) lack of reporting the intensity of therapy given
- variations in therapy regimen between trials
Parkinson’s disease Appendix H: Deleted Text Appendix

unclear qualifications and experience of person delivering the intervention short trial duration and lack of long-term follow-up
small sample sizes without power calculations provided
lack of reporting methods of randomisation or allocation concealment lack of reporting drop-outs from trials
lack of intention-to-treat analysis.

10.3 Physiotherapy

Physiotherapy or physical therapy can be defined as: ‘A health care profession which emphasises the use of physical approaches in the promotion, maintenance and restoration of an individual’s physical, psychological and social well-being, encompassing variations in health status.’

138
Physiotherapy primarily addresses the physical components of rehabilitation, essentially to maximise the functional capacity of a person and their role within society.

Where people receiving physiotherapy have a longer-term condition, such as PD, physiotherapy is generally regarded as an active, ongoing process and one that should be client-focused in its approach and regularly reviewed.

Physiotherapy might incorporate only education and advice ensuring maintenance of a current level of fitness and ability, or involve exercises specific to the needs of the person with PD to regain movement, prevent falls, maximise respiratory function or reduce pain. It also has a role alongside medical and surgical intervention to enhance the person's potential with these interventions.

In addition to physiotherapy, other physical adjuncts to therapy may include approaches such as the Alexander Technique, yoga, Conductive Education or Pilates – techniques which not only promote movement, but also are linked with social well-being.

The principles of physiotherapy are:

- early implementation of exercise programme to prevent de-conditioning and other preventable complications
- utilisation of a meaningful and practical assessment procedure to allow monitoring and identification of rehabilitation priorities
- the identification of deterioration and timely, appropriate intervention
- the opportunity for targeted therapy for restoration or compensation of function
- the involvement of patients and carers in decision-making and management strategies.

What is the effectiveness of physiotherapy interventions versus standard therapy in the care of people with PD?

### 10.3.1 Methodology

A Cochrane systematic review and an RCT were found which addressed the effectiveness of physiotherapy versus standard therapy or placebo in the treatment of PD. Another study was found which addressed the effectiveness of the Alexander Technique versus no therapy or
The physiotherapy RCT\textsuperscript{309} (N=8) investigated the effect of a 16-week aerobic exercise programme on aerobic capacity and movement initiation time for PD.

The Alexander Technique RCT\textsuperscript{370} (N=88) randomised participants to three groups: controls (N=30) or Alexander Technique (N=29) or massage group (N=29). The massage group received two massage sessions per week for 12 weeks (the massage group was used as control for touch and attention). The Alexander Technique consisted of two 40-minute lessons per week for 12 weeks, then 5 weeks after completion the participants received a short audio tape that led them through a 20-minute lying down exercise.

The Cochrane review\textsuperscript{368} included 11 randomised trials; four of these trials\textsuperscript{371–374} reported significant outcomes in relation to physiotherapy treatment for people with PD, with a total of 280 people. The participants in these trials received physiotherapy directed to trunk and limb functions and were treated for 8–30 hours over 5–52 weeks. The method of physiotherapy was usually described in a very broad manner; even the time spent by the therapist with the patient was not specified in half of these trials.
10.3.2 Evidence statements

For a summary of the effectiveness of physiotherapy techniques see Table 10.1 below.

<table>
<thead>
<tr>
<th>Table 10.1 Effectiveness of physiotherapy techniques (1+)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Conventional physiotherapy techniques</strong></td>
</tr>
<tr>
<td><em>Activities of daily living</em></td>
</tr>
<tr>
<td>Length 20 2014</td>
</tr>
<tr>
<td>5 months 2014</td>
</tr>
<tr>
<td>5 months 2014</td>
</tr>
<tr>
<td>Clinical rating scales</td>
</tr>
<tr>
<td>Total UPDRS3 20</td>
</tr>
<tr>
<td>5 months 20</td>
</tr>
<tr>
<td>Webster rating scales 2014</td>
</tr>
<tr>
<td>5 months 20</td>
</tr>
<tr>
<td>Parkinson's Home Visiting Assessment Tool (H/ V) 3</td>
</tr>
<tr>
<td>Motor impairments</td>
</tr>
<tr>
<td>Walking velocity 2014</td>
</tr>
<tr>
<td>5 months 2014</td>
</tr>
<tr>
<td>Spinal rotation 2014</td>
</tr>
<tr>
<td>5 months 2014</td>
</tr>
<tr>
<td>Exercise outcome 2014</td>
</tr>
<tr>
<td>Aerobic capacity 2014</td>
</tr>
<tr>
<td>Power output 2014</td>
</tr>
</tbody>
</table>
Table 10.1 Effectiveness of physiotherapy techniques (1+) – continued

<table>
<thead>
<tr>
<th>Conventional physiotherapy techniques</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexander technique(^{370})</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SPDDS 'at best'</td>
<td>88</td>
<td>Post-intervention vs controls 0.04</td>
</tr>
<tr>
<td>SPDDS 'at worst'</td>
<td></td>
<td>6 months vs controls 0.04</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6 months vs controls 0.01</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Post-intervention vs controls 0.03</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6 months vs controls NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Post-intervention vs controls NS</td>
</tr>
<tr>
<td>BDI scores</td>
<td></td>
<td>6 months vs controls 0.04</td>
</tr>
</tbody>
</table>

The references cited in this table refer to individual papers within the Cochrane review.\(^{388}\)

With respect to medication changes,\(^{370}\)

The rate of medication change was statistically in favour of Alexander Technique treatment compared with control (p=0.001).

Fewer participants in the Alexander Technique group changed their medication and yet were not experiencing worsening symptoms (p=0.047). (1+)

10.3.3 From evidence to recommendation

There is encouraging RCT evidence of the effectiveness of some of the physiotherapy interventions for people with PD. However, further definitive trials are required to confirm these findings. Additional work is necessary to define what physical therapy interventions are effective in the different stages of the disease. The GDG acknowledge that physiotherapists would not use many of the outcome measures reported in the trial evidence (see Table 10.1). The GDG agree that there is a need for quality-of-life evaluation rated by the patient.

In addition to this evidence, the experience of the GDG members supports the use of physiotherapy interventions in people with PD.
RECOMMENDATIONS

R78 Physiotherapy should be available for people with PD. Particular consideration should be given to:

- gait re-education, improvement of balance and flexibility
- enhancement of aerobic capacity
- improvement of movement initiation
- improvement of functional independence, including mobility and activities of daily living
- provision of advice regarding safety in the home environment.
The Alexander Technique may be offered to benefit people with PD by helping them to make lifestyle adjustments that affect both the physical nature of the condition and the person’s attitudes to having PD.

10.4 Occupational therapy

Occupational therapy (OT) is a profession concerned with promoting health and well-being through occupation. The primary goal of OT is to enable people to participate in the activities of everyday life. Occupational therapists achieve this outcome by enabling people to do things that will enhance their ability to participate or by modifying their environment to better support participation.

Occupational therapists have expertise in assisting people who have disabilities to manage the practical aspects of everyday life. Referral to an occupational therapist can enable people with PD to maximise their current abilities, retain independence for as long as possible and develop their own coping strategies to deal with future problems.

The principles of OT are:

- early intervention to establish rapport, prevent activities and roles being restricted or lost and, where needed, develop appropriate coping strategies
- client-centred assessment and intervention
- development of goals in collaboration with the individual and carer with regular review
- employment of a wide range of interventions to address physical and psychosocial problems to enhance participation in everyday activities such as self-care, mobility, domestic and family roles, work and leisure.

Current UK practice emphasises functional goals centred around independence, safety and confidence, including activities such as transfers, mobility and self-care.

A wide variety of interventions are used in PD. Owing to the individualised nature of the therapeutic process, these may include practising skills, cognitive and sensory cueing strategies, problem solving, advice, education, provision of equipment and environmental adaptations.

What is the effectiveness of occupational therapy versus standard medical therapy in the
10.4.1 Methodology

A Cochrane review[^379] was found on the effectiveness of OT versus placebo (or no interventions) in people with PD. The review included two randomised, parallel group trials, with a total of 84 people (N=64[^380] and N=20[^381]).

There were significant differences between the methodologies of the two studies. One trial[^380] conducted 20 hours of treatment over 5 weeks with 1-year follow-up while the other trial[^381] conducted 12 hours of treatment over 1 month with no follow-up. The methodological limitations of these studies are covered in section 10.3.

Due to the lack of RCT evidence, papers with lower-level study designs (e.g., non-randomised and/or uncontrolled trials) were also included in the search, but no further papers were found which addressed the effectiveness of OT in the treatment of people with PD.
10.4.2 Evidence statements

With respect to clinical outcome measures, Barthel Index score, an assessment of ADL, was maintained over 1 year in those treated with occupational therapy.

The group without the OT intervention lost an average of 4.6 points (out of a total score of 100) (p values not available).

The other study reported small differences in mean changes between groups on all outcome measures (motor impairment, activities of daily living, and quality-of-life measures) (p values not available).

10.4.3 From evidence to recommendation

In view of the methodological flaws in the trials and the small numbers of randomised participants, and only one outcome measure reported from one trial, there is insufficient evidence to support the efficacy of OT interventions in PD. However, the GDG support the value of many of the aspects of this therapy, particularly with respect to the provision of aids and adaptations to maintain functional independence in people with PD. There is evidence to support this from one trial where there was maintenance of ADL scores in the treated group but a decline in those not treated. Further trials are required to evaluate the role of different aspects of OT.

Despite this lack of evidence, the experience of the GDG members supports the use of OT interventions in people with PD. It is recognised that, in practice, some of these interventions may be carried out by health professionals other than occupational therapists.

RECOMMENDATION

R80 Occupational therapy should be available for people with PD. Particular consideration should be given to:

- maintenance of work and family roles, home care and leisure activities
- improvement and maintenance of transfers and mobility
- improvement of personal self-care activities such as eating, drinking, washing and
10.5 Speech and language therapy

Deterioration in speech is a common manifestation of PD that increases in frequency and intensity with the progress of the disease.

The specific dysarthria resulting from PD is known as hypokinetic dysarthria and it is characterised by:

- monotony with reduced loudness and pitch range
- difficulties in initiating speech
- variable rate
short rushes of speech
imprecise consonant
breathily or harsh voice.

Treatment programmes have focused on specific components of the dysarthria such as respiratory exercise and prosodic exercises. These treatments can be used with individuals or in groups.

Lee Silverman Voice Treatment (LSVT) is a speech therapy programme developed specifically for individuals with PD. It focuses on improving voice loudness with immediate carry over into daily communication. The intensive nature of the programme helps individuals with PD to recognise that their voice is too soft, convince them that a louder voice is within normal limits and makes them comfortable using the new louder voice. It is now provided by certified clinicians in England.

Some people with PD may benefit from use of augmentative and alternative communication devices, which can include the use of:

- alphabet boards
- pacing boards
- voice amplifiers
- digitised speech output systems
- recorded voice messages
- delayed auditory feedback
- microcomputer-based wearable biofeedback device.

What is the effectiveness of speech and language therapy versus standard medical therapy or control in the treatment of speech disturbance in PD?

10.5.1 Methodology

A systematic review was found which addressed the efficacy of speech and language therapy versus standard medical therapy in people with PD.

The review included three RCTs, with a total sample size of 63. One of these trials used the LSVT technique, whereas the rest used the more conventional speech and language therapy techniques. No raw numerical data were available from one of these studies, so data
on only 41 participants were available from the review’s analysis. Another included study showed the intervention groups differed significantly from one another at baseline on a number of outcome measures, but no further analysis was provided.

There were significant differences in the intensity of the speech and language therapy intervention between studies. One trial treated participants for 10 hours over 4 weeks, another trial provided treatment for 16 hours over 4 weeks and a third trial treated people for 35–40 hours over 2 weeks.

10.5.2 Evidence statements

With respect to the assessment of speech impairment:

One study found total impairment with the Frenchay Dysarthria Assessment improved in the intervention group compared with the placebo (p=0.05), showing an overall
improvement in the dysarthria score, while all participants in the untreated group showed lower scores with a significant deterioration \( p<0.05 \).

Another study\(^3\) reported that the scores of the Dysarthria Profile were comparable at baseline, but immediately after therapy the scores were significantly higher in the treatment group \( p<0.05 \).

With respect to vocal loudness:

In two trials objective loudness improved by 11 dB\(^3\) and by 5.4 dB\(^3\) \((p<0.005)\) immediately after therapy.

This gain was reduced by 3.5 dB\(^3\) after 6 months but was still significantly in favour of therapy \( p<0.05 \).\(^3\)

Mean objective loudness of speech when the participants were asked to describe a picture improved by 5.2 dB \( p<0.025 \) and this improvement was maintained over 6 months \( 4.2 \text{ dB, } p<0.02 \).\(^3\)

The reading loudness of participants receiving LSVT was more than the placebo group immediately after therapy \( p<0.001 \) and improvement was mostly maintained \( p<0.005 \) at 6 months.\(^3\)

Mean objective loudness improved when people were asked to give a prolonged ‘a’ \( 12.1 \text{ dB, } p<0.001 \) and this was mostly maintained \( 9.4 \text{ dB, } p<0.001 \) at 6 months.\(^3\)

Maximum vocal loudness increased after therapy\(^3\) by 16 dB \( p<0.01 \).

Mean pitch range increased in the therapy group by 66 Hz \( 162.7 \text{ to } 228.3 \) and remained virtually static in the placebo group.\(^3\)

10.5.3 From evidence to recommendation

Although there is good preliminary evidence of the efficacy of speech and language therapy for speech disorders in PD, this is based on data from only 41 people with maximum follow-up of only 12 weeks. Much of the positive data concerns the unique North American therapy LSVT. While some therapists in England and Wales have attended the mandatory training programme for this intervention, it is not widely available at present. The GDG was also concerned about the practicalities of 16 1-hour treatment sessions in the context of the NHS financial climate.
Parkinson’s disease Appendix H: Deleted Text Appendix

There is little evidence comparing speech and language therapy to standard medical therapy or control. The GDG were aware of a body of evidence that addresses use of LSVT compared with other speech and language therapy techniques. In addition to this, the experience of the GDG members supports the use of speech and language therapy intervention in people with PD.

In the section on dysphagia (Chapter 9) the potential contribution that could be made by speech and language therapist interventions is discussed.
RECOMMENDATION

R81 Speech and language therapy should be available for people with PD. Particular consideration should be given to:

- improvement of vocal loudness and pitch range, including speech therapy programmes such as LSVT
- teaching strategies to optimise speech intelligibility
- ensuring an effective means of communication is maintained throughout the course of the disease, including use of assistive technologies
- review and management to support the safety and efficiency of swallowing and to minimise the risk of aspiration.
11 Palliative care in Parkinson’s disease

11.1 Introduction

In the absence of any curative treatment, the management of PD remains largely palliative despite the huge advances that have been made in medical knowledge. The principles of palliative care should be applied throughout the course of the disease and not limited to the terminal end-of-life period.

Palliative care can be defined in the following way:

*The active total care of patients whose disease is not responsive to curative treatment. Control of pain and other symptoms and of psychological, social and spiritual problems is paramount.*

The goal of palliative care is achievement of the best quality of life for patients and their families.\(^\text{394}\)

Palliative care is an approach that improves the quality of life of patients and their families facing the problems associated with life-threatening illness. It does not necessarily mean the use of specialist care services but should focus on prevention and relief of suffering with early identification, impeccable assessment, and treatment of pain and other physical, psychological and spiritual problems.

The issues common to malignant and non-malignant conditions, that are the focus of palliative care, can be categorised\(^\text{395}\) as:

- physical: pain, breathlessness, anorexia, immobility and constipation
- social: loss of employment, role change, fear for dependants
- psychological: depression, fear and anxiety, uncertainty, guilt
- existential: religious, non-religious, meaning of life, why?
11.2 The palliative phase of Parkinson’s disease

The needs of patients in the palliative care stage of PD are not always identified or satisfied. Over time, progression of the underlying disease process makes interventions less effective and they may be associated with intercurrent illnesses. As a result, patients become increasingly disabled and dependent. This physical disability is often combined with cognitive dysfunction and depression.

The ‘palliative phase’ in PD has been defined by:

- inability to tolerate adequate dopaminergic therapy
- unsuitability for surgery
- the presence of advanced comorbidity.

The duration of time spent in each of the stages of PD is variable. From an audit of 73 patients undertaken in Cornwall, the mean duration of disease was 14.6 years. The time spent in the four stages was: diagnosis 1.5 years, maintenance 6 years, complex 5 years, and palliative care
2.2 years. This reinforces the view that ‘palliative care’ in PD does not equate with imminent end of life, but that the emphasis of care will shift from a ‘therapeutic’ pharmacological approach to one that places greater emphasis on quality of life issues. This is in recognition of the shortened remaining lifespan of the patient and the inadequacy of current medications to meet the increase in needs.

The care of people with PD is best undertaken in a multidisciplinary way throughout each stage of the disease. The palliative care approach should be utilised by all health professionals throughout these stages. It should also be possible to seek advice from specialist palliative care teams, not just at the end of life, but at any stage after diagnosis with the main aims of care to provide symptom relief, prevent complications, minimise distress, maintain patient dignity and provide counselling. With more complex difficulties, the specialist palliative care team may, on agreement, become temporarily or regularly involved with input for the patient or their family, and in supporting the usual professional carers.

The NSF for Long-term (Neurological) Conditions (2005) focuses on the palliative care needs of patients with chronic disabling conditions such as PD in ‘Quality requirement 9: palliative care’.

### 11.2.1 Palliative care and carers

Management of the palliative stage must always be in the context of the patient and the family/caregiver. Recognising the needs of carers of people with PD at an early stage will help enable patients to be maintained at home for as long as possible. Many will have been in the role of carer for a significant number of years and have become ‘experts’ in PD themselves. Realistic goals need to be agreed jointly by the patient/family and the multidisciplinary team caring for the patient. Respite periods, both for short and longer periods and to meet planned and emergency needs, are particularly important. The White Paper ‘Your health, your care, your say’ highlights the need for carer support. It may also be useful to refer to a carer care pathway to recognise some of the problems carers may experience. When looking at specific information and support for carers, the DAS provides useful information sheets for carers.

### 11.2.2 Care homes

While the majority of people with PD will cope at home for many years, increasing dependency in the palliative stage, when the care needs exceed the ability of their family or community to cope, will frequently lead to admission into care home settings. This may be due to increased disability or the result of a combination of disability and social factors when the burden of caring becomes too great. In particular, PD studies suggest that care home admission is
often provoked by hallucinations. Admission of patients into care homes carries with it a greater mortality.\textsuperscript{401,402} These trials found that all PD patients admitted into care homes died within 2 years of admission. PD may affect 5–10\% of nursing home residents.\textsuperscript{403} Guidance on caring for people in care homes in the palliative stage is available.\textsuperscript{404–406}

\textbf{11.2.3 Social costs}

Social services will play an increasingly greater role in palliative care stages; in particular to address issues that may arise from increased disability and dependency. Results from a study\textsuperscript{10} looking into the economic impact of PD showed that:
Total social services costs accounted for 34% of total costs and tended to increase with increasing age.

Total NHS costs accounted for 38% of total costs and tended to fall with increasing age. Total annual direct costs were £4,189 for patients living at home, £15,355 for patients whose time was divided between home and an institution; and £19,338 for patients in full-time institutional care.

Wherever the patient resides, their condition should be monitored to ensure comfort and quality of life is maintained. However it may be difficult to assess their needs in a hospital outpatient environment. Day hospital attendance may be easier or a PDNS or other key worker may visit at home. Visiting in the home environment is less stressful for the patient, carer and care staff, and allows time for more detailed discussion, advice, education and counselling.

11.2.4 Withdrawal of drugs

In later stages of PD there may be the need to withdraw dopaminergic drugs due to lack of drug efficacy and increasing sensitivity to unwanted effects such as hallucinations. As a general guide, medication withdrawal should be managed with help from the specialist clinician and PDNS. Where possible drug withdrawal should be gradual in order to achieve the best balance between relief of symptoms and minimal side effects. Patients and carers at this stage will often agree to reduce medications, exchanging greater levels of physical disability for increased mental clarity. This situation should however be reviewed on an ongoing basis as frequent adjustments may be required to maintain this balance.

11.2.5 Pressure ulcers

Immobility in the palliative care phase of PD places individuals at risk of pressure ulcer development, and an assessment of risk for pressure ulcers should be a priority. Most pressure ulcers occur over a bony prominence, but if contractures of the limbs have developed with immobility and the altered body shape of PD, this may result in pressure sores appearing in more unusual locations.

Carers will require support and education in understanding how to move and handle patients safely. Additional information can be found in:

NICE documents:
11.2.6 End-of-life issues

In July 2004 the Department of Health (England) started an initiative so that all adult patients nearing the end of life, irrespective of diagnosis, will have access to high-quality specialist palliative care. The focus was to train and equip healthcare professionals with the knowledge and skills to support patients to live and die in the place of their choice. Three key documents make up the basis of this ‘End of Life Initiative’.
Preferred Place of Care Plan410
Gold Standards Framework411
Liverpool Care of the Dying Pathway.412

Increasingly, initiatives such as these have resulted in district general hospitals (DGHs), primary care and care homes achieving:

increased advance care planning

greater choice for patients in where they wish to live and die
decreased emergency admissions of patients who wish to die at home
decreased number of older people transferred from a care home to a DGH in the last week of life.

What are the end-of-life palliative care needs of PD patients and what treatments are available?
These aspects are currently being explored within the neurological conditions policy group of the National Council for Palliative Care, working closely with the NDS.
www.ncpc.org.uk/policy_unit/neuro_pg.html

11.2.7 Methodology

No trials were found which addressed end-of-life palliative care needs of PD patients and what treatments are available.

11.2.8 From evidence to recommendation

The needs of patients in the palliative care stage of PD are often under-recognised and considered too late in their care. Better understanding of the complexity of the manifestations of the disease, its innate variability, and the roles of the extended team members, which may or may not include the palliative care team, can help to improve care and reduce distress. Care needs to be supported by good care planning since many problems can be predicted or avoided with appropriate strategies.
11.3 Ethical issues

Patients and their families need to be allowed to have time to come to terms with the fact that the disease has reached a stage where no more can be done. Decisions may need to be made about management and treatment in the future, and end-of-life decisions (ie do-not-resuscitate policies and advance directives (living wills)). These are never easy issues to discuss but they can provide an opportunity for the person with PD to state treatment preferences should they lose
their capacity for decision making in the future. They derive their authority from the principle of informed consent and the promotion of personal autonomy and should be considered before mental or physical disability precludes their completion.

Additional information that may be of help includes the British Geriatrics Society Compendium advance directives section (www.bgs.org.uk), and the BMA (www.bma.org.uk).
12 Research recommendations

12.1 Future research recommendations

The questions below are not in order of priority.

Question 1: Do any of the agents with preclinical neuroprotective properties in PD models have any clinically worthwhile protective effects in PD?

| Population | People with early PD; some trials with patients on no medication; other trials may randomise patients stabilised on symptomatic medication
| Any gender, age, ethnic group
| Trials performed in early stages |
| Intervention | Systematic reviews in the USA have identified 12 agents that require study (Table 6.2). The UK could contribute to the raft of ongoing studies that are funded by the National Institute for Neurologic Disorders and Stroke (NINDS) and the Michael J Fox Foundation
| Support should also be given to innovative surgical approaches to neuroprotection |
| Comparison | Each putative neuroprotectant versus placebo in double-blind parallel design or delayed-start design trial |
| Outcome | Total UPDRS change |

Table 6.2 NINDS selected candidate neuroprotective drugs in Parkinson's disease

<p>| Co-enzyme Q10* |
| Creatine* |
| GM-1 ganglioside |
| GPI-1485* |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Mino cycine*</td>
<td></td>
</tr>
<tr>
<td>Nicotine</td>
<td></td>
</tr>
<tr>
<td>Oestrogen</td>
<td></td>
</tr>
<tr>
<td>MAOB inhibitors (rasagline® and selegiline)</td>
<td></td>
</tr>
<tr>
<td>Dopamine agonists (ropinirole® and pramipexole®)</td>
<td></td>
</tr>
</tbody>
</table>
Explanatory paragraph

At present there is no agent that slows the progression of PD. Patients want such a ‘cure’ for their condition. The NHS requires neuroprotectants to reduce the burden of disability caused by PD, thereby reducing the direct and indirect costs of caring for an increasing number of people with the condition.

While the pharmaceutical industry is trying to develop new putative neuroprotectants, 12 existing agents have been identified which may slow PD progression (Table 6.2). A systematic trial programme examining these agents is ongoing in the USA (Net-PD) funded by the NINDS and the Michael J Fox Foundation. Agents are being screened in small ‘futility studies’ using historical control data for decline in total UPDRS scores. Agents that delay progression by more than 30% will go through to larger definitive studies.

The first futility study showed that both minocycline and GPI-1485 significantly delay decline in total UPDRS by more than 30%. However, a small placebo comparator group also showed a similar effect, raising doubts about the use of historical controls.

Future Net-PD trials may use patients already established on symptomatic therapies. There are many more such patients than those who are untreated thereby allowing future neuroprotection trials to be much larger.

The recent rasagiline delayed-start design trial versus placebo (see section 6.5) raised the possibility that this may be a useful trial design to examine neuroprotection. Further pharmaceutical industry trials using this design are planned. This would be another option for UK neuroprotection trials.

UK investigators have recently carried out neurorestoration trials with intra-putaminal infusion of GDNF, although these have now been stopped. Support for further surgical approaches to neuroprotection in PD should be considered.

Question 2: Which people with PDD benefit from cholinesterase inhibitor drugs and/or memantine, and is the use of these agents cost-effective?
### Parkinson’s disease Appendix H: Deleted Text Appendix

| Population | Patients with PD of more than 2 years’ duration (to exclude dementia with Lewy bodies patients) and dementia defined according to DSM-IV criteria or new MDS Task Force criteria for PDD (due mid-2006) Patients stratified according to pattern and severity of cognitive impairment and neuropsychiatric burden (eg visual hallucinations)
| Coexistent use of stable atypical antipsychotic regimen will be permitted
| Any sex, age, ethnic group |
| Intervention | Donepezil/rivastigmine/galantamine |
| Comparison | Cholinesterase inhibitor/enantamine versus placebo in RCT design |
| Outcome | Change in cognition according to validated scales (eg ADAS-cog, new MDS Task Force instrument for PDD - due mid-2006) Neuropsychiatric Inventory Caregiver stress scales |
Explanatory paragraph

A recent systematic review indicates that 24–31% of PD patients have dementia, and that 3–4% of the dementia in the general population is due to PDD. The estimated prevalence of PDD in the general population aged 65 years and older is 0.2–0.5%. PDD is associated with increased mortality, caregiver stress and nursing home admission.

A large RCT of rivastigmine in PDD showed improvements in primary and secondary endpoints but the clinical significance of these benefits is uncertain. It is likely that the modest mean improvements reflect heterogeneity of response, with some patients responding far better than others; this is supported by expert opinion via open-label prescribing. In addition, health economic analysis has not been performed in trials of cholinesterase inhibitors in PDD using disease-specific models.

Identifying responsive subgroups of patients with PDD with demonstrable cost-effectiveness would focus effective targeting of cholinesterase inhibitors and/or memantine. The process of identifying these patients would also lead to the development of protocols for prescribing and assessment, together with robust guidelines regarding whether drug usage is maintained or discontinued.

Question 3: Is treating mild to moderate depression in PD with an antidepressant cost-effective?

<table>
<thead>
<tr>
<th>Population</th>
<th>People with any stage of PD with mild to moderate depression according to a depression rating scale. Patients with severe depression will be excluded, as treatment is mandatory</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Any sex, age, ethnic group.</td>
</tr>
<tr>
<td></td>
<td>Treated and not treated in secondary care.</td>
</tr>
<tr>
<td>Intervention</td>
<td>Any SSRI class of antidepressant</td>
</tr>
<tr>
<td>Comparison</td>
<td>SSRI antidepressant versus no treatment in a pragmatic open-label design</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Quality of life rated by disease specific (PDQ-39) and generic (SF-36, EuroQol) measures.</td>
</tr>
<tr>
<td></td>
<td>Health economics.</td>
</tr>
</tbody>
</table>
Cross-sectional studies have shown that depression affects around 40% of patients with PD and has a major impact on quality of life. In most cases depression is mild to moderate in severity and is often missed by the clinician caring for the patient.

The GDG recommends a study that would screen secondary care PD clinic populations for mild to moderate depression. Participants would then be treated with any SSRI class antidepressant or no such treatment in an open-label fashion. This would be a large-scale pragmatic trial.

If screening for and treating mild to moderate depression is cost-effective, this will add to the evidence base for the management of depression in PD and may have considerable impact on the next update of this guideline.
Question 4: Are supportive therapies in PD cost-effective? (a) Is physiotherapy in PD cost-effective?

<table>
<thead>
<tr>
<th>Population</th>
<th>People with any stage of PD Any sex, age, ethnic group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>Best practice NHS physiotherapy</td>
</tr>
<tr>
<td>Comparison</td>
<td>Pragmatic parallel design trial comparing no treatment with physiotherapy</td>
</tr>
<tr>
<td>Outcome</td>
<td>Quality of life rated by disease-specific (PDQ-39) and generic (SF-36, EuroQol) measures Health economics Disease-specific and therapy-specific outcomes including: gait, balance, posture, transfers, and chair andorraine</td>
</tr>
</tbody>
</table>

Explanatory paragraph

The evidence to support the use of physiotherapy in PD is limited and yet patients feel that it is effective. Many patients are referred for such therapy in the NHS with little idea of its value or whether it has any long-term benefits. In contrast, many other patients cannot access such therapy due to limited provision of service.

The GDG recommends a pragmatic trial performed in units that already have access to physiotherapy services. This is likely to be in the elderly care setting because neurologists have limited access to such treatments. An NHS subvention will be required to ensure adequate therapy resources are available for the trial.

Many prevalent cases of PD will have already received such therapies, so the trial will recruit incident cases. This will require a long recruitment period, a large number of centres or both.

A large trial of cueing therapy (The Rescue Project) in PD has recently been completed but is yet to report. The data from this can act as pilot material for the new trial.

If physiotherapy is cost-effective, the provision of service needs to be increased. If it is not cost-effective, services can be diverted to other conditions.

Future trials will then need to examine which components of physiotherapy are effective and
whether it is effective in the earlier stages of the disease.
(b) Is OT in PD cost-effective?

| Population | People with any stage of PD  
| Any sex, age, ethnic group  
| Trial based in secondary care with primary care support |
| Intervention | Best practice NHS occupational therapy |
| Comparison | Pragmatic parallel design trial comparing no treatment with OT |
| Outcome | Quality of life rated by disease-specific (PDQ-39) and generic (SF-36, EuroQol) measures  
| Health economics  
| Secondary outcomes to include disease-specific and therapy-specific measures |

**Explanatory paragraph**

The evidence to support the use of OT in PD is limited and yet patients feel it is effective. Many patients are referred for such therapy in the NHS with little idea of its value or whether it has any long-term benefits. In contrast, many other patients cannot access such therapy due to limited provision of service.

The GDG recommends a pragmatic trial performed in units that already have access to occupational therapy services. This is likely to be in the elderly care setting because neurologists have poor access to such treatments. An NHS subvention will be required to ensure adequate therapy resources are available for the trial.

Many prevalent cases of PD will have already received such therapies, so the trial will recruit incident cases. This will require a long recruitment period, a large number of centres or both.

A pilot study of OT in PD is underway in Birmingham. This will provide invaluable data upon which to plan the substantive trial.

If OT is cost-effective, the provision of service needs to be increased. If it is not cost-effective, services can be diverted to other conditions.

Future trials will then need to examine what components of OT are effective.
(c) Is NHS speech and language therapy in PD cost-effective?

<table>
<thead>
<tr>
<th>Population</th>
<th>People with any stage of PD who have developed speech problems as defined by the observing clinician</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Any sex, age, ethnic group</td>
</tr>
<tr>
<td></td>
<td>Trials based in secondary care with primary care support</td>
</tr>
<tr>
<td>Intervention</td>
<td>Best practice NHS speech and language therapy</td>
</tr>
<tr>
<td>Comparison</td>
<td>Pragmatic trial comparing NHS speech and language therapy with no treatment</td>
</tr>
<tr>
<td>Outcome</td>
<td>Quality of life rated by disease-specific (PDQ-39) and generic (SF-36, EuroQol) measures</td>
</tr>
<tr>
<td></td>
<td>Health economics</td>
</tr>
<tr>
<td></td>
<td>Measures of intelligibility</td>
</tr>
<tr>
<td></td>
<td>Secondary outcomes to include disease-specific and therapy-specific</td>
</tr>
</tbody>
</table>

Explanatory paragraph

The evidence to support the use of speech and language therapy in PD is limited and yet patients feel that it is effective. The provision of this service in the NHS is patchy with some patients not receiving speech and language therapy when it may be appropriate.

The GDG recommends a trial that is preceded by survey work to identify current and best practice speech and language therapy for PD in the UK. Similar work has already been performed for physiotherapy and OT to prepare for analogous trials.

In this pragmatic trial, standard NHS speech and language therapy would be compared with no treatment. While most PD units will have access to some speech and language therapy service, this may be insufficient for trial purposes so an NHS subvention would be required.

It is likely that a pilot study will be required to assess issues concerning availability of services, recruitment rates, etc.

If speech and language therapy is cost-effective, the provision of service needs to be increased. If it is not cost-effective, services can be diverted to other conditions.

Future trials will then need to examine what components of speech and language therapy are effective.
Question 5: Which diagnostic investigations for PD and potential biomarkers of its progression are clinically useful and cost-effective?

| Population        | People with suspected PD  
|                  | Any sex, age, ethnic group  
|                  | Trials performed in secondary care  

| Interventions     | (1) Development of existing and novel diagnostic tests to differentiate PD from (a) no-parkinsonism (ie normality and essential tremor) and (b) other parkinsonian disorders (ie PSP, MSA, corticobasal degeneration)  
|                  | (2) Development of biomarkers to follow the progression of PD, mainly to be used in accommodation trials  

| Comparison        | Diagnostic accuracy of test versus UK PD90 Brain Bank Criteria or $^{125}$I-FP-CIT SPECT  

| Outcome           | Well-designed diagnostic studies using receiver-operator characteristic curves were appropriate to establish standard diagnostic criteria of investigations (eg sensitivity and specificity)  

Explanatory paragraph

The diagnosis of PD remains clinical. $^{125}$I-FP-CIT SPECT may be of additional help in a small proportion of clinically uncertain cases. The diagnostic error rate on presentation may be as high as 10% in expert hands, which may lead to inappropriate therapy and distress following revision of the diagnosis.

A systematic approach led by university researchers and funded by the government would expedite the evaluation of existing and new diagnostic techniques.

The considerable debate surrounding biomarkers to measure the progression of PD has highlighted the need for further studies in this area. More work on existing techniques (eg SPECT and PET) is required and the development of new potential markers of progression is urgently required.

12.2 General research recommendations
Parkinson’s disease Appendix H: Deleted Text Appendix

These general research recommendations are in addition to the prioritised research recommendations covered in the preceding section. These were gaps in the evidence base that were identified by the GDG when reviewing the literature for the guideline. The GDG recognises that there are many areas of ongoing research activity in the diagnosis, treatment and management of PD. The following were agreed as broad areas for future research development.

Methodology

There were methodological limitations in many of the studies reviewed in the guideline. The GDG agreed that there was a need to make some general recommendations on the design of future research trials in PD.
The following issues should be considered in future trial design:

Sample size calculations should be performed before the study to ensure large enough numbers of patients are included to prevent false-negative conclusions.

UK Brain Bank diagnostic criteria should be used to ensure all trial participants have idiopathic PD.

Trials should attempt to include a more representative spectrum of patients with PD, particularly the elderly and those with comorbidity.

Outcome measures should include patient-rated quality-of-life instruments and health economics evaluations.

Patients should be followed for prolonged periods.

An intention-to-treat analysis of the data from all randomised participants should be performed.

All reporting of results should be to CONSORT standards.\textsuperscript{414}

### Diagnosis

In the development of diagnostic tests for PD in the future, study designs should be improved to include, for example:

blindness of investigators

assessment of established cases then assessment of newly diagnosed cases with prospective follow-up

reporting of appropriate statistics (including sensitivity, specificity, positive and negative predictive values).

More research is needed in the use of MRI, magnetic resonance volumetry, MRS, PET, MiBzSPECT, IBZM-SPECT, transcranial ultrasound and smell testing as diagnostic tools to accurately differentiate PD from controls, those with essential tremor and those with other parkinsonian conditions before further conclusions can be reached regarding their value.

Many of these investigations are expensive with limited availability. It would be particularly useful to develop inexpensive tests for PD based on serum or cerebrospinal fluid biomarkers or more sophisticated bedside tests; for example, olfaction, eye movements, neuropsychological
testing and detailed movement analysis.

Studies should be done to examine the possibility of combining two or more diagnostic tests to improve accuracy. This is particularly applicable to less expensive investigations. In addition, studies should also compare promising diagnostic tests directly (eg SPECT scanning with objective smell identification).

**Neuroprotection**

Careful consideration must be given to the design of neuroprotection trials in PD in the future to avoid the mistakes of the past.

A systematic approach to the development of neuroprotection trials in PD should be adopted in England and Wales along the lines of, and possibly in collaboration with, the NINDS in the USA. From a societal perspective, it would be more cost-effective to slow or halt the progression of PD than to continue to treat it symptomatically.
The UK has recently led neurorestoration trials using intra-putaminal GDNF infusions in PD. Support for similar trials in the future will be imperative.

Methods to improve neuroprotection trial design include:

Washout of drug at the end of the trial should be prolonged or trial should be done in patients not requiring symptomatic medication (ie very early disease)

Future longitudinal clinicopathological studies are required to evaluate the ultimate diagnosis and prognosis of patients bearing an initial clinical diagnosis of PD who are found to have normal SPECT and/or PET images.

Misdiagnosis must be taken into account when sample size calculations are performed. Larger and longer studies may be able to show more clinically meaningful effects. Standardisation of imaging methodology with blind evaluation of results should be better. There should be repeated imaging after dose titration and after drug withdrawal at end of trial.

If the predicted therapeutic effect is mild or slight, trials need to be much larger (ie thousands of patients).

Large explanatory trials in early disease should be rolled on into pragmatic long-term trials reflecting real-life practice with quality-of-life and health economics outcomes.

Symptomatic therapy

Future clinical trials examining the effectiveness of symptomatic therapies in PD should be longer and larger than those in the past to provide more reliable evidence of the long-term effects of treatments. Such trials should use robust clinical criteria for the diagnosis of PD. Results should be reported on an intention-to-treat basis using CONSORT reporting guidelines. Crossover trials should report the results of the first half of the study separately from the overall results and should have a sufficiently long washout period to prevent carry-over effects.

More data on the comparative efficacy and safety of the most commonly used symptomatic therapies for early PD are required. In particular, we need more information on the relative merits of levodopa, dopamine agonists, amantadine, anticholinergics and MAO-B inhibitors in terms of quality-of-life and health economics outcomes.

Clinicians require more data on the comparative efficacy and safety of adjuvant therapies for later PD once levodopa has been commenced and motor complications have developed. There is insufficient information on which to base a decision whether to add a dopamine agonist, a
COMT inhibitor or an MAOB inhibitor.

The PD MED trial is comparing levodopa, dopamine agonists and MAOB inhibitors in early PD and adjuvant therapy in later PD with dopamine agonists, COMT inhibitors and MAOB inhibitors using quality-of-life and health economics outcomes.

Non-motor features

Depression is common in PD, but further work is required to:

- develop suitable ways to screen for mild depression in clinic populations
- obtain information on the value of cognitive behavioural therapy
- obtain more trial data on the efficacy and safety of SSRIs and other modern classes of antidepressant in PD.
Further work is needed to evaluate the role of electroconvulsive therapy in drug and cognitive behavioural therapy-refractory depression.

Additional trials should be performed with memory-enhancing agents in PDD. Trials are needed to compare the effects of atypical antipsychotics with those of memory-enhancing agents in PDD.

Further research is required to evaluate treatments for daytime hypersomnolence, constipation, bladder disturbance, autonomic dysfunction, and RBD associated with PD.

**Other key interventions**

In the development of evidence to support physiotherapy intervention, future research should include large, well-designed trials to investigate:

- the optimal stage in the condition for referral to a physiotherapy practitioner
- the benefit of exercise for people in the different stages of the condition in relation to maintenance of their movement capability and function
- the role of optimising physical capacity to delay the onset and manifestation of disability
- the benefit of physiotherapy in preventing falls in people with PD
- the benefit of physiotherapy in maintaining confidence to move in people with PD
- the benefit of multi- and interdisciplinary intervention (including physiotherapy) in enabling a good quality of life in people with PD and their family and carers
- physiotherapy as an adjunct to change in medical and surgical intervention.

Further large, well-designed trials are required to evaluate the impact of occupational therapy for people with PD, including large, well-designed trials to investigate:

- the optimal stage for referral to OT
- the benefit of OT in maintaining or optimising safety and independence in transfers, mobility and personal care, and in reducing risk/ frequency of falls
- the benefit of OT in maintaining or optimising work, family, leisure and recreational roles and activities, according to the specific wishes and needs of the individual with PD
- the value of OT in the management of anxiety and depression
Parkinson's disease Appendix H: Deleted Text Appendix

the benefit of provision of information and advice about assistive aids, equipment and wheelchairs, and about practical and financial support and services

the benefit of OT in improvement of hand function, including handwriting/management of micrographia

the value of education and advice about the self-management of symptoms, especially where these are experienced in 'a pre-drug management phase', where symptoms are drug resistant or where drug side effects limit their use

the value of a multi-interdisciplinary intervention (including OT) in enabling a good quality of life in people with PD, their families and carers.
Further research is required into the impact of speech and language therapy intervention for people with PD, including large, well-designed trials to investigate:

- different therapy programmes and their impact on features such as vocal loudness and overall communication competency/intelligibility
- treatment for dysphagia
- trials of different intensities of treatments and their impact on communication over time
- the optimal timing for intervention
- the benefit of using assistive augmentative communication devices for people with PD
- the benefit of speech and language therapy intervention on quality of life, such as feelings of social isolation
- the impact of communication difficulties on family and carers and whether this can be reduced with intervention.
APPENDICES
Appendix A: The scope of the guideline

Guideline title

Parkinson's disease: diagnosis, management and treatment of Parkinson's disease in primary and secondary care

Background

The National Institute for Health and Clinical Excellence (NICE or 'the Institute') has commissioned the National Collaborating Centre for Chronic Conditions to develop a clinical guideline on Parkinson's disease (PD) for use in the NHS in England and Wales. This follows referral of the topic by the Department of Health and Welsh Assembly Government (see below). The guideline will provide recommendations for good practice that are based on the best available evidence of clinical and cost-effectiveness.

The Institute's clinical guidelines will support the implementation of national service frameworks (NSFs) in those aspects of care where a framework has been published. The statements in each NSF reflect the evidence that was used at the time the framework was prepared. The clinical guidelines and technology appraisals published by the Institute after an NSF has been issued will have the effect of updating the framework.

Clinical need for the guideline

Parkinson's disease is a progressive neurodegenerative condition leading to death of the dopamine-containing cells of the substantia nigra. The 'cardinal signs' of the disease are rest tremor, rigidity, and hypokinesia. Postural instability and falls occur later during the course of the condition. Additional common findings are asymmetric onset of symptoms and symptomatic response to L-dopa (levodopa). Although predominantly a movement disorder, cognitive impairments including dementia do occur. All of these problems lead to significant disability and handicap with impaired quality of life for both patients and their carers and increased healthcare costs.
Parkinson's disease Appendix H: Deleted Text Appendix

Parkinson's disease is one of the commonest neurological conditions. It is estimated to affect up to 160 per 100,000 of the general population with an annual incidence of 15–20 per 100,000. Many population studies have shown the rising prevalence with age (up to 2% of the population aged 80 and over). Around 1 in 7 cases are diagnosed below the age of 60 years.

The costs of treatment have been estimated at between £560,000 and £1.6 million per 100,000 of the population. Significant cost drivers include the onset of motor fluctuations, psychiatric symptoms, and institutional care. Parkinson's disease is a frequent cause of falls, fractures, and hospital admission and is therefore a costly disease, especially in the later stages.\textsuperscript{10,362,415}

The guideline

The guideline development process is described in detail in three booklets that are available from the NICE website (see ‘Further information’). \textit{The guideline development process: information for stakeholders}\textsuperscript{13} describes how organisations can become involved in the development of a guideline.
This document is the scope. It defines exactly what this guideline will (and will not) examine, and what the guideline developers will consider. The scope is based on the referral from the Department of Health and Welsh Assembly Government (see below).

The areas that will be addressed by the guideline are described in the following sections.

**Population**

**Groups that will be covered:**

- both sexes over 20 years of age
- diagnoses: Parkinson's disease and parkinsonism
- treatment: idiopathic Parkinson's disease only.

**Groups that will not be covered:**

- juvenile onset Parkinson's disease (<20 years)
- pregnant females
- treatment: parkinsonism (a neurological disorder that manifests with hypokinesia, tremor, or muscular rigidity) and other tremulous disorders (eg essential tremor) – except for accurate differential diagnosis.

**Healthcare setting**

The guideline will cover the care received from primary, secondary and tertiary NHS care settings.

**Clinical management**

The guideline will cover the following aspects of management.
Parkinson’s disease Appendix H: Deleted Text Appendix

Diagnosis and monitoring:

- clinical expert diagnosis (using UK PDS Brain Bank Criteria)
  - versus non-expert diagnosis
  - versus post-mortem gold standard

- other diagnostic tests (eg acute levodopa and apomorphine tests, radionuclide imaging: PET and SPECT, magnetic resonance imaging, magnetic resonance volumetry, magnetic resonance spectroscopy, growth hormone stimulation test).

Communication and education:

- communication of the diagnosis and patient understanding

- patient education (self-help), both specific and generic issues, including falls prevention

Pharmacotherapy:

- prevention of progression – the use of neuro-protective therapy (eg dopamine agonists, MAO-B inhibitors, amantadine, co-enzyme Q10, vitamins).

- functional disability – treatment of early disease with:
  - immediate-release levodopa
  - modified-release levodopa
Parkinson’s disease Appendix H: Deleted Text Appendix

Appendix A: The scope of the guideline

- dopamine agonists
- MAOB inhibitors
- amantadine
- anticholinergics
- beta-blockers.

Adjunct pharmacotherapy:
- dopamine agonists
- COMT inhibitors
- MAOB inhibitors
- amantadine
- intermittent apomorphine injections and continuous infusion
treatment of non-motor symptoms (e.g. sleep disturbance).

Non-pharmacological management:
current surgical options (e.g. deep brain stimulation)
physiotherapy
speech and language therapy
occupational therapy
Parkinson’s disease nurse specialists

Neuropsychiatric conditions
psychosis management specific to PD
depression management specific to PD
dementia management specific to PD.

Palliative care:
end-of-life issues specific to PD.

The guideline will not cover the following aspects of intervention/management.
radical therapies that do not form common clinical management: fetal cell
transplantation; stem cells; genes that code protein responsible for producing dopamine;
drugs that block the action of glutamate; GDNF; viral transfection
Appendix F: Deleted Text Appendix

comorbidities in Parkinson’s disease (except where treatment will differ from treatment of these comorbidities in patients without Parkinson’s disease)

generic health problems where the care for people with Parkinson’s disease does not differ to that of the general population (eg constipation).

Audit support within guideline

The guideline will include Level 1 clinical audit criteria.

Referral from the Department of Health and Welsh Assembly Government

The Department of Health and the Welsh Assembly Government asked the Institute in May 2002:

‘To prepare clinical guidelines for the NHS in England and Wales for the diagnosis, management and treatment of Parkinson’s disease in both primary and secondary care settings, including examination of the evidence for the effectiveness of management of the condition by physiotherapy, speech, language and occupational therapies, self-help, drug therapies and surgery.’
## Appendix B: Details of questions and literature searches

<table>
<thead>
<tr>
<th>Question</th>
<th>Details of questions and literature searches</th>
<th>Study type</th>
</tr>
</thead>
</table>
Table B1 Details of questions and literature searches – continued

<table>
<thead>
<tr>
<th>Question</th>
<th>Description</th>
<th>Study type</th>
<th>Database</th>
</tr>
</thead>
<tbody>
<tr>
<td>MON1</td>
<td>What is the most appropriate frequency of follow-up after the initial diagnosis of Parkinson’s disease?</td>
<td>All study types</td>
<td>Medline 1966-2005 Embase 1980-2005 Cochrane 1980-2005 CINAHL 1982-2005</td>
</tr>
<tr>
<td>Parkinson's disease Appendix H: Deleted Text Appendix</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table B1: Details of questions and literature searches – continued

<table>
<thead>
<tr>
<th>Question</th>
<th>Description</th>
<th>Study type</th>
<th>Database(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Question</td>
<td>Description</td>
<td>Study type</td>
<td>Databases</td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td>------------</td>
<td>-----------</td>
</tr>
</tbody>
</table>
### Table B1: Details of questions and literature searches – continued

<table>
<thead>
<tr>
<th>Question</th>
<th>Description</th>
<th>Study type</th>
<th>Sources</th>
</tr>
</thead>
</table>
Note: The final cut-off date for all searches was 28 February 2005.
Appendix C: Parkinson’s Disease Society Communication Table

<table>
<thead>
<tr>
<th>Table C1: Communicating with people with Parkinson’s and their carers (2005) (Adapted from Parkinson’s Disease Society report)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General</strong></td>
</tr>
<tr>
<td>Maintain a good knowledge of Parkinson’s disease including the symptoms, comorbidities, care and treatment.</td>
</tr>
<tr>
<td>All staff who come into contact with people with Parkinson’s need to have training and updating on the core symptoms, pharmacology and care.</td>
</tr>
<tr>
<td>Use clear language and avoid medical jargon when communicating with people with Parkinson’s.</td>
</tr>
<tr>
<td>Essential.</td>
</tr>
<tr>
<td>Check if the person has understood information provided.</td>
</tr>
<tr>
<td>Essential.</td>
</tr>
<tr>
<td>Give the person extra time to respond to questions.</td>
</tr>
<tr>
<td>Essential.</td>
</tr>
<tr>
<td>Ensure information is appropriate, accessible and available in a range of formats.</td>
</tr>
<tr>
<td>Essential.</td>
</tr>
<tr>
<td>Provide an appropriate setting to communicate, eg a quiet room without interruptions or distractions.</td>
</tr>
<tr>
<td>Essential.</td>
</tr>
<tr>
<td><strong>Diagnosis</strong></td>
</tr>
<tr>
<td>Communicate the diagnosis in a manner that is sensitive to the needs of the individual, ie if the person wants more information, make this available; if they demonstrate shock or bewilderment, offer a follow-up appointment for further discussion of the symptoms and treatment.</td>
</tr>
<tr>
<td>Essential.</td>
</tr>
<tr>
<td>Allow extensive opportunities for questions and discussion.</td>
</tr>
<tr>
<td>The consultation time should be sufficient to allow for this.</td>
</tr>
<tr>
<td>Offer a follow-up discussion.</td>
</tr>
<tr>
<td>Essential.</td>
</tr>
<tr>
<td>If the consultation reveals a demand for additional specialist information, the person should be referred promptly to the relevant professional (eg Parkinson’s nurse, psychiatrist, speech and language therapist, counsellor).</td>
</tr>
<tr>
<td>Essential.</td>
</tr>
<tr>
<td>Offer written information to supplement the diagnosis. This should include details of specialist organisations such as the Parkinson’s Disease Society (PDS).</td>
</tr>
<tr>
<td>Essential.</td>
</tr>
<tr>
<td>Put the person in contact with specialist support, eg Parkinson’s nurse, POS community support worker. This should include</td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>multidisciplinary support (speech and language therapy, physiotherapy, occupational therapy, social)</td>
</tr>
</tbody>
</table>

continued
### Table C1: Communicating with people with Parkinson’s and their carers (2005). (Adapted from Parkinson’s Disease Society report) – continued

<table>
<thead>
<tr>
<th>Diagnosis – continued</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Provide information for carers.</td>
<td>Important but not in all circumstances – the needs of the patient should come first.</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Maintenance</td>
<td></td>
</tr>
<tr>
<td>Provide the person with a point of contact for further information.</td>
<td>The PDS recommends that all people with Parkinson’s should have access to a PDNS.</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Ensure the person has relevant and current information about the condition and treatment specific to their needs and stage of the condition. Provide them with information about all their options, eg medications, home care, therapy.</td>
<td>Essential. Frequency of reviews varies according to the individual but is optimally 6 months. Consultation can take place additionally and in the interim via telephone and email contact.</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Consult the person regularly about their physical and emotional needs and financial needs.</td>
<td>Essential.</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Consult the carer about the physical and emotional needs of the person they are caring for, and their own support needs.</td>
<td>Essential.</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>If the person goes into hospital, ask them whether they are self-medicating, and, if so, facilitate this with access to their drugs at the time prescribed for them.</td>
<td>Essential.</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Offer the person access to self-management resources, eg the Expert Patient Programme, if appropriate.</td>
<td>Essential.</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Advanced stage care</strong></td>
<td></td>
</tr>
<tr>
<td>Ensure that people and carers receive regular information about the condition, the medications, the financial support and the support networks.</td>
<td>These should be available in a variety of formats, such as print, audio and/or video.</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Ensure that staff are aware of the complexities of the stage of the disease and care for their holistic needs and those of their carers.</td>
<td>Essential.</td>
</tr>
<tr>
<td>Inclusion emotional, spiritual and psychological needs</td>
<td></td>
</tr>
</tbody>
</table>
Appendix D: NICE Falls Quick Reference Guide: The assessment and prevention of falls in older people

Key priorities for implementation

Case/risk identification

Older people in contact with healthcare professionals should be asked routinely whether they have fallen in the past year and asked about the frequency, context and characteristics of the fall.

Older people reporting a fall or considered at risk of falling should be observed for balance and gait deficits and considered for their ability to benefit from interventions to improve strength and balance. (Tests of balance and gait commonly used in the UK are detailed in the full guideline.)

Multifactorial falls risk assessment

Older people who present for medical attention because of a fall, or report recurrent falls in the past year, or demonstrate abnormalities of gait and/or balance should be offered a multifactorial falls risk assessment. This assessment should be performed by healthcare professionals with appropriate skills and experience, normally in the setting of a specialist falls service. This assessment should be part of an individualised, multifactorial intervention.

Multifactorial assessment may include the following:

- identification of gait history
- assessment of gait, balance and mobility, and muscle weakness
- assessment of osteoporosis risk
- assessment of the older person's perceived functional ability and fear relating to falling
- assessment of visual impairment
Parkinson's disease Appendix H: Deleted Text Appendix

assessment of cognitive impairment and neurological examination
assessment of urinary incontinence
assessment of home hazards
cardiovascular examination and medication review
multifactorial interventions.

Multifactorial interventions

All older people with recurrent falls or assessed as being at increased risk of falling should be considered for an individualised multifactorial intervention.

In successful multifactorial intervention programmes the following specific components are common (against a background of the general diagnosis and management of causes and recognised risk factors):
Parkinson's disease Appendix H: Deleted Text Appendix

Parkinson's disease

strength and balance training
home hazard assessment and intervention
vision assessment and referral
medication review with modification/withdrawal.

Following treatment for an injurious fall, older people should be offered a multidisciplinary assessment to identify and address future risk, and individualised intervention aimed at promoting independence and improving physical and psychological function.

Encouraging the participation of older people in falls prevention programmes including education and information giving

Individuals at risk of falling, and their carers, should be offered information orally and in writing about what measures they can take to prevent further falls.

Professional education

All healthcare professionals dealing with patients known to be at risk of falling should develop and maintain basic professional competence in falls assessment and prevention.
Appendix E: Economic modelling – dopamine agonists

Background

Levodopa (LD) remains the mainstay of treatment for PD but with long-term use it causes abnormal involuntary movements (dyskinesias) and fluctuations in motor performance (end-of-dose deterioration and unpredictable ‘on/off’ fluctuations). To avoid these motor complications, oral dopamine agonists have been used to treat early PD on their own (ie monotherapy).

However, dopamine agonists cost in the region of three times as much as levodopa per year (GDG). The incremental cost-effectiveness of this approach has not been considered in the UK. The large pragmatic PD MED trial will examine the cost effectiveness of these two approaches in the management of early PD.

Aim

The aim of the model was to perform a cost-minimisation analysis based on the assumption of equivalent effectiveness of dopamine agonist versus levodopa therapy in early PD over a 1-year time horizon.

Methods

A cost-minimisation model was constructed from the perspective of the NHS. The effectiveness outcome measure used quality of life. The data sources of the costs and benefits are described in further detail in Tables E1 and E2. No discount rate was used over a 1-year time horizon in accordance with standard practice. A one-way sensitivity analysis was run to assess the impact of variables on the incremental cost of dopamine agonists.

Incremental cost = (C1 – C2)

Where:
C₁ = Estimated cost of dopamine agonist treatment
C₂ = Estimated cost of levodopa treatment

Data sources and assumptions

Tables E1 and E2 list the baseline cost parameters along with the sources of data. Assumptions and methods of calculating estimates are described in further detail below.

Costs

One study suggests medication costs over a 4-year period are the only cost categories assessed in which there was a statistically significant difference by treatment group (mean = $8,938 per patient for the pramipexole arm and $5,399 for the initial levodopa arm, p<0.001). The other cost categories assessed included acute hospitalisations, outpatient provider visits, diagnostic procedures, test and surgeries, emergency department visits, nursing home care,
rehabilitation hospital care, durable medical devices, lost wages and home health aid service. Therefore, it was assumed all other cost factors were similar between the alternatives and only the cost of medications were used to compute the incremental costs of dopamine agonist over the levodopa strategy.

<table>
<thead>
<tr>
<th>Table E1</th>
<th>Mean total daily dosage[^158]</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dopamine agonist group</strong></td>
<td></td>
</tr>
<tr>
<td>Experimental dosage</td>
<td>427 ± 112 mg (LD)</td>
</tr>
<tr>
<td>Supplemental LD dosage</td>
<td>274 ± 442 mg</td>
</tr>
</tbody>
</table>

The mean total daily dosage in each alternative was derived from a 4-year RCT comparing pramipexole versus levodopa in initial treatment for PD[^158]. In this study, carbidopa/levodopa was taken as 12.5/50 mg or 25/100 mg capsules or matching placebo capsules and pramipexole was taken 3 times per day as 0.25 mg, 0.5 mg or 1 mg salt tablets or matching placebo tablets. Therefore, these tablet sizes were used to derive the unit costs of the medications. The choice of pramipexole as the dopamine agonist was based solely on the clinical reason that it is representative of the class.

The daily cost of the experimental drug therapy and supplemental levodopa was estimated by multiplying the daily dosages in mg with the cost per mg. Total daily cost was the sum of the experimental drug cost and supplemental levodopa cost. Total cost of therapy over one year was calculated as total daily cost multiplied by 365 days.

### Additional cost of dopamine agonist treatment

The additional cost of dopamine agonist treatment over a 1-year period was calculated by subtracting the cost of levodopa treatment from the cost of dopamine agonist treatment.

<table>
<thead>
<tr>
<th>Table E2</th>
<th>Unit costs of medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost per</td>
<td></td>
</tr>
<tr>
<td>mg</td>
<td></td>
</tr>
</tbody>
</table>

[^158]: Additional costs were determined by multiplying the daily dosages in mg with the cost per mg.
### Parkinson's Disease Appendix H: Deleted Text Appendix

<table>
<thead>
<tr>
<th>Drug</th>
<th>BNF</th>
<th>Description</th>
<th>30-tab Pack</th>
<th>100-tab Pack</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pramipexole</td>
<td>2.467</td>
<td>180 micrograms base = 250 micrograms salt (0.25 mg)</td>
<td>£18.50</td>
<td>£61.67</td>
</tr>
<tr>
<td></td>
<td>1.963</td>
<td>700 micrograms = 1 mg salt (1 mg)</td>
<td>£58.89</td>
<td>£196.32</td>
</tr>
<tr>
<td>Levodopa</td>
<td>0.002</td>
<td>BNF carbodopa 12.5 mg (as monohydrate), levodopa 60 mg</td>
<td>£7.03</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.001</td>
<td>BNF carbodopa 25 mg (as monohydrate), levodopa 100 mg</td>
<td>£10.05</td>
<td></td>
</tr>
</tbody>
</table>
Effectiveness

The mean change of quality of life scores on both the PDQUALIF and the EuroQol VAS were not significantly different between the dopamine agonist group and levodopa group and there were no significant treatment differences in the seven subscales of the PDQUALIF in the 4-year randomised control trial. The GDG agreed there was no clear clinically important difference between the two treatment strategies as many dyskinesias are mild and non-disabling and therefore well tolerated by patients. After 4 years of treatment, there is only one additional moderately disabling dyskinesia (1.0%), two mildly disabling dyskinesias (2.0%) and 17 non-disabling dyskinesias (16.8%) in 101 individuals in the levodopa group versus the pramipexole group, whereas the mean improvements in total, motor and activities of daily living UPDRS scores were greater in the levodopa group versus the pramipexole group.

Results

<table>
<thead>
<tr>
<th>Table E3</th>
<th>Mean total daily cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Experimental dosage</td>
<td>0.7839 (LD)</td>
</tr>
<tr>
<td>Supplemental LD dosage</td>
<td>0.3080</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table E4</th>
<th>Mean total cost over 1-year period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pramipexole</td>
<td>2,680</td>
</tr>
<tr>
<td>Levodopa</td>
<td>286</td>
</tr>
<tr>
<td>Incremental cost</td>
<td>2,394</td>
</tr>
</tbody>
</table>

Under the base-case analysis, the additional cost of dopamine agonist treatment versus levodopa over one year is £2,394.
Sensitivity analysis

The estimates used in the model are subject to uncertainty. Therefore, a one-way sensitivity analysis was carried out to assess the impact of key variables using the model. A one-way sensitivity analysis varies one parameter while maintaining the other parameters at base-line values. The variables included are:

1. Unit cost of levodopa
2. Unit cost of pramipexole
3. Mean total daily dosage of experimental levodopa in levodopa treatment
4. Mean total daily dosage of supplemental levodopa in levodopa treatment
(5) mean total daily dosage of experimental pramipexole in pramipexole treatment and
(6) mean total daily dosage of supplemental levodopa in pramipexole treatment.

Results for the upper and lower estimates are given in Table E5. The higher range of the unit cost of levodopa was derived from the higher unit cost of alternative pack size and the lower range was estimated as minus 10%. The lower range of the unit cost of pramipexole was derived from the lower unit cost of alternative pack size and the higher range was estimated as plus 10%. The ranges of the mean total daily dosages were estimated as ± two standard errors derived from the standard deviations and population size in the study.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Baseline value</th>
<th>Range evaluated</th>
<th>Incremental cost with lower range estimate</th>
<th>Incremental cost with higher range estimate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unit cost of levodopa</td>
<td>0.011</td>
<td>0.010–0.016</td>
<td>2.405</td>
<td>2.351</td>
</tr>
<tr>
<td>Unit cost of pramipexole</td>
<td>2.4607</td>
<td>1.963–2.713</td>
<td>1.883</td>
<td>2.644</td>
</tr>
<tr>
<td>Mean daily dosage of experimental levodopa</td>
<td>427</td>
<td>409–445</td>
<td>2.402</td>
<td>2.387</td>
</tr>
<tr>
<td>Mean daily dosage of supplemental levodopa</td>
<td>274</td>
<td>202–346</td>
<td>2.424</td>
<td>2.365</td>
</tr>
<tr>
<td>Mean daily dosage of experimental pramipexole</td>
<td>2.78</td>
<td>2.60–2.96</td>
<td>2.233</td>
<td>2.555</td>
</tr>
<tr>
<td>Mean daily dosage of supplemental pramipexole</td>
<td>494</td>
<td>353–515</td>
<td>2.361</td>
<td>2.427</td>
</tr>
</tbody>
</table>

The unit cost of pramipexole had the most impact on the ICER and resulted in the widest range of all the incremental cost estimates (£1,883 to £2,644). The mean daily dosage of experimental levodopa had the least impact on incremental cost.

Discussion
The baseline estimates result in an incremental cost (IC) of £2,394 for pramipexole treatment over a 1-year period.

All baseline values were assessed within ranges of uncertainty. The unit cost of pramipexole had the most impact on the IC and resulted in the widest range of all the IC estimates (£1,883 to £2,644). All other variables resulted in a range of incremental costs with an approximate difference of £322 or less between the upper and lower estimates.
Appendix E: Economic modelling – dopamine agonists

This study assumed all other costs, such as acute hospitalisations etc (see ‘Costs’ under ‘Data Sources and assumptions’ in this appendix), were similar between the pramipexole and levodopa groups based on the results of an American 4-year study. Evidence of this in the UK setting awaits further research. The study also assumed the quality of life measures are sufficiently sensitive to reflect benefit differences between the alternatives. This study compared initial dopamine agonist therapy with levodopa therapy; however, combination therapy was not included as an alternative.

The model was developed from one RCT based on pramipexole on the basis of available evidence. Other dopamine agonists are currently available and may or may not have similar incremental costs. This is an important consideration as the unit cost of pramipexole had the most impact on the incremental cost.

Conclusion

The baseline estimates result in an incremental cost of £2,394 for pramipexole treatment over a 1-year period. The unit cost of pramipexole had the most impact on the IC and resulted in the widest range of all the IC estimates (£1,883 to £2,644). On the basis of equivalent quality of life between the treatments, the levodopa strategy is the less costly option. The analysis is specific to pramipexole and does not consider the broader range of dopamine agonists available. This model is a simplified version of the costs and benefits of dopamine agonist versus levodopa therapy and a variety of assumptions have been used in the baseline analysis. Therefore, the results should be interpreted with caution.
Appendix F: Economic modelling – surgery

Background

Bilateral subthalamic stimulation has become established for the management of moderate to severe motor complications in the later stages of PD that are unresponsive to changes in medical therapy.

A literature review was performed and four economic studies met quality criteria. The economic results are presented along with the clinical evidence of deep brain stimulation.

Whilst conclusive evidence on the cost effectiveness of this procedure awaits the results of ongoing large pragmatic trials in the UK (PD SURG) and US, the GDG considered the topic valuable for further consideration in this guideline.

Aim

The aim of the model was to compare the additional cost of bilateral deep brain stimulation of the subthalamic nucleus (DBS-STN) therapy to the benefits in quality of life gained by this procedure. Treatment option 1 is the intervention: DBS-STN and post-operative care over a 5-year period. Treatment option 2 is standard therapy over a 5-year period. The cost per quality-adjusted life year (QALY) gained was calculated.

Methods

A cost-effectiveness model was constructed from the perspective of the NHS. The effectiveness outcome measure used was quality-adjusted life years (QALYs) and the cost per QALY was calculated. The data sources of the costs and benefits are described in further detail in Tables F1–F4. Costs and benefits were discounted at 3.5% in accordance with current NICE recommendations. A one-way sensitivity analysis was run to assess the impact of variables on the incremental cost-effectiveness ratio (ICER).
Incremental cost per QALY = (C₁ − C₂)/(Q₁ − Q₂)

Where:

C₁ = Estimated cost of DBS-STN procedure and post-operative care
C₂ = Estimated cost of standard care
Q₁ = Estimated quality-adjusted life years after DBS-STN
Q₂ = Estimated quality-adjusted life years with no DBS-STN.

Data sources and assumptions

Tables F1–F4 list the baseline cost and effectiveness outcomes along with the sources of data. Assumptions and methods of calculating estimates are described in further detail below.
### Table F1 Costs of standard care of PD patients

<table>
<thead>
<tr>
<th>Item</th>
<th>Minimum</th>
<th>Maximum</th>
<th>Baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual cost of care per patient in Hoehn and Yahr stages III-IV</td>
<td>8,216</td>
<td></td>
<td>Ref 10</td>
</tr>
<tr>
<td>Total costs for 5-year period with 3.5% discount</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

### Table F2 Costs of DBS-STN procedure

<table>
<thead>
<tr>
<th>Item</th>
<th>Minimum</th>
<th>Maximum</th>
<th>Baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td>DBS-STN (including device)</td>
<td>12,740</td>
<td>14,450</td>
<td>13,595</td>
</tr>
<tr>
<td>Follow-up appointment</td>
<td>70</td>
<td>376</td>
<td>223</td>
</tr>
<tr>
<td>Annual follow-up appointment*</td>
<td>582</td>
<td>582</td>
<td>582</td>
</tr>
<tr>
<td>Inpatient follow-up for adjustment of stimulator including batteries*</td>
<td>3,000</td>
<td>6,000</td>
<td>4,500</td>
</tr>
<tr>
<td>Total procedure costs with 3.5% discount*</td>
<td>29,193</td>
<td>45,672</td>
<td>37,432</td>
</tr>
</tbody>
</table>

*A 3.5% discount rate applies to these figures

---

### Table F3 Costs of post-operative medication

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual post-operative drug costs per patient</td>
<td>£1,414</td>
<td></td>
<td>Ref 10</td>
</tr>
<tr>
<td>% of patients with no medication after DBS-STN</td>
<td>26.19%</td>
<td></td>
<td>Ref 276</td>
</tr>
<tr>
<td>Total costs for 5-year period assuming 26.19% with no</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

### Table F4 Benefits after DBS-STN with annual 3.5% discount rate

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Period</td>
<td>Initial</td>
<td>0.488</td>
</tr>
<tr>
<td>1st year</td>
<td></td>
<td>0.873</td>
</tr>
<tr>
<td>2nd year</td>
<td></td>
<td>0.851</td>
</tr>
<tr>
<td>3rd year</td>
<td></td>
<td>0.629</td>
</tr>
<tr>
<td>4th year</td>
<td></td>
<td>0.807</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>----</td>
<td>-----</td>
</tr>
<tr>
<td>5th year</td>
<td>43</td>
<td>0.087</td>
</tr>
<tr>
<td>Total potential</td>
<td></td>
<td>3.147</td>
</tr>
<tr>
<td>Total including 7% mortality rate</td>
<td></td>
<td>2.927</td>
</tr>
</tbody>
</table>
Explanation of assumptions and data used

Costs

Standard care

The annual cost of care per patient with Parkinson’s disease in the UK without undergoing DBS-STN was derived from one UK study that estimated the annual cost of care in 1998. The study indicated that Hoehn and Yahr stage significantly influenced cost by stage (p<0.001). Therefore the annual NHS costs in Hoehn and Yahr stages III–IV were averaged to derive the annual standard cost of care of patients with moderate to severe motor complications in the later stages of PD.

To calculate the total cost of care per patient over a 5-year period, the annual cost of care per patient per year is considered stable for the 5-year period and was adjusted by a 3.5% discount rate.

DBS-STN procedure

The cost of the DBS-STN procedure per patient was estimated from cost data obtained from 7 of the 17 centres in the UK offering DBS-STN at the time of the study. Costs of annual follow-up appointment and inpatient follow-up for adjustment of stimulator including batteries after year 1 were discounted at an annual rate of 3.5%. This resulted in a figure similar but conservatively higher (£37,432 (1998) vs £32,526 (2002)) than an estimate in a study assessing the total health service costs of deep brain stimulation of the subthalamic nucleus, including pre-operative assessment, surgery and post-operative management over a 5-year period based on one centre in the UK.

Post-operative medication

The annual post-operative drug costs were derived from the same study used to estimate the cost of standard care. In the study, drug costs were lower in older age groups. The highest drug cost per patient per year in the under 65-year-old age group was used as a conservative estimate in favour of standard care.
The study that estimated the 5-year follow-up of DBS-STN found 11 of the 42 patients no longer required levodopa. Therefore 26.19% (11/42) was used as the baseline value for the percentage of patients no longer requiring medication.

To calculate the cost of post-operative medication per patient over a 5-year period, the annual cost of care per patient per year is considered stable for the 5-year period and was adjusted by a 3.5% discount rate. 26.19% of this cost was subtracted from the result to give the total cost of post-operative medication over the 5-year period.

**Total DBS-STN costs**

The total cost of the DBS-STN was the sum of the DBS-STN procedure and post-operative medication costs over the 5-year period.
Additional costs of DBS-STN

The additional cost of DBS-STN therapy over a 5-year period was calculated by subtracting the cost of standard care from the cost of DBS-STN therapy.

Quality-adjusted life-years

Standard care

As a conservative estimate in favour of standard care, the study assumed there is no change in quality of life from the initial value over the 5-year period. Quality-adjusted life-years (QALYs) were discounted at 3.5%.

DBS-STN therapy

The initial quality of life and the quality of life 12 months after DBS-STN was derived from one study assessing the quality of life of 60 patients before DBS-STN surgery and 12 months after using a disease-specific quality of life instrument, the PD Quality of Life (PDQ-L) scale.

There are limited data on the quality of life after DBS-STN beyond the first 12 months and very limited data for converting quality of life outcomes of Parkinson's disease health states, such as UPDRS, into quality-adjusted life-years. Therefore, as UPDRS III has been found to correlate with improvements in QOL, for years 2 through 5, it was assumed that per cent changes in UPDRS III scores correspond with improvements in quality of life. The Qol. study found UPDRS III (motor functions) improved by 55% and UPDRS II (activities of daily living) improved by 45% after 12 months. A second study found UPDRS III improved by 54% and UPDRS II improved by 49% after 5 years. Therefore, it was assumed that the quality of life improvements found after 12 months would also remain improved at its 43% increase from baseline after 5 years.

In the UPDRS study over a 5-year follow-up, there was a 7% (3, N=42) rate of mortality, 5% rate of dementia (2, N=42), 19% with eye-lid opening apraxia (8, N=42) and other side effects. To include the 7% mortality, only 93% of the total possible QALY gain was included. The other side effects were assumed to be captured in the quality of life assessment. Total QALY gain in each year was added with a 3.5% annual discount rate.
Results

Table F5  DBS-STN therapy

<table>
<thead>
<tr>
<th>QALY</th>
<th>3.147</th>
</tr>
</thead>
<tbody>
<tr>
<td>QALY including 7% mortality</td>
<td>2.927</td>
</tr>
</tbody>
</table>
Table F6  Standard therapy

| QALY | 2.203 |

Table F7 Incremental results of baseline values

<table>
<thead>
<tr>
<th>Incremental QALY</th>
<th>0.944</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incremental QALY including 7% mortality</td>
<td>0.723</td>
</tr>
<tr>
<td>Incremental cost-effectiveness ratio (ICER)</td>
<td>£14,900 per QALY</td>
</tr>
<tr>
<td>ICER including 7% mortality</td>
<td>£19,500 per QALY</td>
</tr>
</tbody>
</table>

Under the base-case analysis including 7% mortality, the additional cost is £19,500 per QALY gained.

Sensitivity analysis

The estimates used in the model are subject to uncertainty. Therefore, a one-way sensitivity analysis was carried out to assess the impact of key variables used in the model. A one-way sensitivity analysis varies one parameter while maintaining the other parameters at baseline values. The variables included are:

1. cost of DBS-STN (including device)
2. cost of follow-up appointment
3. cost of inpatient follow-up for adjustment of stimulator including batteries
4. total costs of DBS-STN procedure with 3.5% discount
5. drug costs after DBS-STN
6. total costs of standard care
7. total QALY gains in standard care
8. total QALY gains in DBS-STN therapy.
Results for the upper and lower estimates are given in Table F8. The ranges of DBS-STN procedure component costs were derived from the minimum and maximum values given in the cost data literature. The range of the total costs of standard care were estimated from +/- two standard errors (867) from the standard deviation (6,235) and sample size of 207 of the annual cost of care. The range of the total DBS-STN procedure cost was estimated as half (0.5) and twice (2.0) the value. The range of the QALY gains were estimated as +/- two standard errors (0.04), from a standard deviation of 0.16 of the per cent increase in quality of life and sample size of 60.
The total DBS-STN procedure costs with 3.5% discount had the most impact on the ICER and resulted in the widest range of all the ICER estimates (£8,073 to £30,854 per QALY). The cost of DBS-STN (including device) and cost of follow-up appointment had the least impact on the ICER.
When possible, the model used conservative estimates that favoured standard care. With these estimates, the ICER value of £18,500 per QALY falls within an accepted range of cost effectiveness. This result is lower than the cost per QALY estimated in the American study –
$49,194 (US$ 2000) per QALY<sup>267</sup> – attributable to methodological and pricing differences between the countries.

Due to the assumptions of UPDRS III and quality of life and the exclusion of side-effects and mortality, the estimate of the QALY gains are associated with the most uncertainty. Nevertheless, the high and low estimates in the sensitivity impact on the ICER resulted in a range of £15,575 to £25,940 per QALY varying QALYs in standard care and £15,796 to £25,350 per QALY varying QALYs after DBS-STN, still falling within a normally accepted range. Even if the improvement in QALY is less than the observed improvement in UPDRS III used to estimate the QALY gain, with the baseline incremental cost of approximately £14,079, only an increase in 0.4693 (achieved by year 3 in baseline analysis) or greater from DBS-STN over a 5-year period would be required to achieve a cost per QALY of £30,000 or less. Doubling the incremental cost of DBS-STN (£28,158) would require an increase in only 0.9386 (achieved by year 5 in baseline analysis) in quality of life or greater to achieve a cost per QALY of £30,000 or less. Therefore, unless the actual total net QALY gain over a 5-year period is less than 0.4693, DBS-STN is still arguably likely to be cost effective.

The benefits in this model are assessed only for a 5-year period. This means that any benefits from DBS-STN accrued after 5 years are not accounted for in the model. This makes each benefit in the 5-year period cost more than it would over time, assuming further benefits after 5 years. Therefore, cost effectiveness may improve over greater lengths of time, but with only small improvements in the ICER. Additionally, the benefits over time are limited by increases in costs of care after DBS-STN as PD progresses and by mortality.

The sensitivity analysis indicates the higher the costs of care of standard therapy, the more favourable the ICER. This may indicate that using DBS-STN in patients with higher costs of care, potentially those with greater severity of PD, is more cost effective, but only if the QALY gains remain the same. Since the higher cost patients may or may not gain on average the same benefits, the sensitivity analysis results do not help to identify those patients better suited to DBS-STN therapy. The lower the cost of the DBS-STN procedure, the more favourable the ICER. This suggests that ICER values will improve if the technology becomes available at lower costs in the future.

**Conclusion**

Bilateral deep brain stimulation of the subthalamic nucleus is a clinical alternative to standard care for the management of moderate to severe motor complications in the later stages of PD that are unresponsive to changes in medical therapy. Costs and benefits of DBS-STN accrued over greater lengths of time (5 years) in comparison to standard care indicate the potential for cost-effective use of the technology in particular individuals with the clinical potential to
benefit from the procedure. The estimate suggests DBS-STN therapy costs approximately £19,500 per QALY over a 5-year period in comparison to standard PD care in the UK (£1 998). The results are relatively robust based on one-way sensitivity analysis. This model is a simplified version of the costs and benefits of DBS-STN therapy versus standard care and a variety of assumptions have been used in the baseline analysis. Therefore, the results should be interpreted with caution.
Appendix G: Economic modelling for Parkinson’s disease nurse specialist care

Background

The Parkinson's Disease Society is encouraging the development of Parkinson's disease nurse specialists (PDNS) across the UK. There are in the region of 180 nurses already in post with plans to increase this to 240 over the next few years (GDG).

A literature search was performed to identify economic evaluations of PDNS care. One study met quality criteria302 and is presented along with the clinical evidence of Parkinson's disease nurse specialist intervention.

In practice there may be interactions between PDNS care and standard care, which makes it difficult to separate the costs and benefits discretely between the interventions. The GDG considered monitoring medications, as opposed to diagnosing, which is an appropriate example of where PDNS care may substitute standard care with equivalent outcomes. Therefore, the GDG felt it was of value to investigate in this guideline the cost implications of PDNS care based on equivalent effectiveness of completely substituted activities.

Aim

The aim was to estimate the costs and costs saved with equivalently effective and completely substituted PDNS care in comparison to standard care over a 1-year period from the NHS perspective. The additional costs of PDNS care and the cost savings per home visit, per clinic consultation and per hospital-based visit were calculated.

Methods

The annual cost per PDNS was estimated using the sum of the annual salary and training costs
discounted at 3.5%. Additional costs of PDNS care were estimated using the unit costs of other professionals’ time used in discussing patient care.

Cost savings were estimated from the perspective of the NHS. Estimates were derived from unit costs and discounted at 3.5% (Table G1). Savings were calculated for PDNS care by (a) home visit (b) clinic consultation and (c) hospital-based visit. To calculate savings per intervention, the unit costs of standard care were used to estimate the resources saved by PDNS care.

The net cost of PDNS care over 1 year was calculated as the sum of the annual salary, training costs and additional costs of PDNS care minus the cost savings.
Data sources

Table G1  Unit costs derived from Unit costs of health and social care 2004

<table>
<thead>
<tr>
<th>Service Description</th>
<th>Cost (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GP home visit lasting 13.2 minutes (plus 12 minutes travel time)</td>
<td>65</td>
</tr>
<tr>
<td>District nurse home visit (A-F)</td>
<td>20</td>
</tr>
<tr>
<td>GP clinic consultation lasting 12.6 minutes</td>
<td>28</td>
</tr>
<tr>
<td>Nurse practitioner in primary care surgery consultation</td>
<td>14</td>
</tr>
<tr>
<td>Hospital-based consultant: per patient-related hour (A-F)</td>
<td>114</td>
</tr>
<tr>
<td>Hospital-based staff nurse, 24-hour ward per hour of patient contact</td>
<td>41</td>
</tr>
<tr>
<td>Expected annual cost of training at 3.5% discount rate (District nurse)</td>
<td>5,149</td>
</tr>
<tr>
<td>Salary per year of district nurse</td>
<td>28,362</td>
</tr>
<tr>
<td>Additional cost per visit to GP by PDNS to discuss patient care</td>
<td>28</td>
</tr>
<tr>
<td>Additional cost per visit to carer to discuss patient care</td>
<td>0</td>
</tr>
<tr>
<td>Additional cost per visit to consultant to discuss patient care</td>
<td>38</td>
</tr>
</tbody>
</table>

Table G2  Nurse activity – assessing patients

<table>
<thead>
<tr>
<th>Setting</th>
<th>Average number or per cent of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Per week</td>
<td>13.7</td>
</tr>
<tr>
<td>At home</td>
<td>75%</td>
</tr>
<tr>
<td>At GP</td>
<td>14%</td>
</tr>
<tr>
<td>At hospital consultant clinics</td>
<td>11%</td>
</tr>
</tbody>
</table>

Table G3  Nurse activity – discussing patients

<table>
<thead>
<tr>
<th>Category</th>
<th>Number of visits</th>
</tr>
</thead>
<tbody>
<tr>
<td>To GPs</td>
<td>5</td>
</tr>
<tr>
<td>To carers</td>
<td>2</td>
</tr>
<tr>
<td>To consultants</td>
<td>1</td>
</tr>
</tbody>
</table>

Assumptions
Parkinson’s disease Appendix H: Deleted Text Appendix

The main assumptions to this costing approach are as follows:

PDNS care substitutes for standard care for ongoing monitoring of treatment at equivalent effectiveness.

Nurse activity reflects substituted activities.

PDNS care is provided at the unit costs and includes the costs for consultant time spent discussing patient care.

Consultant time is costed per 20-minute visit.
Healthcare resources for patients by PDNS, such as medication, are similar to standard care.\textsuperscript{362}

Administration activities are included in salary.

Cost of visit to GP to discuss patient care = cost of nurse time included in salary + cost of GP time = £28.

Cost of visit to carer to discuss patient care = cost of nurse time included in salary = £0.

Cost of 20-minute visit to consultant to discuss patient care = cost of nurse time included salary + cost of consultant time = £38.

The results from a randomised control trial suggest PDNS care maintains clinical effectiveness and improves patients’ sense of well-being.\textsuperscript{362} This supports the assumption that PDNS care has at least equivalent effectiveness to consultant care.

It is not always clear whether PDNS care is substituting some or all of the consultant care or is serving as additional care.\textsuperscript{364} In this analysis, consultant care is face-to-face contact with a consultant for PD care needs by a patient. Therefore, the cost-saving estimates pertain only to situations where care is a substitution, such as monitoring medications, and not where the care may be additional to standard care or duplicating standard care.

### Results

<table>
<thead>
<tr>
<th>Table G4</th>
<th>Net cost of PDNS over 1-year period with 3.5% discount rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost of training per year</td>
<td>+5,149</td>
</tr>
<tr>
<td>Cost of salary per year</td>
<td>+24,554</td>
</tr>
<tr>
<td>Additional costs of other health professionals’ time discussing patients in one year</td>
<td>+8,874</td>
</tr>
<tr>
<td>Cost savings of other health professionals’ costs from assessing patients in one year</td>
<td>-39,264</td>
</tr>
<tr>
<td>Net cost of PDNS care over one year</td>
<td>-637</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table G5</th>
<th>Additional costs of nurse activity – discussing patient care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of visits per year</td>
<td></td>
</tr>
</tbody>
</table>

Parkinson’s disease Appendix H: Deleted Text Appendix

Appendix G: Economic modelling for PDNS care
<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>To GPs</td>
<td>261</td>
<td>7,305</td>
</tr>
<tr>
<td>To carers</td>
<td>104</td>
<td>0</td>
</tr>
<tr>
<td>To consultants</td>
<td>52</td>
<td>1,983</td>
</tr>
<tr>
<td>Total costs</td>
<td></td>
<td>9,288</td>
</tr>
<tr>
<td>Total costs at 3.5% discount rate</td>
<td></td>
<td>8,974</td>
</tr>
</tbody>
</table>

*Estimated from Table G3 with 1 year = 52.2 weeks.
Table G6 Cost savings of PDNS care when substituting standard care

<table>
<thead>
<tr>
<th>Average number of patients</th>
<th>Per year</th>
<th>At home</th>
<th>At GP</th>
<th>At hospital consultant clinics</th>
<th>Total</th>
<th>Total costs at 3.5% discount rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Per year</td>
<td>714</td>
<td>536</td>
<td>100</td>
<td>79</td>
<td>40,638</td>
<td>39,284</td>
</tr>
</tbody>
</table>

*Estimated from Table G2.

Sensitivity analysis

The estimates used in the model are subject to uncertainty. Therefore, a one-way sensitivity analysis was carried out to assess the impact of key variables used by the model. A one-way sensitivity analysis varies one parameter while maintaining the other parameters at baseline values. The variables included are: (a) cost of training per year, (b) cost of salary per year, (c) additional costs of other health professionals’ time discussing patients in one year, and (d) cost savings of other health professionals’ costs from assessing patients in one year. Plus or minus 10% was used as an estimate of the variability of the parameters.

Table G7 One-way sensitivity analysis

<table>
<thead>
<tr>
<th>Cost of training per year</th>
<th>5,149</th>
<th>4,634–5,664</th>
<th>-1,152</th>
<th>-123</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost of salary per year</td>
<td>24,504</td>
<td>22,054–26,955</td>
<td>-3,087</td>
<td>+1,813</td>
</tr>
<tr>
<td>Additional costs of other health professionals’ time discussing patients in one year</td>
<td>8,974</td>
<td>8,076–9,871</td>
<td>-1,535</td>
<td>+200</td>
</tr>
<tr>
<td>Cost savings of other health professionals’ costs from assessing patients in one year</td>
<td>39,264</td>
<td>35,338–43,190</td>
<td>+3,289</td>
<td>-4,564</td>
</tr>
</tbody>
</table>
The cost savings of other health professionals’ costs had the most impact on the ICER, ranging from an additional cost of £3,289 to cost savings of £4,564. Increasing and decreasing the cost of PDNS training by 10% resulted in cost savings of PDNS. However, by altering the other three parameters, costs range from cost savings to additional costs implying the model is not robust to changes in the assumptions.

Discussion

Based on the average nurse activity in the randomised controlled trial in the UK (Tables G2 and G3),362 for one year of one PDNS, approximately £640 is saved. Cost savings appear when PDNS care is substituting for standard care. However, in practice there may be variability in the interactions between types of care. There may be substituted care, additional care, duplication of care or a combination of these.362 Nevertheless, the more PDNS care substitutes for standard care in a practice, the greater the potential for the outcomes to approach these average cost savings. How much PDNS care substitutes, duplicates or increases benefit for the same cost in comparison to standard care is not known. As the sensitivity analysis indicates, the cost savings from other health professionals’ costs had the most impact on the ICER ranging from cost savings of £4,564 to an additional cost of £3,289. The costing of other health professionals reflects the average activity of PDNS. Therefore, how much PDNS care is substituting standard care at equivalent effectiveness needs to be assessed in further studies to improve cost estimates.

Only unit costs were used to assess the benefit of PDNS care versus standard care in terms of cost savings. However, unit costs may not fully represent all costs and benefits. This may have under-estimated the benefit of PDNS care. There may be increased patient benefits gained from a greater responsiveness of PDNS care to emerging scientific evidence, such as the earlier reduction in selegiline use found in nurses versus doctors362 or improved access to care. There may be an improved sense of patient well-being while maintaining clinical effectiveness.417 There also may be interactions of care as an additional benefit to PDNS care working in standard care that has not been measured. Currently, however, there is insufficient evidence available to measure such benefits.

On the other hand, the unit costs may underestimate the costs of PDNS care. The resources used in PDNS care are assumed to be equivalent to those used in standard care. However, PDNS care may use more or less or higher or lower cost resources resulting in higher or lower costs that are not reflected in the estimate. The RCT is the only study that gives an indication of the cost components in PDNS care versus standard care362 and suggests that these are similar between the groups. However, apomorphine was excluded from the total cost of healthcare. Therefore, further evidence on the costs of resources used is needed to inform cost-effectiveness analyses.
Parkinson’s disease Appendix H: Deleted Text Appendix

The initial cost of establishing PDNS care will be incurred by the NHS. Therefore it would be helpful to evaluate whether initial costs can be recovered over time to warrant the initial investment. However, this is also contingent on the resource implications of the care. This cost-savings estimate is based on one PDNS with average nurse activity. While activity with less substitution of standard care or higher resources used would reasonably decrease the cost savings and potentially result in a net cost, it has not been determined how having more than one PDNS would affect costs and cost savings. The net estimate should not be interpreted as the complete indication of the benefit of PDNS care, nor do the estimates provide an indication of
the appropriate amount of PDNS care that should be available. Instead, the net estimates suggest on average the cost savings of one PDNS based on average nurse activity.

A sensitivity analysis was performed to investigate changes to the cost inputs used in this analysis on the net cost. Increasing and decreasing the cost of PDNS training by 10% was the only parameter that maintained cost savings of PDNS. Increasing the cost of salary per year and the additional costs of other health professionals’ time discussing patients and reducing the cost savings of other health professionals’ costs from assessing patients by 10% resulted in additional costs. This suggests that further data are needed to assess the cost effectiveness of PDNS. The baseline analysis pertains to average PDNS care across the UK; however, this does not limit the applicability of the methods to individual centres to assess differences in both costs and cost-savings estimates.

The incremental costs compared with the incremental benefits was not estimated due to the difficulty in separating PDNS care from standard care and the limited evidence on measurable benefits. One study estimated PDNS care costs of £200 per patient per year. However, it is likely this value depends on the total number of patients, PDNSs and nurse activity. Furthermore, PDNS care versus standard care and nurse activity may not be consistent between services. Therefore, cost-effectiveness results may not be generalisable. Due to the difficulty in disentangling PDNS care and consultant care in different practices and the limited measurable benefits, a more general net cost approach, based on completely substituted care with equivalent effectiveness and average nurse activity, was performed.

**Conclusion**

Increasing the cost of salary per year and the additional costs of other health professionals’ time discussing patients and reducing the cost savings of other health professionals’ costs from assessing patients by 10% resulted in additional costs. Therefore, the cost effectiveness of PDNS care requires further evidence. This highlights the need for further studies to measure the benefits of PDNS care to adequately assess the cost effectiveness. Due to the interactions of care and data limitations, benefits have been simplified in the form of cost savings from standard unit costs. The cost-saving estimates are subject to the assumptions and therefore the results should be interpreted correspondingly.
Appendix H: Glossary

H.1 Guide to assessment scales

Activities of daily living (ADL)

Beck depression inventory (BDI)

Alzheimer's disease assessment scale – cognitive subscore (ADAS-cog)

Alzheimer's disease cooperative study – activities of daily living (ADCS-ADL)

Alzheimer's disease cooperative study – clinician's global impression of change (ADCS-CGIC)

Attitudes to self scale

Clinical global impression (CGI) scale

Barthel index
Parkinson’s disease Appendix H: Deleted Text Appendix

Measures the impact of PD on 14 categories; each category is scored on a 0–4 scale, with higher scores reflecting greater disability and the need for assistance. The overall score ranges from 0 to 56.

A test for measuring cognitive function in people suffering from dementia. The scale can range from 0 to 70, with higher scores indicating more severe impairment and lower scores indicating improvement.

A test for measuring quality of life in people suffering from dementia. Scores range from 0 to 78, with higher scores indicating better function.

A test for assessing a change in condition (ie improvement, worsening or no change) of a person suffering from dementia as judged by the clinician. Scores can range from 1 to 7, with a score of 1 indicating marked improvement to a score of 7 indicating marked worsening.

Measures ‘feelings and attitudes towards our bodies/selves’. Consisted of 15 semantic paired opposites (eg tense/relaxed). Positive score was 0 and negative score was 6 (range of total scores 0–90).

Measures the impact of PD on 10 categories of ‘activities of daily living’. The range of scores is 0–100 with higher scores indicating better functionality.

A test used to measure manifestations and severity of depression. The BDI is a 21-item self-rating scale depression. Each item comprises 4 statements (rated 0–4) describing increasing severity of the abnormality concerned.

An 18-item scale measuring psychiatric symptoms. Some items can be rated simply on observation; other items involve an element of self-reporting. There are 24 symptom constructs; each rated on a 7-point scale of severity ranging from ‘not present’ (1) to ‘extremely severe’ (7).

A participant’s illness is compared with change over time, and rated on a scale of very much improved to very much worse. A three-item scale (severity of illness; global improvement; and efficacy index) is used to assess treatment response in participants.
Core assessment program for intracerebral transplantations (CAPIT) dyskinesia rating scale

Hamilton Rating Scale for Depression (HRSD/HAM-D)

Delis-Kaplan executive function system (D-KES) verbal fluency test

Hoehn and Yahr staging

Dementia rating scale (DRS) total score

Epworth sleepiness scale (ESS)

EuroQol EQ-5D (VAS)

Frenchay dysarthria assessment
A pre-operative neurological evaluation. People are evaluated in the ‘on’ and ‘off’ phases according to CAPIT protocol. The protocol incorporates UPDRS, a dyskinesia rating scale and timed motor tests to demonstrate efficacy of surgical interventions.

Assesses key areas of cognitive function (problem solving, thinking flexibility, fluency, planning, deductive reasoning) in both spatial awareness and verbal communication. Higher scores indicate better performance.

A test to assess cognitive function in older adults with neurological impairment. The test provides a measurement of attention, initiation, construction, conceptualization, and memory.

A subjective scale in which participants rate the likelihood that they will fall asleep or doze in daily sedentary settings (eg watching TV). Each question receives a score of 0 to 3, making the maximum score 24.

A questionnaire that provides a simple descriptive profile and a single index value for health status. The questionnaire also includes a visual analogue scale (VAS) to allow the patient to indicate their general health status. On this scale, choosing 100 indicates the best possible health status.

A tool developed to diagnose dysarthria by quantitatively evaluating speech across a range of parameters including orofacial muscle movements and a measurement of intelligibility.

A 17–21 item observer-rated scale to assess the presence and severity of depressive states. A score of 11 is generally regarded as indicative of a diagnosis of depression.

To establish the severity of PD, stages of disease are classified from I to V where:

- I indicates unilateral disease
- II indicates bilateral without postural instability
- III indicates postural instability
- IV indicates considerable disability but ability to walk independently
- V indicates wheelchair-bound or walking only with assistance.

**Health related quality of life (HRQL)**

A combination of a person's physical, mental and social well-being; not merely the absence of disease.
<table>
<thead>
<tr>
<th>Test/Scale</th>
<th>Abbreviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maintenance of wakefulness test</td>
<td>MWT</td>
</tr>
<tr>
<td>Mini-mental state examination</td>
<td>MMSE</td>
</tr>
<tr>
<td>Modified Columbia rating scale</td>
<td>MCRS</td>
</tr>
<tr>
<td>Modified Hoehn and Yahr scale</td>
<td></td>
</tr>
<tr>
<td>Montgomery-Asberg depression rating scale</td>
<td></td>
</tr>
<tr>
<td>Neuropsychiatric inventory 10-item</td>
<td>NI-10</td>
</tr>
<tr>
<td>New York University Parkinson's disease scale</td>
<td>NYUPDS</td>
</tr>
<tr>
<td>Northwestern University disability scale</td>
<td>NUDS</td>
</tr>
<tr>
<td>Nottingham Health Profile</td>
<td></td>
</tr>
</tbody>
</table>
An evaluation of the person's ability to maintain wakefulness for 20-minute periods in a quiet, darkened room with the participant in a reclined position. This test evaluates the person's degree of alertness and his/her tendency to fall asleep at inappropriate times.

Assessment scale of global cognitive function, with scores ranging from 0 to 30. Higher scores indicate better mental function; <23 is usually indicative of cognitive impairment.

22-item scale (maximum possible score 240) that evaluates parkinsonian and dyskinesia severity, where global disability is rated as 0 (absent) to 4 (severe).

A modified eight-point version of the original scale.

A depression rating scale used to monitor a participant's depressive state over time. Scores range from 0 to 60, with higher scores indicating a greater degree of depression.

A test that evaluates dementia-related behaviours. Scores range from 1 to 120, with higher scores indicating more severe or more frequent behavioural problems.

Determines clinical efficacy by rating participants on 5 symptoms using a 5-point scale ranging from 0 (normal functioning) to 4 (marked impairment).

Assessed impairments in activities of daily living on 6 categories, with a scale ranging from 0 (normal functioning) to 10 (marked disability).

Generic health-related quality of life measure. The instrument is used to evaluate perceived distress across various populations. There are 38 items with 6 domains. Scores range from 0 to 100 where higher scores indicate a greater health problem.

A questionnaire comprising 37 items addressing four health domains (parkinsonian symptoms, systemic symptoms, social function, and emotional function).

A questionnaire consisting of 32 questions addressing seven health domains (e.g., social role, self-image/sexuality, sleep). The total score ranges from 0 to 128, with lower scores signifying better quality of life.

A self-administered questionnaire, which comprises 39 items addressing eight domains of health, which participants consider to be adversely affected by the disease. Scores range from 0 to 100, where lower scores indicate a better-perceived health status. The results are presented as eight discrete domain scores and not as a total score.
<table>
<thead>
<tr>
<th>Test Description</th>
<th>Test Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient's Global Impression (PGI) scale</td>
<td>Ten-point Clock Drawing Test</td>
</tr>
<tr>
<td>Positive and Negative Symptoms Scale (PANSS)</td>
<td>Timed-tapping scores</td>
</tr>
<tr>
<td>Scale for the Assessment of Positive Symptoms (SAPS)</td>
<td>Trail Making Test</td>
</tr>
<tr>
<td>Schwab and Englund scale ADL (SEADL)</td>
<td></td>
</tr>
<tr>
<td>Self-assessment Parkinson's Disease Disability Scale (SPDDS)</td>
<td>Unified Parkinson's Disease Rating Scale</td>
</tr>
<tr>
<td>Short Form 36 (SF 36)</td>
<td></td>
</tr>
<tr>
<td>Sickness Impact Profile (SIP)</td>
<td></td>
</tr>
</tbody>
</table>
A participant rates the change in their illness over time on a scale of '1' very much improved to '7' very much worse.

A psychotic rating scale of 30 items, each assessed on a seven-point scale from absent to extreme. It is divided into subscales covering both positive (PANSS-P) and negative symptoms (N).

Assesses the severity of psychotic symptoms.

The scale reflects the participant’s ability to perform daily activities in terms of speed and independence, and is comprised of 20 points.

Participants rate how easy or difficult it was to perform 25 separate actions at their best and at their worst times on a 5-point scale (range of total scores 25 to 125). Higher scores indicate increased difficulty.

The SF-36 assesses functioning and well-being in any participant group with chronic disease. Thirty-six items in eight domains are included, which cover functional status, well-being, and overall evaluation of health. Scored range from 0 to 100, where a higher score indicates a better-perceived health status.

SIP is a general quality of life scale. It consists of 136 items, which measure 12 distinct domains of quality of life. Participants identify those statements, which describe their experience. Higher scores represent greater dysfunction.

A test in which the participant is asked to draw a clock face marking the hours and then draw the hands to indicate a particular time.

The number of times the participant hits with a finger two spots some 40 cm apart in a 20-second interval.

The test consists of two parts. In Part A participants connect, in order, numbers 1–25 in as little time as possible. Part B requires the participant to connect numbers and letters in an alternating pattern (ie 1–A–2–B) in as little time as possible.

A scale used to measure severity of Parkinson's disease. It has six parts, and a higher score denotes greater disability.

Mentation, behaviour, and mood (4 items).
Activities of daily living (13 items).
Motor examination (14 items).
Complications of treatment (11 items).
### H.2 Glossary of terms

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>UPDRS Total score</td>
<td>Sum total of subscores.</td>
</tr>
<tr>
<td>UPDRS V</td>
<td>Modified Hoehn and Yahr staging (8 items).</td>
</tr>
<tr>
<td>UPDRS VI</td>
<td>Schwab and England activities of daily living score (20 items).</td>
</tr>
<tr>
<td>UPSIT</td>
<td>University of Pennsylvania Smell Identification Test. There are 40 microencapsulated scented pads in a booklet. Each individual scented pad is scratched with a pencil and sniffed one at a time. From a list of 4 choices for each pad, a correct answer must be chosen or a guess made. Changes in the scale over time can reflect changes due to disease progression or therapeutic interventions. The scores range from 0 to 30; higher scores indicate greater disease severity.</td>
</tr>
<tr>
<td>Webster Rating Scale</td>
<td></td>
</tr>
</tbody>
</table>

**Adverse events**

**Baseline**

**Akinesia**

**Bias**

**Algorithm (in guidelines)**

**Blinding (masking)**

**Allied health professional (AHP)**

**Allocation concealment**
Parkinson's disease Appendix H: Deleted Text Appendix

Bradykinesia

Carer (caregiver)

A harmful, and usually relatively rare, event arising from treatment.

Clinical audit

Absence or reduced functionality of movements.

A flowchart of the clinical decision pathway described in the guideline.

Allied health professionals are involved in the delivery of health services pertaining to the identification, evaluation and prevention of diseases and disorders.

The process used to prevent advance knowledge of group assignment in an RCT, and potential bias that may result.

The initial set of measurements at the beginning of a study (after run-in period where applicable), with which subsequent results are compared.

The effect that the results of a study are not an accurate reflection of any trends in the wider population. This may result from flaws in the design of a study or in the analysis of results.

A feature of study design to keep the participants, researchers and outcome assessors unaware of the interventions that have been allocated.

Slowness of movement.

Someone other than a health professional who is involved in caring for a person with a medical condition, such as a relative or spouse.

A systematic process for setting and monitoring standards of clinical care.
<table>
<thead>
<tr>
<th>Term</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cochrane Review</td>
<td>Diagnostic study</td>
</tr>
<tr>
<td>Cohort</td>
<td>Direct costs</td>
</tr>
<tr>
<td>Confidence interval (CI)</td>
<td>Discount rate</td>
</tr>
<tr>
<td>Control</td>
<td>Discounting</td>
</tr>
<tr>
<td>Cost-effectiveness analysis (CEA)</td>
<td>Disease-modifying therapy</td>
</tr>
<tr>
<td>Dysarthria</td>
<td></td>
</tr>
<tr>
<td>Cost-minimisation analysis (CMA)</td>
<td>Dysarthria profile</td>
</tr>
<tr>
<td>Crossover trials</td>
<td></td>
</tr>
<tr>
<td>DBS</td>
<td></td>
</tr>
</tbody>
</table>
Parkinson’s disease Appendix H: Deleted Text Appendix

A systematic review of the evidence from randomised controlled trials relating to a particular health problem or healthcare intervention, produced by the Cochrane Collaboration.

A group of participants.

A range of values, which contains the true value for the population with a stated 'confidence' (conventionally 95%).

A person in the comparison group who receives a placebo, no intervention, usual care or another form of care.

An analytic tool in which costs and effects of a programme and at least one alternative are calculated and presented in a ratio of incremental cost to incremental effect. Effects are health outcomes, such as cases of a disease prevented, years of life gained, or quality-adjusted life-years, rather than monetary measures as in cost-benefit analysis.

An analytic tool used to compare the net costs of programmes that achieve the same outcome.

Type of trial comparing two or more interventions in which participants, upon completion of the course of one treatment, are switched to another.

Deep brain stimulation

Any research study aimed at evaluating the utility of a diagnostic procedure.

An attempt to distinguish between two or more diseases with similar symptoms.

The value of all goods, services and other resources that are consumed in the provision of an intervention or in dealing with the side effects or other current and future consequences linked to it.

The interest rate used to compute present value or the interest rate used in discounting future values.

The process of converting future values and future health outcomes to their present value.

Refers to any treatment that beneficially affects the underlying pathophysiology of PD (also known as 'neuroprotection').

Slurred or otherwise impaired speech.

A description of the dysarthric person's problems, to supply the speech therapist with indications of where to begin in treatment.
Appendix H: Glossary

Dyskinesia

Dysphagia

Dystonia

Evidence-based healthcare

Ergot

Expert

False positive

FEES

Follow-up

Generalisability

Gold standard

Good practice points

Guideline development group

Hazard ratio (HR)

Heterogeneity

Homogeneity

Hypersomnolence Hypokinesia

Inclusion criteria

Incremental cost

Incremental cost effectiveness ratio (ICER)
Parkinson's disease Appendix H: Deleted Text Appendix

The impairment of the power of voluntary movement, resulting in fragmentary or incomplete movements.

Difficulty in swallowing.

Disordered tonicity of muscle.

The process of systematically finding, appraising, and using research findings as the basis for clinical decisions.

This is a fungus: Claviceps purpurea. Ergot derivatives are nowadays mostly used for their potential to enhance the neurotransmitter, dopamine.

A qualified medical specialist (see specialist).

A positive diagnostic test result in a person who does not possess the attribute for which the test is conducted.

Fibreoptic endoscopic examination of swallow safety.

An attempt to measure the outcomes of an intervention after the intervention has ended.

The degree to which the results of a study or systematic review can be extrapolated to other circumstances, particularly routine healthcare situations in the NHS in England and Wales.

See 'Reference standard'.

Recommended good practice based on the clinical experience of the Guideline Development Group.

An independent group set up by NICE to develop a guideline. They include healthcare professionals and patient/carer representatives.

A statistic to describe the relative risk of complications due to treatment, based on a comparison of event rates.

In systematic reviews, heterogeneity refers to variability or differences between studies in estimates of effect.

In a systematic review, homogeneity means there are no or minor variations in the results between individual studies included in a systematic review.

Excessive sleepiness.

Decreased muscular activity, bradykinesia, reduced or slowed movement.

Explicit criteria used to decide which studies should be considered as potential sources of evidence.

The cost of one alternative less the cost of another.

The ratio of the difference in costs between two alternatives to the difference in effectiveness between the same two alternatives.
Parkinson's disease

**Appendix H: Deleted Text Appendix**

**Parkinson's disease**

<table>
<thead>
<tr>
<th>Term</th>
<th>Acronym</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intention-to-treat analysis (ITT analysis)</td>
<td>NCC-CC</td>
</tr>
<tr>
<td>Negative predictive value</td>
<td></td>
</tr>
<tr>
<td>Neuroleptic malignant syndrome</td>
<td></td>
</tr>
<tr>
<td>LD</td>
<td></td>
</tr>
<tr>
<td>Lee Silverman Voice Treatment (LSVT)</td>
<td>NICE NSF</td>
</tr>
<tr>
<td>Odds ratio (OR)</td>
<td></td>
</tr>
<tr>
<td>MAOB inhibitor</td>
<td></td>
</tr>
<tr>
<td>Meta-analysis</td>
<td></td>
</tr>
<tr>
<td>Off time</td>
<td></td>
</tr>
<tr>
<td>Mortality</td>
<td></td>
</tr>
<tr>
<td>On time</td>
<td></td>
</tr>
<tr>
<td>Motor fluctuations</td>
<td></td>
</tr>
<tr>
<td>MSA</td>
<td></td>
</tr>
<tr>
<td>National Collaborating Centres (NCC)</td>
<td></td>
</tr>
</tbody>
</table>
An analysis of the results of a clinical study in which the data are analysed for all study participants as if they had remained in the group to which they were randomised, regardless of whether or not they remained in the study until the end, crossed over to another treatment or received an alternative intervention.

Levodopa.

A treatment for voice and speech disorders associated with Parkinson's disease to improve loudness, voice quality, and articulation.

Monoamine oxidase type B inhibitor.

A statistical technique for combining (pooling) the results of a number of studies that address the same question and report on the same outcomes to produce a summary result.1

The number of deaths in a given population and during a given time.

Periods of the day with poor or absent motor response to medication alternating with periods of improved motor function.

Multiple system atrophy.

Professionally led groups established by NICE to harness the expertise of the Royal Medical Colleges, specialist societies and person/carer organisations when developing clinical guidelines.

National Collaborating Centre for Chronic Conditions.

The proportion of people with a negative test result who do not have the disease.

A rare idiosyncratic reaction to neuroleptic medication. The syndrome is characterised by fever, muscular rigidity, altered mental status, and autonomic dysfunction.

National Institute for Health and Clinical Excellence.

National service framework.

The odds of an event happening in the treatment group, divided by the odds of it happening in the control group.

The duration of time when anti-parkinsonian medication is not controlling the person's symptoms or is 'wearing-off'.

The duration of time when anti-parkinsonian medication is controlling PD symptoms.
Open label trial design

p values

Randomisation

PD
PDNS
PDS

Phenomenological study

Randomised controlled trial (RCT)

Placebo

Reference standard (or gold standard)

Positive predictive value (PPV)

Present value

PSP

Quality of life

Quality-adjusted life-year (QALY)
Parkinson's disease Appendix H: Deleted Text Appendix

A clinical trial in which the investigator and participant are aware which intervention is being used for which person. These trials may or may not be randomised.

The probability that an observed difference could have occurred by chance. A p value of less than 0.05 is conventionally considered to be 'statistically significant'.

Parkinson's disease.

Parkinson's disease
nurse specialist.
Parkinson's Disease Society.

A qualitative study design, the goal of which is to describe a 'lived experience'.

An inactive and physically indistinguishable substitute for a medication or procedure, used as a comparator in controlled clinical trials.

The proportion of people with a positive test result who actually have the disease.

The value which healthcare professionals and people with PD would attribute at present to an outcome (or avoidance of an outcome) in the future.

Progressive supranuclear palsy.

Refers to the patient's ability to enjoy normal life activities, sometimes used as an outcome measure in a clinical trial.

A measure of health outcome which assigns to each period of time a weighting, ranging from 0 to 1, corresponding to the health-related quality of life during that period, where a weight of 1 corresponds to optimal health, and a weight of 0 corresponds to a health state judged equivalent to death; these are then aggregated across time periods.

Allocation of participants in a study into two or more alternative groups using a chance procedure, such as computer-generated random numbers. This approach is used in an attempt to reduce sources of bias.

A comparative study in which participants are randomly allocated to intervention and control groups and followed up to examine differences in outcomes between the groups.

The most specific and sensitive test to diagnose a disease or agreed desirable standard treatment and against which other tests or treatments can be compared. An ideal 'gold standard' test would have 100% sensitivity and specificity.
Parkinson’s disease Appendix H: Deleted Text Appendix

Parkinson’s disease

Relative risk (RR)

Rigidity
Sample size

Sensitivity (of a test)

Sensitivity analysis
Statistical power

Sialorrhea
Single blind study

Somnolence
Specialist

Specificity (of a test)

Stakeholder
Parkinson’s disease Appendix H: Deleted Text Appendix

The number of times more likely or less likely an event is to happen in one group compared with another.

Abnormal stiffness or inflexibility.

The number of participants included in a trial or intervention group.

The proportion of people classified as positive by the gold standard who are correctly identified by the study test.

A measure of the extent to which small changes in parameters and variables affect a result calculated from them. In this guideline, sensitivity analysis is used in health economic modelling.

Increased saliva or drooling.

A study where the investigator is aware of the treatment or intervention the participant is being given, but the participant is unaware.

Sleepiness or unnatural drowsiness.

A clinician whose practice is limited to a particular branch of medicine or surgery, especially one who is certified by a higher medical educational organisation.

The proportion of people classified as negative by the gold standard who are correctly identified by the study test.

Any national organisation, including patient and carers’ groups, healthcare professionals and commercial companies with an interest in the guideline under development.

In clinical trials, the probability of correctly detecting an effect due to the intervention or treatment under consideration. Power is determined by the study design, and in particular, the sample size. Larger sample sizes increase the chance of small effects being detected correctly.

A result is deemed statistically significant if the probability of the result occurring by chance is less than 1 in 20 (p<0.05).

A precise method of locating deep brain structures by using three-dimensional coordinates. The surgical technique may either involve stimulation or lesioning of the located site.

Research that summarises the evidence on a clearly formulated question according to a pre-defined protocol using systematic and explicit methods to identify, select and appraise relevant studies, and to extract, collate and
report their findings. It may or may not use statistical meta-analysis.

**Time horizon**

The period of time for which costs and effects are measured in a cost-effectiveness analysis.

**Uptake**

The absorption of a substance (often a radionuclide such as Fluoro-dopa) into the brain tissue, which can then be visualised through imaging techniques.

**Videofluoroscopy**

Videofluoroscopy is a test for assessing the integrity of the oral and pharyngeal stages of the swallowing process. Involves videotaping fluoroscopic images as the patient swallows a bolus of barium.

**Washout period**

The stage in a crossover trial when one treatment is withdrawn before the second treatment is given.

**Withdrawal**

When a trial participant discontinues the assigned intervention before completion of the study.
Appendix I: List of registered stakeholders

Addenbrooke's NHS Trust
Age Concern Cymru
Age Concern England
Airedale General Hospital
Alliance Pharmaceuticals Ltd
Amersham Health
Anglesey Local Health Board
Ashfield and Mansfield District PCTs
Association for Continence Advice (ACA)
Association of British Health-Care Industries
Association of British Neurologists
Association of Professional Music Therapists
Association of the British Pharmaceuticals Industry (ABPI)
Barts and the London NHS Trust
Bayer PLC
Birmingham Clinical Trials Unit
Birmingham Heartlands & Solihull NHS Trust
Boehringer Ingelheim Ltd

Bolton, Salford & Trafford Mental Health Bradford South & West Primary Care Trust Brain and Spine Foundation
Bristol-Myers Squibb Pharmaceuticals Ltd Britannia Pharmaceuticals Ltd
British Association for Counselling and Psychotherapy
British Association for Psychopharmacology
British Dietetic Association
British Geriatrics Society
British National Formulary (BNF)
British Neuropsychiatry Association
Parkinson's disease Appendix H: Deleted Text Appendix

British Nuclear Medicine Society British
Psychological Society, The British Society of
Neuroradiologists

British Society of Rehabilitation Medicine BUPA
Cephalon UK Ltd

Chartered Society of Physiotherapy Cheltenham
& Tewkesbury PCT Cochrane Movement
Disorders Group College of Occupational
Therapists Community District Nurses
Association

Community Psychiatric Nurses’ Association
Continence Foundation

Co-operative Pharmacy Association
Cyberonics SA/NV

Department of Health

Derbyshire Mental Health Services NHS Trust

Dudley Beacon & Castle Primary Care Trust
Eisai Limited

Elan Pharmaceuticals Ltd
Eli Lilly and Company Ltd
Faculty of Public Health

Gateshead Health NHS Trust
GE Health Care

Gedling Primary Care Trust
GlaxoSmithKline UK

Greater Peterborough Primary Care
Partnership-North PCT

Guys & St Thomas NHS Trust
Hammersmith Hospitals NHS Trust
Hampshire Partnership NHS Trust
Healthcare Commission

Help the Aged

213
Help the Hospices
Hereford Hospital NHS Trust
Herefordshire Primary Care Trust
Hertfordshire Partnership NHS Trust
Independent Healthcare Forum
Institute of Rehabilitation
Institute of Sport and Recreation Management
James Parkinson Centre
Kyowa Hakko UK Ltd
Long Term Medical Conditions Alliance
Lundbeck Limited
Mansfield District PCT
Medius Pharma Limited
Medicines and Healthcare Products Regulatory Agency (MHRA)
Medtronic Limited
Merck Pharmaceuticals
Mid Staffordshire General Hospitals NHS Trust
National Council for Disabled People, Black, Minority and Ethnic community (Equalities)
National Mental Health Partnership
National Patient Safety Agency
National Public Health Service – Wales
National Schizophrenia Fellowship (Rethink)
National Tremor Foundation

Neurological Alliance
Newcastle, North Tyneside and Northumberland MH Trust
NHS Direct
NHS Health and Social Care Information Centre
NHS Modernisation Agency, The NHS Quality Improvement Scotland
North Essex Mental Health Partnership Trust
North Staffordshire Combined Healthcare
NHS Trust
Parkinson’s disease Appendix H: Deleted Text Appendix

- Novartis Pharmaceuticals UK Ltd Orion Pharma (UK) Ltd
- Orphan Europe UK Ltd
- Parkinson’s Disease Nurse Specialist Association (PDNSA)
- Parkinson’s Disease Society Pfizer Limited
- Plymouth Primary Care Trust Primary Care Neurology Society
- Princess Alexandra Hospital NHS Trust
- PromoCon (Disabled Living)
- Relatives and Residents Association Roche Products Limited
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of General Practitioners Wales
- Royal College of Nursing (RCN) Royal College of Physicians of London Royal College of Psychiatrists
- Royal College of Speech and Language Therapists
- Royal Pharmaceutical Society of Great Britain
- Sanofi-Synthelabo
- Schwarz Pharma
- Scottish Intercollegiate Guidelines Network (SIGN)
- Selby & York PCT
- Sheffield Teaching Hospitals NHS Trust
- Sherwood Forest Hospitals NHS Trust
- Social Care Institute for Excellence (SCIE)
- Society of British Neurological Surgeons
- Solvay Healthcare Limited
- South Birmingham Primary Care Trust
- Sue Ryder Care
- Teva Pharmaceuticals Ltd
- The Medway NHS Trust
- The Progressive Supranuclear Palsy [PSP Europe] Association
The Royal Society of Medicine
The Royal West Sussex Trust
Trafford Primary Care Trusts
UK Clinical Pharmacy Association

University College London Hospitals NHS Trust

Valeant Pharmaceuticals

Walton Centre for Neurology and Neurosurgery NHS Trust

Welsh Assembly Government (formerly National Assembly for Wales)

West Cornwall PCT

Wirral Hospital NHS Trust
Parkinson's disease Appendix H: Deleted Text Appendix
References


Parkinson’s disease Appendix H: Deleted Text Appendix


31 Yarrow, S. Survey of members of the Parkinson’s Disease Society. London: Parkinson’s Disease Society of the United Kingdom and Policy Studies Institute, 1999. Ref ID: 786


Parkinson’s disease Appendix H: Deleted Text Appendix


175 Lieberman A, Gopinathan G, Miller E et al. Randomized double-blind cross-over study of sinemet-


Parkinson’s disease Appendix H: Deleted Text Appendix


213. Golbe LI, Duvoisin RC. Double-blind trial of R-deprenyl for the “on-off” effect complicating Parkinson’s


Parkinson's disease Appendix H: Deleted Text Appendix


Parkinson’s disease Appendix H: Deleted Text Appendix

References


259 Lenz FA, Tasker RR, Kwan HC et al. Selection of the optimal lesion site for the relief of parkinsonian tremor on the basis of spectral analysis of neuronal firing patterns. Applied Neurophysiology. 1987; 50(1–6):338–43. Ref ID: 19843


Parkinson's disease Appendix H: Deleted Text Appendix


288 Chaudhuri KR, Schapira A, Martinez-Martín P et al. The holistic management of Parkinson’s disease using a novel non-motor symptom scale and questionnaire. Advances in Clinical Neurosciences and
289 Goetz CG, Koller WC, Poewe W et al. Treatment of depression in idiopathic Parkinson’s disease. 
Movement Disorders. 2002; 17(suppl 4):S112–S119. Ref ID: 19760

290 Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s 

291 Shabnam G, Chung TH, Deane KHO et al. Therapies for depression in Parkinson’s disease (Cochrane 

292 Fregni F, Santos CM, Myczkowski ML et al. Repetitive transcranial magnetic stimulation is as effective 
as fluoxetine in the treatment of depression in patients with Parkinson’s disease. Journal of Neurology, 

293 Leemans AF, Vreeling FW, Luijckx GJ et al. SSRIs in the treatment of depression in Parkinson’s disease. 

294 Wermuth L, Sorensen PS, Timm S et al. Depression in idiopathic Parkinson’s disease treated with 

trial of the effect of nortriptyline in patients with Parkinson’s disease treated with L-DOPA. Acta 


Parkinson’s disease Appendix H: Deleted Text Appendix


Parkinson's disease

Appendix H: Deleted Text Appendix

Parkinson's disease


Parkinson's disease Appendix H: Deleted Text Appendix


References


Parkinson’s disease Appendix H: Deleted Text Appendix


394 World Health Organisation. WHO definition of palliative care. Available from:


398 MacMahon DG, Thomas S, Campbell S. Validation of pathways paradigm for the management of PD. *Parkinsonism & Related Disorders*. 1999; 5(5S) Ref ID: 19912


References


418 Curtis L, Netten A. Unit costs of health and social care data 2004. Personal Social Services Research
Parkinson's disease

Error! No text of specified style in document.